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ABSTRACT 
 
Characterization of polymers of nucleotide biosynthetic enzymes 
                                             
Sajitha Anthony 
    Jeffrey Peterson, Ph.D. 
 
 
 
Mammalian cells contain various proteins that assemble into 
filamentous structures. Examples include cytoskeletal proteins such as actin 
and even metabolic enzymes like acetyl-CoA carboxylase. Within the last 
decade, CTP synthase (CTPS) and inosine monophosphate dehydrogenase 
(IMPDH) have been found to assemble into filaments. Both are rate-limiting 
enzymes involved in nucleotide biosynthesis. Their assemblies are linked to 
nucleotide depletion.  Filaments containing CTPS and/or IMPDH have been 
identified within the cells of different organisms such as bacteria, yeast, flies 
and mammals. 
CTPS and IMPDH2 can co-assemble into filaments. To determine 
whether additional proteins can co-assemble with CTPS and IMPDH2, we 
implemented the Bio-ID system followed by mass spectrometry. Histidine 
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ammonia lyase was identified as a candidate and preliminary 
immunofluorescence studies found that it localizes to the filaments. Histidine 
ammonia lyase releases ammonia in its enzymatic reaction which may be 
used by CTPS which requires ammonia. 
CTPS and IMPDH2 are also capable of assembling individually into 
filaments. CTPS filaments can regulate both cell shape and enzymatic 
activity within bacterial cells. On the other hand, the function of IMPDH2 
polymerization is unclear. What is known is that IMPDH2 polymerization 
can be regulated by the binding of its allosteric regulators GTP and ATP 
which bind to the Bateman domain of the enzyme. ATP triggers the assembly 
of enzymatically active filaments composed of extended octamers. GTP, on 
the other hand, promotes enzymatically inactive octamers which are 
compressed in form and it is unknown whether these octamers can 
polymerize. To determine whether IMPDH2 polymerization changed 
IMPDH2 enzymatic activity, point mutants of IMPDH2 that either prevent or 
reinforced octamer polymerization were engineered. No difference in activity, 
substrate affinity, or GTP inhibition sensitivity was found between 
polymerized and non-polymerized IMPDH2. Cellular isotope tracing 
experiments validated these results. Surprisingly, electron microscopy 
revealed that compact octamers can polymerize.  
These findings demonstrate that IMPDH 2 polymerization has no 
effect on enzymatic activity. IMPDH is also involved in activities unrelated to 
xvii 
 
its enzymatic activity such as gene regulation. Polymerization may be a way 
to regulate its involvement in these activities 
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Chapter 1: Introduction 
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 Nucleotide biosynthesizing enzymes form macromolecular 
structures within cells 
Nucleotides fulfill many different roles within the cell, therefore the 
process of nucleotide biosynthesis is very important and must be strictly 
regulated (Garrett, 1995). Rate limiting nucleotide biosynthesizing enzymes 
such as CTP synthetase (CTPS) and inosine monophosphate dehydrogenase 
(IMPDH) are indispensable for this regulation (Lane and Fan, 2015). Because 
of the critical role that IMPDH and CTPS play in nucleotide synthesis, their 
activities have become therapeutic targets in the fight against cancer, 
infections, and autoimmune disease (Yokota, 2002; McKeran and Watts, 
1976; McCluskey et al., 2016 ). Within the past ten years, it has been 
discovered that each of these two enzymes can assemble into macromolecular 
structures within the cell (Carcamo et al., 2014; Liu et al., 2010; Ingerson-
Maher et al., 2010; Noree et al., 2010). These enzymes can assemble 
individually as well as together (Carcamo et al., 2014; Calise et al., 2016; 
Keppeke et al., 2015). The structures are elongated and filamentous in 
appearance and can be found in both the nucleus and the cytoplasm 
(Carcamo et al., 2014; Carcamo et al., 2011; Juda et al., 2014). Their 
assembly and disassembly has been linked to nucleotide levels within the cell 
(Calise et al., 2016), but whether these structures regulate nucleotide 
synthesis or if filaments of IMPDH play any other biological role, is unclear. 
It is also unknown if IMPDH and CTPS can assemble with additional 
3 
 
proteins. Therefore, the goal of my research was to address these two 
unknowns. In this first chapter, I will first discuss the important roles played 
by nucleotides within the cell, how nucleotides are produced and catabolized, 
as well as the important enzymes involved in these processes. Additionally, I 
will briefly discuss the diseases that could result if any of these nucleotide 
biosynthesizing or catabolizing processes malfunction. Then finally, a 
detailed of discussion about IMPDH and CTPS will occur. In chapters 2 and 3 
I will discuss my research concerning these two enzymes and then finally, in 
chapter 4, I will discuss my overall models for IMPDH filament assembly as 
well as IMPDH and CTPS co-assembly. 
 
The many roles of nucleotides in 
cellular metabolism 
The importance of nucleotides in 
dividing and quiescent cells 
Nucleotides are the subunits 
that make up the structure of nucleic 
acids such as DNA and RNA. DNA and RNA are two crucial molecules within 
the cell which contain genetic information. There are two major types of 
nucleotides: purines and pyrimidines (Figure 1). In quiescent cells, 
Figure 1. The molecular structures 
of pyrimidine and purine bases. A 
nucleotide is a derivative of either 
one 
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nucleotides are needed to replace the RNA and protein that are constantly 
being turned over within the cell (Berg JM, 2002; GM., 2000; Hacker et al., 
2015; Lane and Fan, 2015). mRNA turnover, in particular, is an important 
part of gene expression within eukaryotic cells (Raghavan et al., 2002; Wang 
et al., 2002; Wilusz and Wilusz, 2004; Yang et al., 2003). Turnover is also 
important for regulating protein levels within a cell (Schoenberg and Maquat, 
2012). In addition, mRNA production and decay are both needed to sustain 
cellular homeostasis (Schoenberg and Maquat, 2012). Transcripts that are 
abnormal or no longer needed are degraded to prevent the production of 
harmful proteins (Schoenberg and Maquat, 2012; Wilusz et al., 2001). Old 
proteins and misfolded proteins are constantly being replaced within the cell 
(Schoenberg and Maquat, 2012; Wilusz et al., 2001). Nucleotides are also 
needed to maintain genomic integrity in quiescent cells (Lane and Fan, 2015). 
For example, nucleotides are used by DNA repair pathways (Lane and Fan, 
2015).  In proliferating cells, the need for nucleotides is more obvious as these 
cells need to duplicate their DNA and synthesize RNA in order to divide 
(Lane and Fan, 2015). Dividing cells must be able to make new nucleotides at 
the same rate that cell division occurs (Lane and Fan, 2015). Therefore, 
during late G1 phase of the cell cycle, there is an increase in the expression of 
genes that are involved in nucleotide synthesis (Hordern and Henderson, 
1982; Lane and Fan, 2015). Nucleotide levels are also important in the 
quiescent, differentiated, neuronal cells of the nervous system. Although 
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quiescent and non-cycling, they have high metabolic activity and a high 
demand for ATP (Fasullo and Endres, 2015; Federico et al., 2012).  
 
Nucleotides as intermediates in cellular communication 
Nucleotides are also involved in cellular signaling as second 
messengers (Krawutschke et al., 2015; Seifert, 2015). Second messengers are 
produced within the cell as a response to extracellular signals (Krawutschke 
et al., 2015; Seifert, 2015). These second messengers then trigger a change 
within the cell (Krawutschke et al., 2015; Newton, 2016). Cyclic AMP is one 
of the most common second messengers within the cell (Krawutschke et al., 
2015). Cyclic GMP is another second messenger that commonly occurs and is 
used for intracellular signaling in the vascular and nervous system (Domek-
Lopacinska and Strosznajder, 2005; Krawutschke et al., 2015). Within the 
vascular system, Cyclic GMP’s regulation of the endothelial permeability and 
vascular tone lowers blood pressure (Krawutschke et al., 2015). Cyclic GMP 
also prevents the clumping of platelets (Krawutschke et al., 2015). The less 
commonly known second messengers cyclic CMP and cyclic UMP appear to be 
found in all mammals, but not in lower organisms such as E. coli (Hartwig et 
al., 2014; Seifert, 2015). This suggests that these molecules are relatively new 
and are possibly taking over activities that were not adequately fulfilled by 
the more ancient Cyclic AMP and Cyclic GMP within mammalian cells 
(Hartwig et al., 2014; Seifert, 2015).  
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The role of nucleotides in the nervous system 
 Nucleotides serve as important messengers within the nervous system 
(Averaimo and Nicol, 2014; Fasullo and Endres, 2015). For example, cAMP 
plays a crucial role in shaping the development and connectivity of neurons 
while ATP functions as a co-stimulator in motor, sensory-motor, 
hypothalamus, parasympathetic, and sympathetic nerves (Averaimo and 
Nicol, 2014; Fasullo and Endres, 2015). ATP is also important for 
neuroprotection and plays a role in stem cell derived neuro-regeneration 
(Averaimo and Nicol, 2014; Fasullo and Endres, 2015). Guanosine nucleotides 
are important for affecting glutamatergic neurotransmission via the 
stimulation of glial reuptake of L-glutamate (Deutsch et al., 2005; Fasullo 
and Endres, 2015). 
 
Nucleotide sugars as activators of metabolites for lipid synthesis  
Nucleotide sugars are used to activate metabolites which enables them 
to actively take part in different anabolic processes (Berg JM, 2002; Lane and 
Fan, 2015). Examples of such nucleotide sugars include UDP-glucose and 
other UDP hexoses which are needed for carbohydrate synthesis, CDP-
choline for lipid synthesis, GDP sugars such as GDP-mannose which is 
needed for glycosyltransferases, NAD(P) and FAD/FMN which are used for 
redox reactions, and ADP ribosylation which is used for many different 
regulatory functions (Berg JM, 2002). In order to create phospholipids, 
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diacylglyceride and alcohol must be combined, (Berg JM, 2002; Sarri et al., 
2011). In the de novo pathway, the diacylglycerol is activated. The pyrimidine 
nucleotide cytidine triphosphate (CTP) is needed in the first reaction which 
occurs between phosphatidate and CTP to form cytidine 
diphosphodiacylglyceride (CDP-diacylglycerol) (Berg JM, 2002). This 
activated product can then react with the hydroxyl group on the alcohol to 
form a phosphodiester linkage, thus creating phospholipids (Berg JM, 2002). 
The type of phospholipid produced depends on the type of alcohol involved  
(Berg JM, 2002). For example, if the alcohol is serine, the resulting 
phospholipid will be the phospholipid phosphatidyl serine (Berg JM, 2002). 
 
Nucleotides as cofactors in reactions (S-Adenosyl-L-methionine) 
S-Adenosyl-L-methionine, which is synthesized from ATP and 
methionine, is a cofactor involved in numerous enzyme-catalyzed reactions 
within the cell (Roje, 2006). It serves as a source of methyl groups for 
methylation reactions and also a precursor for the production of polyamines 
such as spermidine and spermine (Roje, 2006). In addition, it is a precursor 
for metal chelating compounds like nicotinamine and phytosiderophores 
(Broderick et al., 2014; Roje, 2006).   
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Nucleotides as electron donors  
The pyridine nucleotide NAD(H) is a mediator of electron transfer in 
many different catabolic and anabolic processes. NAD(H) is involved in the 
synthesis of ATP (Nakamura et al., 2012). NAD receives electrons and forms 
NADH (Lodish, 2000; Nakamura et al., 2012). NADH then donates these 
electrons to the electron transport chain in the mitochondria where an 
electrochemical gradient is produced in order to convert ADP to ATP (Lodish, 
2000; Nakamura et al., 2012). 
 
Nucleotides as energy carriers (ATP, GTP) 
Free energy within cells, is chemically stored, captured and 
transported (GM., 2000; Lehninger, 1993). The nucleotide triphosphates are 
important sources of chemical energy which are used to drive many different 
biochemical reactions within the cell (GM., 2000; Lehninger, 1993). Energy is 
released from these nucleotides by the hydrolysis of the terminal phosphate 
bond which releases around 30 kJ/mol of energy (Lehninger, 1993).  
Of all the nucleotides, adenosine triphosphate (ATP) is the main 
carrier of this energy within cells, although UTP, GTP, and CTP are also 
used for particular reactions (Alberts, 2002). ATP is formed by reactions that 
are driven by energy released by oxidative breakdown of foodstuff (Alberts, 
2002). Upon hydrolysis of the terminal phosphate, ATP sends energy through 
chemical pathways via the terminal phosphate group which is passed from 
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one molecule to the next (Lehninger, 1993). When this terminal phosphate is 
cleaved, ADP is left over. ADP is then recycled in the mitochondria to create 
more ATP molecules by the combination of ADP and an inorganic phosphate 
(Pi). 
ATP is often maintained at high concentrations (>1mM) in order to 
maintain cellular energy (Lane and Fan, 2015). There are other tissues in the 
body such as skeletal muscle and cardiac myocytes that maintain an ATP 
level above 5mM (Lane and Fan, 2015). This energy is then used to drive 
endergonic reactions. The other RNTPs are also kept at a certain 
concentration in order to activate and drive anabolic processes (Lane and 
Fan, 2015). Usually, out of all the nucleotides, the concentration of ATP is the 
highest, followed by UTP, then GTP and finally CTP (Lane and Fan, 2015). 
Within normal human cells, ATP is 2537+1,217 µM, GTP is 232+202 µM, 
UTP 227+321 µM and CTP 83+133 µM  (Traut, 1994). Within tumor cells, 
ATP is 3134+2,135 µM, GTP 473+214 µM, UTP 686+542 µM, and CTP 
402+252 µM (Traut, 1994). 
 
The process of purine synthesis and catabolism in the cell 
De novo nucleotide synthesis 
The term de novo is Latin in origin and means “as if for the first time” or 
“anew” (Merriam-Webster, 2017). As the name suggests, in this mode of 
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nucleotide synthesis, purine nucleotides are synthesized from basic 
components which include phosphoribosyl pyrophosphate (PRPP), glutamine, 
and glycine (Berg JM, 2002; Fasullo and Endres, 2015). Purines are 
constructed with the purine base already attached to the ribose ring, in other 
words, PRPP serves as the base on which purine nucleotides are built step by 
step  (Figure 2) (Berg JM, 2002; Lane and Fan, 2015). Ten steps then follow 
which lead up to the creation of inosine monophosphate (IMP) (Figure 2) 
(Berg JM, 2002). IMP can then go down the branch of either one of two 
pathways to produce the final product of GTP or ATP (Figure 2).  
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The salvage pathway 
Free purine bases derived from the diet or the outside environment can 
be attached to PRPP to create purine nucleoside monophosphates, rather 
than being made from scratch (Berg JM, 2002; Lane and Fan, 2015). This is 
referred to as the “salvage pathway” in contrast to the de novo pathway. 
Whether cells use the salvage pathway or the de novo pathway depends on 
Figure 2 De novo purine nucleotide synthesis pathway. The purine base is built on the ribose 
ring PRPP by amidotransferase and transformylation reactions. IMP is the branch point for 
purine synthesis as it can be converted to either AMP or GMP via two separate arms of the 
pathway. The arm leading to AMP needs GTP as energy, while the arm leading to GMP 
needs ATP as energy (green arrows). In red are amino acids which contribute to purine 
nucleotide synthesis. 
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factors such as growth conditions and the tissue type (Lane and Fan, 2015). 
There are two enzymes that are involved in the recovery of purine bases: 
adenine phosphoribosyltransferase (APRT), which catalyzes the production of 
adenine monophosphate (AMP), and hypoxanthine-guanine 
phosphoribosyltransferase (HGPRT), which catalyzes the production of 
guanosine monophosphate (GMP) in addition to inosine monophosphate 
(IMP) which is the precursor for both AMP and GMP (Berg JM, 2002; Torres 
and Puig, 2007).  
 
Adenine + PRPP               AMP + PPi 
Guanine + PRPP               GMP+ PPi 
Hypoxanthine + PRPP               IMP + PPi 
 
The salvage process saves a lot of energy in comparison with the de 
novo pathway (Berg JM, 2002). In order to create GMP and IMP, HGPRT 
salvages the free purine bases hypoxanthine (Torres and Puig, 2007). 
Monophosphates can also be salvaged from the constant turnover of RNA 
within the cell (Lane and Fan, 2015). The breakdown of RNA and DNA 
within the cells releases nucleotide monophosphates, which can then be 
phosphorylated by nucleotide kinases (Lane and Fan, 2015).  
 
APRT 
HGPRT 
HGPRT 
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Regulation of synthesis 
Many of the enzymes that are involved in nucleotide biosynthesis are 
regulated allosterically, namely, by feedback inhibition of pathway products. 
Feedback inhibition is a way to thwart the production of more nucleotides 
when the amount is more than what the cells can utilize (Lehninger, 1993). 
In this way, the rate of nucleotide end product production is balanced to the 
needs of the cell (Lehninger, 1993).  The synthesis of purines is regulated by 
AMP and GMP inhibition of PRPP synthetase, which limits PRPP production 
(Berg JM, 2002; Lane and Fan, 2015). Interestingly, HGPRT reduces the 
amount of de novo synthesis while concurrently salvaging bases because its 
products IMP and GMP both inhibit PRPP (Berg JM, 2002). PRPP 
amidotransferase is also inhibited allosterically by the binding of ATP, ADP, 
and AMP at one site on the enzyme and GTP, GDP, and GMP at another site 
(Herve, 1989; Lane and Fan, 2015). On the other hand, PRPP 
amidotransferase activity is stimulated by PRPP (Johnson et al., 2002; Lane 
and Fan, 2015). Another locus of allosteric regulation occurs when IMP is 
converted to XMP or adenylosuccinate: AMP suppresses adenylosuccinate 
synthetase and GMP suppresses inosine monophosphate dehydrogenase 
(IMPDH) (Berg JM, 2002; Lane and Fan, 2015). In addition to this, GTP is 
needed for AMP production and ATP is needed for GMP production (Figure 2, 
green arrows) (Berg JM, 2002). This co-dependent regulation balances 
adenine and guanine nucleotide synthesis within the cell because increasing 
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amounts of ATP results in increased GMP production and vice versa (Berg 
JM, 2002). The production of deoxyribonucleotides for ribonucleotides is also 
allosterically regulated (Berg JM, 2002). The binding of dATP to 
ribonucleotide reductase inhibits its activity, while the binding of ATP 
reverses this inhibition (Berg JM, 2002). 
 
Catabolism of purine nucleotides 
The breakdown of nucleotides is necessary for the maintenance of 
nucleotide pools (Fasullo and Endres, 2015; Rampazzo et al., 2010). Purine 
Figure 3. Pathways for purine catabolism in animals. The catabolism of the various 
purine nucleosides converges in the synthesis of uric acid. 
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bases cannot be completely broken down (Garrett, 1995). Purine nucleotides 
are first changed into nucleosides by intracellular nucleotidases (Figure 3) 
(Champe, 1994; Garrett, 1995). Adenosine is then converted into inosine by 
adenosine deaminase (Figure 3)  (Champe, 1994; Garrett, 1995). The purine 
bases and the sugars are then released from inosine, xanthosine, and 
guanosine. All the bases are then converted to xanthine which is then 
converted to the final product uric acid (Figure 3) (Champe, 1994; Fasullo 
and Endres, 2015; Garrett, 1995). When the enzymatic activity of xanthine 
oxidase is excessive, the result is abnormally high production of uric acid and 
reactive oxygen species (ROS) (Fasullo and Endres, 2015). Uric acid is not 
efficiently absorbed by the blood, which can result in crystal formation 
(Fasullo and Endres, 2015; Steiger and Harper, 2014). These crystals can 
cause a type of inflammation known as gout (Fasullo and Endres, 2015; 
Garrett, 1995; Steiger and Harper, 2014).  
 
Purine nucleotide salvage deficiencies and neurological pathologies  
Neurons are highly metabolically active even though they are non-
cycling (Fasullo and Endres, 2015; Federico et al., 2012). As a result, they 
have a high demand for ATP (Federico et al., 2012).  They rely more heavily 
on the salvage pathway, rather than the de novo pathway, for nucleotide 
production (Fasullo and Endres, 2015). In tissues of the nervous system, the 
reliance on the de novo pathway for nucleotide productions decreases as a 
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human approaches adulthood (Fasullo and Endres, 2015). Unsurprisingly, 
HGPRT is localized to the cells of the nervous system and is found in high 
concentrations within the brain tissue (Ceballos-Picot et al., 2009; Fasullo 
and Endres, 2015). For this reason, mutations in genes which code for 
enzymes involved in the salvage pathway, particularly those that are found 
in high amounts within the nervous system and brain like HGPRT, result in 
neurological pathologies such as neurodegeneration, and behaviors like self-
mutilation by biting (Fasullo and Endres, 2015).  
The devastating disease called Lesch-Nyhan syndrome results from 
mutations in the gene that codes for HGPRT. Because the nervous system is 
severely impacted by the mutation in this gene, it is no surprise that a 
number of cognitive and behavioral abnormalities result from this disease 
(Fasullo and Endres, 2015; Fu et al., 2014). In addition, there is excessive 
production of uric acid (Fu et al., 2014). This buildup of uric acid results in its 
crystallization in different areas of the body such as is in the urogenital 
system and in the joints (Fu et al., 2014). Urogenital system buildup results 
in renal failure often within the first ten to twenty years of the patients’ lives 
(Fasullo and Endres, 2015; Fu et al., 2014).  
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Purine nucleotide salvage deficiencies and mitochondrial depletion 
syndromes 
Mitochondrial depletion syndromes (MDS) are autosomal and rare in 
occurrence (El-Hattab and Scaglia, 2013; Mandel et al., 2001; Rahman and 
Poulton, 2009). These disorders result in reduced energy production in 
tissues and organs that are affected (El-Hattab and Scaglia, 2013; Elpeleg, 
2003; Rahman and Poulton, 2009). There are three major types of MDS: 
myopathic, encephalomyopathy, and hepatocerebral (Mandel et al., 2001). 
The hepatocerebral form of the disease is a result of mutations in the 
deoxyguanosine kinase (dGUOK) gene (Mandel et al., 2001). There have been 
a total of 22 different point mutations, deletions, and insertions reported in 
this gene. DGUOK, which together with thymidine kinase-2 initiates the 
salvage pathway, is responsible for providing most of the 
deoxyribonucleotides required for mtDNA synthesis (Mandel et al., 2001). 
This enzyme plays an important role in maintaining a balanced pool of 
deoxyribonucleotides within the mitochondria (Mandel et al., 2001). 
 
Deficiencies of the purine de novo synthesis pathway which result in 
immunodeficiency  
Mature T-lymphocytes, an important component of our immune 
system, need nucleotides for their survival (Quemeneur et al., 2003). When T-
cells are activated in response to some immunological challenge, they need to 
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increase their pyrimidine and purine pools (Quemeneur et al., 2003). These 
nucleotides regulate the proliferation and the survival of these cells as well 
as the cell cycle progression (Quemeneur et al., 2003).  
GTP in particular appears to be of extreme importance for T-cell 
function (Nguyen et al., 2015; Yokota, 2002). Reasons for this include the fact 
that G-protein intercepts the connecting of the T-cell receptor to 
phospholipase C7 during antigen induced receptor signal (Yokota, 2002).  It is 
believed that guanine nucleotides are second messengers in the alternate 
CD28 mediated pathway for T cell activation (Yokota, 2002). This is 
supported by the fact that the stimulation of CD28 results in increased 
intracellular cGMP levels (Yokota, 2002). The need for GTP for immune 
function is further demonstrated by the fact that if there is a deficiency of the 
enzyme purine nucleoside phosphorylase, an enzyme involved in purine 
nucleotide metabolism (Papinazath et al., 2011), guanine ribonucleotides 
levels are reduced and severe T-cell immune deficiency results (Yokota, 
2002).  
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Pyrimidine synthesis and catabolism  
De novo pyrimidine synthesis 
Pyrimidine nucleotides are synthesized from basic components that  
 
include carbamoyl phosphate, aspartate, and PRPP (Figure 4) (Fasullo and 
Endres, 2015; Levine et al., 1974). Unlike what occurs in purines, the 
pyrimidine base is created first and then attached to the activated ribose 
PRPP (Figure 4) (Berg JM, 2002; Lane and Fan, 2015).  
Figure 4. De novo pyrimidine nucleotide synthesis pathway. Unlike purines, the ring 
structure of the pyrimidine is assembled as a free base and not built on PRPP. PRPP is 
added to the first completely formed pyrimidine base, orotic acid, resulting in OMP. 
OMP is then converted into UMP, which becomes phosphorylated to UDP. UDP then 
eventually becomes dTMP or CTP. 
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The pyrimidine salvage pathway 
In the case of pyrimidine nucleotides, the base uracil can be salvaged 
by its direct conversion to UMP by the enzyme uracil 
phosphoribosyltransferase (Li et al., 2007; Moffatt and Ashihara, 2002). The 
nucleosides cytidine and uridine can be converted to CMP and UMP by the 
enzyme uridine kinase (Moffatt and Ashihara, 2002). UMP can then be 
phosphorylated by UMP/CMP kinase (CMPK1) to make UDP (Hsu et al., 
2005; Zauri et al., 2015). Nucleotide diphosphate kinase can then 
phosphorylate this and produce UTP (Lascu and Gonin, 2000; Vieira et al., 
2015). In the case of thymine, a ribose can be added to it by thymidine 
phophorylase to form the nucleoside thymidine (Elamin et al., 2016; 
Spinazzola et al., 2002). Thymidine can also be taken up into cells via 
transport proteins (Zupanc and Horschke, 1996). 
Thymidine kinase can phosphorylate thymidine to produce dTMP 
(Zupanc and Horschke, 1996). Thymidylate kinase can phosphorylate dTMP 
to produce dTDP, which can be phosphorylated into dTTP (Zupanc and 
Horschke, 1996). Cytidine can be converted by cytidine deaminase into 
uridine (Lane and Fan, 2015). Uridine-cytidine kinase can phosphorylate 
cytidine and produce CMP (Lane and Fan, 2015). CMPK1 can phosphorylate 
CMP and produce CDP which can be phosphorylated by nucleoside 
diphosphate kinase to produce CTP (Zauri et al., 2015). Cytidine and 
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deoxycytidine can be salvaged via the enzyme cytidine deaminase 
(Chabosseau et al., 2011; Lane and Fan, 2015; Zupanc and Horschke, 1996).  
 
Regulation of pyrimidine synthesis 
 Pyrimidine synthesis can be regulated on the level of CAD gene 
expression (Evans and Guy, 2004). The expression of CAD is controlled at 
both the transcriptional and posttranscriptional level (Evans and Guy, 2004). 
Expression increases when cells go from the resting phase into the 
proliferative phase (Evans and Guy, 2004). 
 The synthesis of pyrimidines is also subject to metabolic control via 
feedback inhibition. UTP inhibits the CPSII domain of the trifunctional 
enzyme CAD (which consists of carbamoyl-phosphate synthetase, aspartate 
transcarbamylase, and dihydroorotase) (Liao et al., 1986; Liu et al., 1994; Ng 
et al., 2015). On the other hand, PRPP allosterically activates CPSase 
activity (Evans and Guy, 2004). CTP inhibits the ATCase portion of CAD by 
binding to it and inducing a conformational change to an inactive form of the 
enzyme (Lehninger, 1993). ATP counteracts this CTP induced conformational 
shift (Lehninger, 1993). It has been found that CAD activity is also regulated 
by phosphorylation of PKA at two separate sites on the enzyme (Carrey et al., 
1985). Phosphorylation results in the activation of the carbamoyl phosphate 
synthetase activity by decrease the ATP Km (Carrey et al., 1985). UTP 
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inhibition is also greatly reduced as a result of this phosphorylation (Carrey 
et al., 1985). 
 The reduction of ribonucleotides to deoxyribonucleotides is regulated 
allosterically (Lehninger, 1993). There are two binding sites on the enzyme—
one site regulates the overall activity of the enzyme, while the second site 
regulates the substrate specificity (Lehninger, 1993). The binding of dATP to 
the activity regulation site actually reduces the activity of ribonucleotide 
reductase because it signals that there is an excessive amount of 
deoxyribonucleotides (Lehninger, 1993). On the other hand, the binding of 
ATP signals just the opposite, resulting in increased activity (Lehninger, 
1993). The binding of ATP or dATP to the substrate specificity site increases 
the reduction of the pyrimidine nucleotides UDP and CDP (Lehninger, 1993). 
TTP binding facilitates GDP reduction (Lehninger, 1993). As the amount of 
dGTP increases, this in turn will stimulatinke ATP reduction to dATP 
(Lehninger, 1993). 
 
Catabolism of pyrimidine nucleotides 
 The pyrimidine ring, unlike the purine, can be cleaved, opened, and 
degraded to structures that are easily absorbed by the bloodstream (Champe, 
1994; Garrett, 1995). Pyrimidines are typically broken down by nucleotidases 
and nucleoside phosphorylases (Fasullo and Endres, 2015). These enzymes 
remove the base from the sugar (Champe, 1994; Fasullo and Endres, 2015). 
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Within mammalian cells, cytosine is broken down into uracil and then uracil 
is broken down by reduction to dihydrouracil (Canellakis, 1956; Fink et al., 
1956a; Fink et al., 1956b). The ring is then opened resulting in β-
ureidopropionase acid and then decarboxylation occurs which produces NH3, 
β-alanine, and CO2 (Canellakis, 1956; Champe, 1994; Fink et al., 1956a; Fink 
et al., 1956b; Garrett, 1995). β-alanine can be recycled and used as a 
precursor for acetyl-CoA synthesis (Champe, 1994; Garrett, 1995). This 
breakdown mainly occurs within the liver (Canellakis, 1956; Dagg et al., 
1964). Thymidine is broken down into aminoisobutyric acid, which can be 
recycled as a precursor for succinyl CoA synthesis (Champe, 1994; Garrett, 
1995; Nielsen et al., 1974). 
 
Pyrimidine nucleotide salvage deficiencies 
There are a number of diseases that result from mutations in enzymes 
involved in the salvage of thymidine such as thymidine kinase II and 
thymidine phosphorylase (Ferraro et al., 2006). Thymidine kinase is 
necessary for mitochondrial dNTP synthesis (Fasullo and Endres, 2015). 
Mutations in this gene cause muscular dysfunction which often results in 
death by respiratory failure as an infant (Fasullo and Endres, 2015; Kalko et 
al., 2014; Tyynismaa et al., 2012). Muscle cells require a lot of functioning 
mitochondria because of the large energy expenditure (Gouspillou and 
Hepple, 2016). In addition to this, mitochondria are involved in the 
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regulation of a number of different processes in the muscle such as 
metabolism, energy sensitive signaling pathways, reactive oxygen species 
production and signaling, calcium homeostasis and apoptosis regulation 
(Gouspillou and Hepple, 2016). Therefore, any mitochondrial dysfunction 
would largely manifest within the muscle tissue. 
 
De novo pyrimidine nucleotide synthesis deficiencies 
The rare genetic disorder called Miller syndrome can be traced to a 
mutation in dihydroorotate dehydrogenase (DHODH), an enzyme involved in 
the fourth step of pyrimidine synthesis, which occurs in the mitochondria (Ng 
et al., 2015). This disease is characterized by abnormalities of the ear and 
eye, micrognathia, skeletal abnormalities, developmental issues, and 
gastrointestinal irregularities (Ng et al., 2015). DHODH plays a role in NF-
кB activity, which is important during development (Kinoshita et al., 2011). 
It is believed that the malfunctioning enzyme interferes with NF-кB during 
development and results in abnormal cell migration, reduced cellular 
proliferation, and an abnormally high amount of apoptosis (Kinoshita et al., 
2011). This then results in the physical abnormalities characteristic of this 
syndrome (Kinoshita et al., 2011). 
Abnormalities in uridine monophosphate synthetase (UMPS), another 
gene involved in de novo pyrimidine nucleotide synthesis, result in hereditary 
orotic aciduria (Fasullo and Endres, 2015). This disease is characterized by 
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growth deficiency, intellectual impediments, megaloblastic anemia and the 
excretion of orotic acid in the urine (Ng et al., 2015). Symptoms can be 
relieved by administration of uridine (Becroft and Phillips, 1965; Haggard 
and Lockhart, 1967).   
 
De novo pyrimidine nucleotide synthesis and immunodeficiency  
Both B and T lymphocytes primarily depend on de novo nucleotide 
synthesis (Quemeneur et al., 2003) due to a lack of the salvage pathway 
enzyme HGPRT (Busuttil, 2014). It thus comes as no surprise that if key 
enzymes involved in de novo nucleotide synthesis are non-functioning or 
inhibited, impaired immune function results from lack of lymphocyte 
proliferation. It has been found that a lack of pyrimidines, in particular, 
induces apoptosis in activated lymphocytes (Quemeneur et al., 2003). A point 
mutation in one rate limiting enzyme involved in de novo nucleotide 
synthesis, CTP synthase 1 (CTPS1), causes immunological dysfunction 
(Kucuk et al., 2016; Martin et al., 2014). The mutation affects a splice donor 
site resulting in the production of an abnormal transcript lacking exon 18 
(Martin et al., 2014). This deleterious mutation results in CTPS1 not being 
expressed in the B and T cells of these patients (Martin et al., 2014). In the 
patients studied, frequent and severe infection, both bacterial and viral, were 
observed (Kucuk et al., 2016; Martin et al., 2014).  Most of the viral infections 
could be traced to herpes viruses such as Epstein-Barr virus, and varicella 
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zoster virus (Kucuk et al., 2016; Martin et al., 2014). As a result of the 
Epstein-Barr virus, some patients eventually developed non-Hodgkin 
lymphoma and some even died (Martin et al., 2014).  
 
Inosine monophosphate (IMPDH) and de novo nucleotide 
synthesis 
The IMPDH reaction 
IMPDH is responsible for taking IMP, which is the common precursor 
of both GTP and ATP, and catalyzing the first committed step to GTP 
synthesis: the conversion of IMP into xanthosine monophosphate (XMP) 
(Figure 2) (Hedstrom, 2009). This process involves the catalysis of two 
different steps: first there is a dehydrogenase reaction which forms NADH 
and a covalent intermediate (E-XMP*) (Hedstrom, 2009). Second, there is a 
hydrolysis reaction in which E-XMP* is cleaved to release XMP (Hedstrom, 
2009).  This sends IMP down the arm of the pathway which creates the 
guanosine nucleotides. In this way, IMPDH is the gateway to guanosine 
nucleotide production. This de novo GMP producing pathway appears to exist 
in virtually every organism except for protozoan parasites like Giardia 
lamblia and Trichomonas vaginalis (Carlton et al., 2007; Morrison et al., 
2007).  Both Trichomonas vaginalis and Giardia lamblia appear to lack the 
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ability to perform de novo nucleotide synthesis and instead rely on the 
salvage pathway (Jarroll et al., 1989; Smyth, 1995). 
 
The structure of IMPDH 
Generally, IMPDH monomers consist of two domains: the catalytic and 
the regulatory domain (Figure 5A)  
 
(Hedstrom, 2009; Makowska-Grzyska et al., 2012). The regulatory domain 
consists of a tandem CBS pair forming what is called a Bateman domain 
(Kemp, 2004).  The Bateman domain is not essential for IMPDH activity and 
there are a few organisms with IMPDH that does not contain them such as B. 
A B C 
Figure 5. Crystal structure of IMPDH. A) Monomer of IMPDH. In purple is the catalytic 
domain, in mustard is the CBS domain. B) Tetramer of IMPDH, each color depicts a 
single monomer. C) Octameric subunit of IMPDH, each color depicts one of the two 
tetramers. PDB ID 1NFB. 
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burgdorferi, the parasite that causes Lyme disease in humans, and C. 
parvum, a parasite of the mammalian digestive tract (Hedstrom, 2009). 
These monomers come together into tetramers (Figure 5B) (Hedstrom, 2009; 
Sintchak et al., 1996). Each IMPDH tetramer has a central square-like region 
which is where the catalytic domains are located, while the CBS domains 
project from the tetramer corners, away from the catalytic domain (Figure 
5B) (Hedstrom, 2009). The link between the catalytic domain and the 
subdomain is flexible and therefore these domains can take on various 
relative orientations which can vary by as much as 120 degrees (Colby et al., 
1999; Hedstrom, 2009). Labesse et al. (Labesse et al., 2013) discovered that in 
Pseudomonas aeruginosa and human IMPDH1, two tetramers can interact to 
form octamers (Figure 5C). The octameric structure of Pseudomonas 
aeruginosa was recently solved by X-ray crystallography (Labesse et al., 
2013).  Analytical ultracentrifugation also revealed these IMPDHpa to have a 
sedimentation coefficient that corresponds to an octamer (Labesse et al., 
2013). Size exclusion chromatography has also verified this octameric 
structure (Labesse et al., 2013). Furthermore, purified human IMPDH1 was 
revealed to form octamers (Labesse et al., 2013). Human IMPDH2 has been 
found to form octamers as well, but this octameric state has not been found 
for IMPDHs from all organisms (Alexandre et al., 2015). Alexandre et al. 
(Alexandre et al., 2015) studied IMPDH from a number of different human 
pathogenic bacterial species. They found that there were some species with 
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octameric IMPDH, which they refer to as Class I IMPDHs (Alexandre et al., 
2015). But there were other species of bacteria that had tetrameric IMPDH 
(Alexandre et al., 2015). These were referred to as Class II IMPDHs 
(Alexandre et al., 2015). 
 
The role of the Bateman domain and nucleotides in the regulation of 
IMPDH activity  
 The Bateman domains are extremely conserved, being found in many 
different types of proteins in a wide variety of organisms from archaebacteria 
Figure 6. Octamers take on different conformations based on the type of nucleotide that 
binds. The binding of GTP to the Bateman domain results in a “closed” confirmation 
where the central catalytic domains are close to each other. This brings two finger 
domains together, resulting in decreased enzymatic activity. The binding of ATP on the 
other hand results in an “open” octamer state. 
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to eukaryotes (Ignoul and Eggermont, 2005; Thomas et al., 2012). They are 
known for their nucleotide binding properties such as those found in the 
master regulator of cellular energy—AMP kinase (AMPK) (Ignoul and 
Eggermont, 2005). AMPK is activated by binding AMP, which signals low 
cellular ATP levels and thus low energy levels (Ignoul and Eggermont, 2005; 
Xiao et al., 2013; Xiao et al., 2011). This results in the activation of catabolic 
pathways such as fatty acid oxidation and the halting of anabolic pathways 
such as fatty acid and cholesterol synthesis (Ignoul and Eggermont, 2005; 
Mihaylova and Shaw, 2011). The importance of this domain is demonstrated 
by the fact that mutations in the Bateman domain have been associated with 
a number of diseases (Thomas et al., 2012) such as Wolff-Parkinson-White 
syndrome (which occurs due to mutations in AMPK’s Bateman domain), 
congenital myotonia (Bateman domain of CLCN1 chloride channel), and 
homocystinuria (Blair et al., 2001; Pusch, 2002; Shan et al., 2001). A 
missense mutation in IMPDH’s Bateman domain causes Leber congenital 
amaurosis and retinitis pigmentosa (Buey et al., 2015).  These domains have 
also been associated with the maintenance of balanced nucleotide pools 
within the cell (Pimkin and Markham, 2008; Pimkin et al., 2009). It has been 
found that if this domain is deleted in bacterial IMPDH, the cell is no longer 
capable of maintaining balanced levels of ATP and GTP (Pimkin and 
Markham, 2008; Pimkin et al., 2009). And although the Bateman domain is 
not necessary for IMPDH activity, it has been found that the binding of 
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nucleotides such as GTP and ATP to this domain of IMPDH in certain 
organisms influences activity (Buey et al., 2015; Labesse et al., 2013). 
Labesse et al. (Labesse et al., 2013) found that ATP binding to two sites in 
the Pseudomonas aeruginosa CBS domain of IMPDH significantly increased 
IMPDH activity, while ATP binding to human IMPDH1 had no effect on 
activity. Furthermore, they found that the binding of ATP induced a 
conformational change in the octamer, forcing it to take on an “open” 
conformation, where the enzymatic domains of the two tetramers are far 
apart (Labesse et al., 2013). Interestingly, guanine nucleotide binding has 
also been found to induce a conformational change but this results in 
inhibition of IMPDH activity in the eukaryotic protein (Buey et al., 2015). 
Rather than the open octamer that ATP binding induces, guanine nucleotide 
binding induces a closed octamer conformation (Buey et al., 2015).  This 
closed octamer brings the finger domains, which are four-stranded beta 
sheets projecting from the IMPDH monomers, into contact with each other 
(Buey et al., 2015). This is believed to result in the protein losing its affinity 
for the substrate IMP thus leading to a loss of enzymatic activity (Buey et al., 
2015). 
 
Activation of IMPDH by monovalent cations 
 It has been found that all IMPDHs are activated approximately 
hundredfold by potassium and other similarly sized monovalent cations such 
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as NH4+ or Rb+ (Xiang et al., 1996). Some IMPDHs are activated or inhibited 
by smaller ions like Na+ (Hedstrom, 2009; Heyde and Morrison, 1976; Xiang 
et al., 1996; Zhou et al., 1997). Human IMPDH2 is activated by K+, NH4+, Na+ 
and Li+ (Hedstrom, 2009; Heyde and Morrison, 1976; Xiang et al., 1996; Zhou 
et al., 1997).  K+ does not appear to affect tetramer stability (Hedstrom, 2009; 
Heyde and Morrison, 1976; Xiang et al., 1996; Zhou et al., 1997). K+ activates 
IMPDH by acting as a “ball and socket” joint that expedites the 
conformational changes necessary to complete the catalytic cycle (Riera et al., 
2011). 
 
Isoforms of IMPDH 
In mammalian cells, there are two isoforms: IMPDH1 and IMPDH2. 
These are encoded by two separate genes (Glesne et al., 1993; Gu et al., 1994; 
Zimmermann et al., 1995). Eighty-four percent of the amino acids are 
identical between these two isoforms, but they are expressed differently in 
various tissues of the body (Gu et al., 1997). IMPDH2 is dominant in most 
tissues and has increased expression in proliferating cells (Gu et al., 1997; 
Zimmermann et al., 1995). On the other hand, IMPDH1 generally has a low 
expression but is highly expressed in certain tissues like the brain, kidney, 
spleen, and pancreas (Gu et al., 1997). In the rat retina, it was found that 
IMPDH2 is highly expressed during development, but after eye opening 
IMPDH1 is highly expressed (Gunter et al., 2008; Thomas et al., 2012). The 
33 
 
expression of IMPDH1 is also dominant in the retina of adult humans 
(Gunter et al., 2008). In addition to this, human photoreceptors have novel 
IMPDH1 mRNAs which are a product of alternative splicing (Bowne et al., 
2006; Xu et al., 2008). 
 
Moonlighting functions of IMPDH  
Using Drosophila as the model organism, IMPDH cellular localization 
was found to be regulated by the cell cycle (Kozhevnikova et al., 2012).  It was 
found to localize to the nucleus during the end of the S and throughout the 
G2 phases (Kozhevnikova et al., 2012). Kozhevnikova et al. (Kozhevnikova et 
al., 2012) also found that oxidative stress results in the nuclear localization of 
IMPDH. Via ChIP-qPCR it has been discovered, that IMPDH binds to all five 
histone genes, E2F, and various other genes, within the nucleus 
(Kozhevnikova et al., 2012). These genes possess a variety of functions which 
include transcriptional regulation, signaling and development (Kozhevnikova 
et al., 2012). The knockdown of IMPDH results in a significant increase in 
the expression levels of histone mRNA and protein levels (Kozhevnikova et 
al., 2012). This depletion of IMPDH also results in the upregulation of the 
other IMPDH target genes (Kozhevnikova et al., 2012). These results suggest 
that IMPDH is acting as a transcriptional repressor (Kozhevnikova et al., 
2012). In addition, the Bateman domains of IMPDH have been found to bind 
to CT rich, single stranded regions within the genome (Kozhevnikova et al., 
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2012). Mutations in the Bateman domain that are associated with retinitis 
pigmentosa have been shown to abrogate the ability of IMPDH to bind to 
these CT rich single stranded DNA regions (Mortimer and Hedstrom, 2005; 
Mortimer et al., 2008; Spellicy et al., 2007). These CT rich regions of the 
genome have a tendency to unwind into single strands and are associated 
with gene control (Kozhevnikova et al., 2012). IMPDH1 binds to the upper, 
single strand CT-rich regions within the loci of genes that it regulates such as 
the His3-His4 promoter, Mlc2 and E2F (Kozhevnikova et al., 2012). 
IMPDH has also been found to associate with polyribosomes, which 
suggests that it could play some role in translation regulation (Cornuel et al., 
2002; McLean et al., 2004; Spellicy et al., 2007). Retinal IMPDH1 associates 
with rhodopsin mRNA-translating polyribosomes (Mortimer and Hedstrom, 
2005; Mortimer et al., 2008; Spellicy et al., 2007). If there is any interference 
of rhodopsin expression, apoptosis of photoreceptor cells occurs (Mortimer 
and Hedstrom, 2005; Mortimer et al., 2008). In light of this, it is unsurprising 
that mutations in IMPDH1 and not IMPDH2 result in retinal diseases.  
IMPDH associates with a number of different proteins including 
protein kinase B, glutamate dehydrogenase, and proteins involved in 
transcriptional regulation (Ingley and Hemmings, 2000). It has also been 
observed that the expression of the tumor suppressor p53 attenuates IMPDH 
activity (Ingley and Hemmings, 2000; Sherley, 1991). 
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Therapeutic targeting of IMPDH activity  
 Because pathogenic bacteria and viruses often rely on their rapid 
proliferation for successful infection, as a rate-limiting enzyme, IMPDH is an 
attractive therapeutic target. In addition, the reliance of lymphocytes on the 
de novo pathway makes the inhibition of IMPDH an effective 
immunosuppressant (McKeran and Watts, 1976; Quemeneur et al., 2003; 
Sintchak et al., 1996). IMPDH1 and 2 gene amplifications and increased 
mRNA expression have been found in a variety of different cancers including, 
but not limited to, brain cancer, ovarian cancer, melanomas, cancer of the 
bladder, renal cell carcinomas, and uterine cancers (Konno et al., 1991; Majd, 
2014; Nagai et al., 1991; Natsumeda et al., 1990). IMPDH inhibitors such as 
mycophenolic acid (MPA), ribavirin, and others are currently being used, are 
in clinical trials, or are beginning to be explored for use as clinical 
therapeutics for infections, immunosuppressants, and neoplastic disease 
(Yokota, 2002). 
 
MPA 
 MPA was first isolated and purified from spoiled corn (Bentley, 
2000). It had demonstrated an anti-microbial ability as it was first found to 
inhibit the growth of Bacillus anthracis (Bentley, 2000). Because MPA is a 
strong inhibitor of mammalian IMPDH as well, it has not been used as an 
antibiotic (Hedstrom, 2009). MPA inhibits IMPDH by trapping the covalent 
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intermediate (E-XMP*) in the IMPDH reaction (Fleming et al., 1996). It 
wasn’t until many years after its discovery that MPA made its way into the 
clinic as an immunosuppressant drug, primarily used to prevent the rejection 
of transplanted organs in patients (Hedstrom, 2009). As lymphocytes of the 
immune system are dependent on de novo guanine nucleotide synthesis for 
their function (Quemeneur et al., 2003), the inhibition of IMPDH was a 
feasible way to achieve this goal.  MPA has also been used for psoriasis 
treatment (Hedstrom, 2009). In addition, there is now interest in MPA as a 
potential anti-cancer treatment because of its antiangiogenic activity: it has 
been found to induce differentiation, replication arrest, and/or cell death in 
many different cancer cell lines such as breast, prostate, melanoma, 
leukemia, and neuroblastoma (Bacus et al., 1990; Chen and Pankiewicz, 
2007; Floryk and Huberman, 2006; Floryk et al., 2004; Kiguchi et al., 1990; 
Messina et al., 2004).  In vitro studies have demonstrated that a lot of cancer 
cells produce GTP via the de novo nucleotide synthesis pathway by 
upregulating IMPDH (Natsumeda et al., 1984; Tong et al., 2009). GTP levels 
are also more elevated than those of ATP in many different cancer types 
(Traut, 1994). Therefore, this antitumor effect of MPA is believed to be linked 
to its inhibition of IMPDH (Majd et al., 2014). 
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Ribavirin 
 Ribavirin, another IMPDH inhibitor, is a nucleoside analog (Witkowski 
et al., 1972). Ribavirin is one of the treatments given to Hepatitis C patients 
(Gish, 2006). It is also used to treat respiratory syncytial virus (Wyde, 1998), 
and Lassa fever virus infections (McCormick et al., 1986). Once ribavirin is 
taken into the cell, it is activated by adenosine kinase and becomes ribavirin 
5’-monophosphate (RVP) (Gish, 2006). In this form, it is an extremely 
effective inhibitor of IMPDH. However, RVP is then transformed even 
further. It becomes a ribavirin triphosphate (RTP) and, in this form, it is an 
inhibitor of RNA capping enzymes (Smith RA, 1980). As a triphosphate, it 
also has the ability to inhibit virus RNA polymerases (Cassidy and Patterson, 
1989; Eriksson et al., 1977) and RTP can be used by viral RNA polymerase 
and become a part of the RNA (Crotty et al., 2000). Because ribavirin inhibits 
IMPDH as well, there is a reduction of wild type competitor nucleotides and 
an increase in RTP incorporation (Crotty et al., 2000). Once incorporated, the 
base changes conformation from syn to anti and becomes locked in that form 
(Crotty et al., 2000). In this form, it easily forms base pairs with incoming 
pyrimidines, which results in deleterious mutations, bringing the virus to 
“error catastrophe” (Crotty et al., 2000). It is believed to be a combination of 
all of these properties that contribute to the anti-viral properties of ribavirin 
(Graci and Cameron, 2006; Parker, 2005).  
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Other inhibitors of IMPDH 
 Another IMPDH inhibitor called mizoribine has been used as a drug 
for immunosuppression and rheumatoid arthritis (Ishikawa, 1999). It inhibits 
the proliferation of T and B cells (Yokota, 2002). Mizoribine is an imidazole 
nucleoside (Yokota, 2002). Once taken into cells, it is activated by 
phosphorylation by adenosine kinase and then inhibits IMPDH and GMP 
synthetase (Yokota, 2002).   
 Phenyl-oxazole urea inhibitors, similar to MPA, trap the covalent 
intermediate E-XMP*. Another such inhibitor, AVN944, has been found to 
have anti-proliferative effects against prostate cancer cell lines by triggering 
the arrest of the cell cycle in the S phase and also by inducing differentiation 
and apoptosis (Yokota, 2002).  
 Tiazofurin is a nucleoside analog that has strong antiviral and 
antitumor effects (Marquez et al., 1986). In vitro studies have shown it to be 
effective against myelogenous leukemia cells (Marquez et al., 1986). 
Tiazofurin is phosphorylated by adenosine kinase, nicotinamide riboside 
kinase and/or 5’-nucleotidase, becoming a monophosphate (Fridland et al., 
1986; Saunders et al., 1990). The monophosphate is then transformed into 
the adenine dinucleotide TAD which can then bind and inhibit the E·IMP 
and E-XMP* forms of IMPDH (Hedstrom, 2009). The amount of TAD that 
builds up is what determines the effectiveness of tiazofurin (Hedstrom, 2009). 
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 Benzamide riboside, like tiazofurin is converted into dinucleotide once 
inside of the cell (Hedstrom, 2009). In this form, it acts as a potent IMPDH 
inhibitor as is evident in the fact that it depletes guanine nucleotide pools 
within the cell (Hedstrom, 2009). 
 In a screen for natural, non-synthetic inhibitors of IMPDH, it was 
discovered that some unsaturated fatty acids inhibit both mammalian 
IMPDH isoforms including linoleic acid and eicosadienoic acid (Mejia et al., 
2013; Mizushina et al., 2007). 
 
IMPDH as filamentous structures 
Physical characteristics of IMPDH 
filaments 
 IMPDH is capable of assembling 
itself into large, filamentous structures 
within the cell (Figure 7). These filaments 
are mostly cytoplasmic in location but can 
also be found within the nucleus (Carcamo 
et al., 2014; Carcamo et al., 2011; Juda et 
al., 2014). Typically, there are only one or 
two rods within a single cell (Carcamo et 
Figure 7. IMPDH2 filaments. 
Hek293 cells treated with 100nM 
methotrexate overnight then fixed 
and stained with an anti-IMPDH2 
antibody (green). One elongated 
filament is indicated by the white 
arrow, and a loop shaped filament 
is indicated by an orange 
arrowhead. DAPI was used to 
visualize the nuclei (blue). 
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al., 2011). The filaments can take on an elongated form (Figure 7, white 
arrow), as well as elongated rings (Figure 7, orange arrowhead) and circular 
or “hairpin” structures (Carcamo et al., 2011). Electron microscopy shows 
that the filaments are not encased within a membrane and therefore likely 
consist purely of protein (Juda et al., 2014). A single filament consists of 
individual fibers of protein with repeating subunits that are about 11 microns 
in length (Juda et al., 2014).  Within mammalian cells, these filamentous 
structures are not associated with the Golgi complex, and do not contain 
proteins such as actin, tubulin, or vimentin (Carcamo et al., 2011; Ji et al., 
2006). These structures have also been ruled out as being primary cilia 
(Carcamo et al., 2011; Willingham et al., 1987).    
 
History of the discovery of IMPDH filaments 
Filamentous IMPDH structures within cells were first observed in 
1987 (Willingham et al., 1987). Using a monoclonal antibody, (Willingham et 
al., 1987) were able to identify filamentous, thread-like structures within 
several different cell types such as mouse and rat cell lines.  The researchers 
referred to these structures as nematin (Willingham et al., 1987). Using 
double label immunofluorescence to anti-nematin and anti-tubulin or anti-
vimentin, they found that nematin did not co-localize with cilia or vimentin 
(Willingham et al., 1987). Immunoprecipitation was performed in an attempt 
to identify the protein with which the antibody was reacting (Willingham et 
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al., 1987). A 58 kD protein was immunoprecipitated (Willingham et al., 1987). 
Today, it is suspected that the 58 kD protein immunoprecipitated by this 
group is IMPDH, because of the similarity in molecular weight. 
 Interestingly, (Ji et al., 2006) discovered that treatment with MPA 
triggers IMPDH to assemble into filaments. They found this to be the case in 
both normal and neoplastic cells (Ji et al., 2006). They hypothesized that 
filament assembly occurred as a result of MPA binding to IMPDH and 
causing a conformational change (Ji et al., 2006). However, the filament 
assembly was reversed upon treatment with GTP and partially reversed upon 
treatment with ATP, suggesting that assembly was associated with a 
reduction of purine nucleotide levels within the cell (Ji et al., 2006). The 
aggregation of IMPDH was also discovered to occur with purified protein (Ji 
et al., 2006). They found that IMPDH filaments did not co-localize with 
mitochondria, Golgi apparatus, endoplasmic reticulum, lipid bodies, or 
cytokeratins (Ji et al., 2006). In addition, just like the previously mentioned 
group, no other interacting proteins were found when co-immunoprecipitation 
and tandem affinity purification with tagged IMPDH were performed (Ji et 
al., 2006). 
Two years later, (Gunter et al., 2008) explored the subcellular 
distribution of transfected IMPDH protein. Like (Ji et al., 2006) they found 
that treatment with IMPDH inhibitors resulted in the assembly of IMPDH2 
into filaments, but unlike (Ji et al., 2006), they did not believe that this was 
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due solely to a conformational change induced by the binding of inhibitor 
(Gunter et al., 2008). This was supported by their finding that when 
untreated CHO cells were transiently transfected with HA tagged IMPDH2, 
the recombinant protein had a diffuse pattern, while HA tagged IMPDH1 
assembled into filaments (Gunter et al., 2008). In addition to this, when they 
inhibited the enzyme that acts just downstream of IMPDH, GMP synthetase, 
they found that IMPDH assembled into filaments (Gunter et al., 2008). 
Furthermore, they quantified GTP levels after MPA treatment using HPLC 
and found that cellular GTP levels dropped by more than 80% (Gunter et al., 
2008). Based on these results, they concluded that filament assembly was 
tied to a lack of GTP nucleotides within the cell as opposed to a 
conformational change induced by drug binding (Gunter et al., 2008). And 
because uninhibited IMPDH still localized to the filament upon GMP 
synthetase inhibition, this also suggested that polymerized IMPDH could be 
enzymatically active. 
Interestingly, (Carcamo et al., 2011) discovered filaments within HEp-
2 cells when they were stained with human autoantibodies from HCV 
patients who were receiving ribavirin treatment. They referred to these 
autoantibodies as “anti-Rods and Rings” (anti-RR) autoantibodies (Carcamo 
et al., 2011). As other groups before them, they found that these structures 
did not contain vimentin nor did they co-localize with cilia (Carcamo et al., 
2011). Furthermore, these structures did not contain tubulin or actin 
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(Carcamo et al., 2011). Using immunoprecipitation analysis, it was found 
that the autoantibody pulled down a 55 kD protein (Carcamo et al., 2011). 
Farther analysis using immunoprecipitation-Western blot confirmed that this 
immunoprecipitated 55 kD protein was IMPDH (Carcamo et al., 2011). In 
addition to this, co-staining of cells with this autoantibody and anti- IMPDH 
showed that both co-localized to the same structure (Carcamo et al., 2011). 
Thus, IMPDH2 was determined to be one of the proteins contained within 
these structures (Carcamo et al., 2011). 
 
Regulation of IMPDH filament assembly 
With few exceptions, IMPDH filaments do not assemble spontaneously 
within cultured mammalian cells and must be induced (Carcamo et al., 2011). 
It has been observed that the assembly of IMPDH into these filaments occurs 
in response to a drop in purine nucleotide levels within the cell (Calise et al., 
2016). This drop in purine levels can occur by perturbation at different points 
along the purine nucleotide biosynthesis pathway such as by inhibition of 
IMPDH. Case in point, these filaments have been found in peripheral blood 
mononuclear cells isolated from patients being treated with either MPA or 
ribavirin (Keppeke et al., 2016). Immunofluorescence and 
immunoprecipitation has been used to determine that the primary target of 
these autoantibodies is IMPDH (Carcamo et al., 2011; Keppeke et al., 2016). 
Autoantibodies against IMPDH are seen in 6% of HCV patients after only one 
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month of treatment with ribavirin. But by the sixth month, greater than 47% 
of the patients have IMPDH autoantibodies (Keppeke et al., 2016). The 
amount of the autoantibody reaches its highest after twelve months of 
treatment with ribavirin (Keppeke et al., 2016). For unknown reasons, 
patients undergoing MPA treatment are much less likely to develop these 
autoantibodies than patients being treated with ribavirin (Keppeke et al., 
2016).  
Methotrexate (MTX), a drug often used for cancer treatment, triggers 
the assembly of IMPDH into filaments within cultured mammalian cells 
(Keppeke et al., 2016). Anti-RR autoantibodies have also been found in a 
patient undergoing MTX treatment for rheumatoid arthritis (Keppeke et al., 
2016). MTX perturbation occurs at a point earlier than IMPDH along the 
purine synthesis pathway. MTX is an anti-folate. It inhibits the enzyme 
dihydrofolate reductase (DHFR), which is necessary for the conversion of 
dihydrofolate into tetrahydrofolate (THF) as shown in Figure 8 (Goodsell, 
1999; Rajagopalan et al., 2002). THF donates one carbon units for the 
production of purine nucleotides (Figure 8) (Yang and Vousden, 2016). 
Aminopterin (AMT), another inhibitor of DHFR, has an even higher affinity 
for DHFR than MTX (Calise et al., 2016).  
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Therefore, AMT induces filament assembly more potently than MTX 
(Calise et al., 2016). As is the case with the other modes of filament assembly, 
MTX or AMT induced filaments can be inhibited from assembling or can be 
disassembled upon supplementation with guanosine which supports the idea 
that it is a drop in guanine nucleotide levels that triggers filament assembly 
(Calise et al., 2016). In support of this idea, the addition of hypoxanthine to 
these MTX or AMT treated cells also prevented and disassembled IMPDH 
filaments (Calise et al., 2016). Hypoxanthine is converted in the salvage 
pathway to the precursor IMP which can then be used for GTP synthesis 
(Calise et al., 2016; Champe, 1994; Garrett, 1995). Unsurprisingly, because 
IMPDH is downstream of hypoxanthine in purine synthesis, if IMPDH is 
inhibited, hypoxanthine cannot prevent or reverse filament assembly (Calise 
et al., 2016).  
Figure 8. One carbon metabolism in nucleotide synthesis. Dietary folate is ingested and 
reduced to dihydrofolate. Dihydrofolate is then converted to tetrahydrofolate (THF) by the 
enzyme dihydrofolate reductase (DHFR). Serine hydroxymethyltransferase (SHMT) then 
converts THF to 5, 10-methylene-THF which is converted to 5, 10-methenyl-THF. 5, 10-
methenyl-THF contributes one carbon unit to the purine ring. 5, 10-methenyl-THF is then 
converted to 10-formyl-THF which donates a second one carbon unit to the purine ring. 
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It has also been found that IMPDH filaments assemble when cells are 
cultured in the standard culture media MEM which lacks serine and glycine 
(Calise et al., 2016). So, this represents yet another perturbation along the 
purine biosynthesis pathway which can induce filament assembly. In the cell, 
an enzyme called serine hydroxymethyl transferase (SHMT) catalyzes a 
reversible reaction which takes serine and converts it into glycine 
(Labuschagne et al., 2014). This reaction produces one carbon units which are 
then integrated into the THF cycle for use in nucleotide synthesis (Figure 8) 
(Labuschagne et al., 2014). The addition of glycine alone to cells cultured in 
MEM increases the amount of filaments assembled as compared to cells 
grown in just MEM (Calise et al., 2016). When Labuschagne et al. 
(Labuschagne et al., 2014) traced the intracellular fate of exogenous 
radiolabeled glycine, they found that it did not enter the one carbon cycle for 
purine production; rather it was converted into serine. Mass spectrometry 
analysis of these glycine-fed cells also showed that the flux of glycine 
downstream to AMP, ADP, GMP, and GDP is reduced (Labuschagne et al., 
2014). This depletion of cellular purines could explain the increase in 
filament assembly because IMPDH filament assembly is linked to purine 
nucleotide depletion. On the other hand, it was found that the addition of 
serine alone to MEM cultured cells inhibited filament assembly (Calise et al., 
2016). The addition of serine would send the SHMT catalyzed reaction in the 
forward direction, towards the production of one carbon units, which are then 
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available for purine production (Figure 8) (Labuschagne et al., 2014). 
Therefore, purine levels are maintained or increased within the cell and 
filaments need not assemble.  On the other hand, the addition of glycine 
would send the reaction in the opposite direction, depleting one carbon units 
and thus reducing nucleotide production. This would explain the increased 
filament assembly upon glycine addition to MEM cultured cells. 
The depletion of glutamine within a culture of mammalian cells also 
triggers a reversible assembly of IMPDH filaments (Calise et al., 2014). 
Glutamine depletion demonstrates additional points of perturbation along 
the de novo purine biosynthesis pathway (Figure2) (Calise et al., 2014). That 
a lack of glutamine triggers filament assembly is unsurprising considering 
that there are three steps in purine synthesis that require the amine-
nitrogen from glutamine to contribute to the purine ring. Therefore, without 
glutamine, there would be a lack of purine production, resulting in a purine 
deficit. Consistent with this idea, IMPDH filaments disassemble upon the 
addition of glutamine or guanosine to glutamine-depleted cells in culture 
(Calise et al., 2014). It has been noted that the disassembly of filaments 
happens quite rapidly, within 15 min  (Calise et al., 2014). 
The triggering of filament assembly also occurs with purified IMPDH 
protein. Labesse et al. (Labesse et al., 2013) discovered that incubation of 
purified human IMPDH1 with ATP, triggers filament assembly. 
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The effect of IMPDH filament assembly on catalytic activity 
The biological role that IMPDH filament assembly fulfills has 
remained elusive. Some have concluded that filament assembly was 
associated with some sort of change in the catalytic activity of the enzyme 
(Labesse et al., 2013; Scott et al., 2004) while others have not seen an 
increase in enzymatic activity associated with filament assembly (Carr et al., 
1993; Labesse et al., 2013; Mortimer and Hedstrom, 2005; Thomas et al., 
2012). The question as to what the activity state of IMPDH is while in 
filament form will be addressed in chapter 3.  
 
IMPDH can co-assemble with CTPS into filaments 
 CTPS, a rate limiting enzyme which catalyzes the conversion of UTP 
into CTP, is also capable of assembling with IMPDH into these filamentous 
structures (Figure 7) (Carcamo et al., 2011). Co-assembly of CTPS and 
IMPDH was first discovered in mammalian cells (Carcamo et al., 2011). 
Antibody staining of filaments in HEp-2 cells obtained by from INOVA 
Diagnostics Inc. revealed that the filaments contained both IMPDH and 
CTPS (Carcamo et al., 2014).  
The co-assembly of IMPDH and CTPS usually only takes place under 
certain conditions (Keppeke et al., 2015). It has been found that if cells are 
treated with an inhibitor that perturbs both pyrimidine synthesis and purine 
synthesis such as 6-diazo-5-oxo-L-norleucine (DON), cells produce filaments 
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primarily containing IMPDH, filaments primarily containing CTPS and 
filaments with a mixture of both (Keppeke et al., 2015). The mixed filaments 
consist of filaments with various proportions of IMPDH and CTPS (Keppeke 
et al., 2015). The propensity to assemble mixed filaments upon DON 
treatment also appears to differ from cell type to cell type (Keppeke et al., 
2015). For example, HeLa cells are more likely to form mixed filaments than 
COS-7 cells (Keppeke et al., 2015). 
It is not clear whether IMPDH and CTPS are directly bound to each 
other when co-assembled in filaments. It is possible that an adaptor protein 
is present that links them (Aughey and Liu, 2015). But the fact that these 
proteins are so close to each other within these mixed filaments suggests that 
there may be some crosstalk between the pyrimidine and purine nucleotide 
pathways (Aughey and Liu, 2015). This crosstalk could involve the co-
regulation of purine and pyrimidine nucleotide synthesis and/or regulation of 
the enzymatic activity of IMPDH and CTPS (Aughey and Liu, 2015).  It is 
also possible that the assembly of IMPDH with CTPS within the filaments 
restricts the mobility of IMPDH and thus its ability to carry out certain 
functions that require it to relocate (Aughey and Liu, 2015). Such functions 
could include acting as a transcription factor within the nucleus (Aughey and 
Liu, 2015). Because IMPDH acts as a transcriptional repressor for certain 
genes (Kozhevnikova et al., 2012), filament assembly may result in the 
increased expression of the genes that IMPDH regulates.  
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 CTPS in pyrimidine synthesis 
 CTPS is a rate limiting enzyme that is involved in pyrimidine 
synthesis, namely, the production of CTP (Figure 4). The activity of CTPS 
was first described in 1955 (Endrizzi et al., 2004).  This enzyme is a 
glutamine amidotransferase which catalyzes three reactions to convert UTP 
into CTP (Azzam and Liu, 2013; Endrizzi et al., 2004; Liu, 2010). The first 
reaction is an ATP dependent kinase reaction which occurs by the 
phosphorylation of UTP at the oxygen atom in position 4 (Figure 9, step 1). 
This is then followed by a glutaminase reaction in which glutamine is 
converted into glutamate resulting in the release of ammonia (Figure 9, step 
2). In vitro, ammonia can be used directly by CTPS (Endrizzi et al., 2004).  
Finally, in a ligase reaction, the phosphate group on the oxygen is replaced by 
the ammonia (Figure 9, step 3) (Liu, 2010). CTPS is essential to all organisms 
from bacteria and yeast to mammals because it is responsible for producing 
the CTP nucleotide, and these cytosine nucleotides are needed for the 
production of the phospholipids of membranes (Goto et al., 2004; Han et al., 
2005). 
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Structural characteristic of CTPS 
 Human CTPS1 consists of 591 amino acids and has a molecular weight  
 
of 67 kD. In its active form, CTPS is a tetramer (Figure 10B) made up of 
monomers containing two domains (Figure 10A & 10C) (Goto et al., 2004; 
Habrian et al., 2016; Kursula et al., 2006). There is an N-terminal 
synthetase-amidoligase domain and a C-terminal glutaminase domain 
(Habrian et al., 2016; Kursula et al., 2006). It is the glutaminase domain that 
detaches ammonia from glutamine and produces glutamate (Goto et al., 2004; 
      UTP                                                                                                          CTP 
Figure 9. CTPS reaction. UTP is phosphorylated and then an amidotransferase reaction 
creates ammonia from glutamine. Ammonia is then sent tunneled through the inside of the 
enzyme to the synthetase domain where reacts with the intermediate and replaces the 
phosphate group becoming UTP. 
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Kursula et al., 2006). The ammonia is then sent through a tunnel or channel 
from the glutaminase domain to the synthetase domain (Goto et al., 2004; 
Habrian et al., 2016; Kursula et al., 2006). In the synthetase-amidoligase 
domain, the ligase reactions occur in which the ammonia replaces the 
phosphate that is currently attached to UTP and thus creates CTP (Kursula 
et al., 2006).  
 
   
Figure 10. Crystal structure of CTPS. Synthesis domain of CTPS (A) which tetramerize (B) 
to become the core of the enzyme, while the glutaminase domains (C) are on  the outside of 
the tetramer, one projecting out from each of the four synthetase domains. 
 
 
Isoforms and expression 
 Mammals have two isoforms of CTPS—CTPS1 and CTPS2 (Higgins et 
al., 2007). Both isoforms have a 74% amino acid identity (Kucuk et al., 2016). 
Both isoforms are ubiquitously expressed although the role that each fulfills 
is not clear (Kucuk et al., 2016). Comparable expression levels of CTPS1 have 
been found in a variety of tissues including leukocytes, thymus, spleen, bone 
                  A                                                     B                                       C                                                                                                                
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marrow, intestine, colon, ovary, brain, heart, kidney, liver, lung, pancreas, 
skeletal muscle and naïve T-cells (Martin et al., 2014). In naïve T-cells, 
CTPS2 expression is considerably higher than that of CTPS1 (Martin et al., 
2014).  It has been discovered that mutations in CTPS1, which produce a 
non-functioning transcript, result in a severely impaired immune response 
even though CTPS2 is fully functional within the lymphocytes (Martin et al., 
2014). Normal T-cells which become activated have up to a twentyfold 
increase in the amount of CTPS1 expressed, as compared to naïve, 
inactivated T-cells (Martin et al., 2014). Although you also see an increase in 
CTPS2 levels upon T-cell activation, the amount of increase is not anywhere 
near as much as what is seen with CTPS1 (Martin et al., 2014). This suggests 
that the functions of CTPS1 and CTPS2, at least in the case of immune 
function, are not interchangeable (Kucuk et al., 2016; Martin et al., 2014). 
This supports the idea that within the T-cells, CTPS1 may be the primary 
isoform responsible for producing the bulk of CTP during the clonal 
expansion that occurs after T-cell activation. 
 The yeast cells Saccharomyces cerevisiae (S. cerevisiae) also have their 
own version of CTPS1 and CTPS2—URA7 and URA8 respectively (Higgins et 
al., 2007; Nadkarni et al., 1995). URA7 is more prevalently expressed than 
URA8 and makes most of the CTP (Nadkarni et al., 1995; Park et al., 2003). 
This is evident in the fact that a yeast cell containing only the URA8 gene 
produces only 36% of the CTP found in WT cells, while cells containing only 
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the URA7 gene maintained 78% (Nadkarni et al., 1995; Ozier-Kalogeropoulos 
et al., 1994). The fact that there is decrease in CTP within the cell upon 
deletion of either isotype, suggests some overlap in function, but the big 
difference in the percentage of decrease shows that they are not functionally 
identical. Nevertheless, these cells are capable of surviving  if at least one 
functional CTPS is present (Nadkarni et al., 1995).  
 
The regulation of CTPS activity 
Allosteric regulation 
 Although the structural mechanisms concerning the regulation of 
CTPS is not completely clear, it is known that all four nucleotides—UTP, 
GTP, ATP, CTP—play a role in activating or inhibiting the enzyme (Habrian 
et al., 2016; Lunn et al., 2008). UTP and ATP prompt the active tetrameric 
form to assemble from the inactive dimers. Both UTP and ATP bind to an 
active site in the synthetase domain (Habrian et al., 2016; Lunn et al., 2008). 
The inhibition of CTPS occurs by the feedback inhibition of its product CTP 
which binds on the synthetase domain (Habrian et al., 2016). CTP actually 
competes with UTP for binding (Habrian et al., 2016). GTP is necessary for 
the activation of glutamine hydrolysis, but at high concentrations, it can 
actually have an inhibitory effect (Habrian et al., 2016).  
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Regulation of CTP by post translational modifications 
 Both CTPS isoforms are also regulated by protein phosphorylation at 
several different sites (Kassel et al., 2010). Phosphopeptide analysis shows 
that protein kinase A, for example, phosphorylates human CTPS1 on many 
different serine residues (Han et al., 2005). Preliminary studies show that 
CTPS2 is also phosphorylated by protein kinase A (Han et al., 2005). This 
phosphorylation was found to occur in S. cerevisiae cells expressing human 
CTPS1 (Han et al., 2005) and it also occurred in vitro (Han et al., 2005). It 
was found that this phosphorylation correlated with an up to 2 fold increase 
in the cellular concentration of CTP (Han et al., 2005). The phosphorylation 
of the yeast version of CTPS1, URA7, is also regulated by protein kinase A, 
although unlike the human CTPS1, there is only one phosphorylation site for 
protein kinase A, Ser424 (Park et al., 1999).  
In addition, in S. cerevisiae it was discovered that protein kinase C 
also phosphorylates purified CTPS on serine and threonine residues at 
multiple sites, such as Ser36, Ser330, Ser354 and Ser424 (Park et al., 2003). It 
was found that phosphorylation at one site on CTPS influenced the 
phosphorylation at another site in a hierarchical manner where multiple 
sites need to be phosphorylated before the kinase gains access to another site 
with a particular function (Park et al., 2003; Roach, 1991). Furthermore, 
phosphorylation at different sites had opposing effects on the enzymatic 
activity level (Park et al., 2003). It was found that phosphorylation at Ser36, 
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Ser354, and Ser454 resulted in elevated enzymatic activity (Park et al., 2003). 
This increased activation was traced to an enhanced affinity of the enzyme 
for ATP and a reduced sensitivity to product inhibition by CTP (Park et al., 
2003). On the other hand, phosphorylation at Ser330 results in a reduction of 
activity (Park et al., 2003).  
 Interestingly, human CTPS1 becomes heavily phosphorylated in cells 
that are starved of serum overnight (Higgins et al., 2007). It was found that 
the kinase primarily responsible for this low serum phosphorylation is 
Glycogen Synthase Kinase 3 (Higgins et al., 2007). The sites Ser574 and Ser575 
were identified as being Glycogen Synthase Kinase 3 phosphorylation sites. 
The phosphorylation of CTPS1 by Glycogen Synthase Kinase 3 under low 
serum conditions was associated with a decrease in CTPS1 enzymatic activity 
(Higgins et al., 2007). 
 
The targeting of CTPS activity as a therapeutic 
 Increased CTPS activity has been found within cancer cells (Hatse et 
al., 1999; Mandel et al., 1963; van den Berg et al., 1993). Under normal 
circumstances, CTPS is a tightly regulated enzyme because its product CTP 
is kept at low levels within cells (Barry et al., 2014; Hatse et al., 1999). CTPS 
activity has been found to be increased in hepatomas of slow, medium and 
rapid rates of growth (Kizaki et al., 1980) and a significant correlation was 
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found between the increased activity and the growth rate of the tumors and 
the transformational state of the cells (Kizaki et al., 1980). High 
concentrations of both uracil and CTP have been found in the peripheral 
blood cells of patients with acute lymphoblastic leukemia and non-Hodgkin 
lymphoma (van den Berg et al., 1993; Verschuur et al., 1998). This 
heightened amount of CTP was traced to increased CTPS expression (van den 
Berg et al., 1993; Verschuur et al., 1998). CTPS activity has also been found 
to be elevated in colon cancer (Weber et al., 1980). Because of these strong 
links between high CTPS expression and cancer, inhibition of its activity as a 
treatment is of interest. In addition, the fact that CTPS plays a central role in 
the production of nucleic acids, phospholipids, and sialic acid, makes it a 
target of interest for treatment of  viral and protozoal infections, as well as 
neoplastic diseases (McCluskey et al., 2016).  
 
Cyclopentenylcytosine Triphosphate (CPEC) and c3Urd 
 CPEC is a carboxylic analog of cytidine and an extremely effective and 
specific competitive inhibitor of CTPS (Huang et al., 2004; Kang et al., 1989). 
This analog diminishes CTP and dCTP pools within the cell (Huang et al., 
2004; Kang et al., 1989). CPEC has been demonstrated to inhibit leukemia 
cells originating from children with acute lymphocytic leukemia and acute 
myeloid leukemia (Huang et al., 2004; Kang et al., 1989). CPEC has also been 
effective against a variety of other cancer cells like such as tumor KB cells, 
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L1210 cells, HT-29 colon carcinoma cells, the promyelocytic leukemia cell like 
HL60, SK-N-BE(2)c and SK-N-SH neuroblastoma cell lines, and glioblastoma 
cells (Huang et al., 2004; Kang et al., 1989). In addition to this, it has 
displayed in vivo antitumor activity in mice with L1210, P388 leukemias, B16 
melanoma, and human colon carcinoma HT-29 tumors (Huang et al., 2004).  
There is interest in using these drugs in combination with the 
chemotherapeutic agents ara-C and 5-aza-2-deoxycytidine because of the 
apparent synergistic effect that CPEC and c3Urd has with them (Hatse et al., 
1999).  
 
Gemcitabine 
 Because CTPS binds a number of different nucleotides, nucleotide 
analogs have been explored as inhibitors for CTPS1 (McCluskey, 2015; 
McCluskey et al., 2016). Gemcitabine is one such analog. This drug, which 
has the ability to induce cellular apoptosis, is currently being used as a drug 
treatment for a number of different solid tumors (Doi et al., 2017; McCluskey 
et al., 2016; Ulrickson et al., 2017).   
Once gemcitabine is taken into the cell via a nucleoside transporter, it 
is converted into 5’-monophosphate (dF-dCMP) by deoxycytidine kinase and 
thymidine kinase 2, and then into 5’ diphosphate (dF-dCDF) (McCluskey et 
al., 2016; Mini et al., 2006). In this form, it inhibits ribonucleotide reductase 
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and depletes nucleotide pools (McCluskey et al., 2016). Further 
phosphorylation then creates the 5’ triphosphate (dF-dCTP) which is the 
most plentiful metabolite of them all, making up 85-90% of gemcitabine 
species within the cell (McCluskey et al., 2016). This triphosphate is then 
mostly taken into genomic DNA although a small amount is incorporated into 
RNA and as a result, DNA polymerases are inhibited (McCluskey et al., 2016; 
Mini et al., 2006). But the free form of this triphosphate that does not get 
incorporated into DNA or RNA can actually interact with a number of CTP 
binding enzymes such as CTP:phosphocholine cytidylyltransferase 
(McCluskey et al., 2016). This then converts it to the cytotoxic gemcitabine-
choline. The deamination of this then produces 2’,2’-difluoro-2’-deoxy-UMP 
(dF-dUMP), which is much less toxic than gemcitabine, which inhibits 
thymidylate synthase and reduces dTMP pools (McCluskey et al., 2016).  
What is interesting is that CTP pools have also been found to be 
depleted as a result of gemcitabine (McCluskey et al., 2016). The cause for 
this has been traced to the fact that dF-dUTP is a CTPS substrate and CTPS 
catalyzes the transformation of dF-dUTP into dF-dCTP (McCluskey et al., 
2016). This product then binds strongly to CTPS, with a 37 fold higher 
affinity than UTP binds, and potently inhibits CTPS activity (McCluskey et 
al., 2016). The fact that CTPS can regenerate dF-dCTP levels from dF-dUTP 
also results in a higher concentration of active drug within patients 
(McCluskey et al., 2016). In addition, the potency of the drug is also increased 
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by the fact that dF-dCTP inhibits CTPS, thus depleting competing CTP pools 
within the cell (McCluskey et al., 2016).   
 
Azaserine 
“Glutamine addiction” describes a state of glutamine dependence that 
has been found in a number of cancers such as that of the lung, leukemias, 
lymphomas, multiple myeloma, triple negative breast cancer, and pancreatic 
cancer (Bolzoni et al., 2016; Rais et al., 2016; Wu et al., 1978). In order to 
proliferate, these cells need macromolecules such as nucleotides, amino acids 
and lipids (Barger and Plas, 2010; McKeehan, 1982; Newsholme et al., 1985). 
Glutamine (and glucose) provides much of the carbon and nitrogen needed to 
create these macromolecules (Barger and Plas, 2010; McKeehan, 1982; 
Newsholme et al., 1985). Therefore, if cancer cells have access to a glutamine 
supply, this results in unrestrained tumor growth (Eagle, 1955; Medina et al., 
1992; Rais et al., 2016; Souba, 1993). As a result of this dependence, the use 
of glutamine inhibitors has been explored as a cancer treatment (Rais et al., 
2016).   
Azaserine was first isolated from Streptomyces fragilis and was 
characterized to have anti-tumor effects (Anderson et al., 1956; Greenlees, 
1956; Tarnowski and Stock, 1957). Azaserine is a glutamine analog that 
inhibits many different glutamine utilizing reactions (Livingston et al., 1970). 
One of the most studied pathways associated with azaserine’s anti-tumor 
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properties, is the de novo purine synthesis pathway (Livingston et al., 1970). 
In this pathway, Azaserine inhibits the conversion of FGAR into FGAM—L-
glutamine and ATP are required for this reaction (Livingston et al., 1970). 
The mechanism by which Azaserine prevents FGAR from converting into 
FGAM is believed to be that Azaserine binds to a sulfhydryl group on the 
enzyme that catalyzes this reaction, FGAR amidotransferase, thus  
preventing the attachment of L-glutamine to the enzyme (French, 1963). This 
renders the enzyme inactive. The binding of Azaserine to this enzyme is 
irreversible, as was concluded when it was discovered that L-glutamine was 
incapable of reversing this inhibition (Greenlees, 1956). In general, Azaserine 
irreversibly inhibits all enzymes dependent on glutamine by covalently 
binding to  nucleophilic groups in the glutamine-binding site (Garrett, 1995). 
In addition to this, Azaserine also affects pyrimidine nucleotide synthesis by 
preventing the conversion of UTP into CTP. 
The de novo synthesis of adenine is also impeded by this inhibitor 
(Barclay and Phillipps, 1966; Turker and Martin, 1985). This may be because 
Azaserine reduces the production of NAD and NADP—the nitrogen of L-
glutamine is a precursor for NAD’s amido nitrogen (Barclay and Phillipps, 
1966; Fairbanks et al., 1995).  
There is evidence supporting the idea that the inhibition of nucleotide 
production is not the only means by which this compound exerts its anti-
tumor effects, particularly when it comes to certain tumor types. This was 
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discovered when growth inhibiting effects of Azaserine were still seen in 
Ehrlich ascites tumors even though various purines and purine precursors 
such as FGAR were also present (Hedegaard and Roche, 1966). McFall et al. 
(McFall et al., 1960) found that if you added guanosine to Ehrlich ascites 
tumors there was a great increase in the adenine and guanine cellular pools, 
but growth inhibition still remained. It has been suggested that the means by 
which these anti-tumor effects are implemented is by interference of  
Azaserine with the cell’s ability to replicate its DNA (Simard and Bernhard, 
1966). This possibility was supported by the observation that one group of 
investigators found that cells exposed to Azaserine experienced a large 
increase in size and amount of DNA. When these cells then attempted to 
divide, a lesion developed in the DNA which was the assumed cause of the 
subsequent cellular death (Hedegaard and Roche, 1966). The proliferation of 
cancerous cells needs energy in the form of ATP (Barger and Plas, 2010; 
McKeehan, 1982; Newsholme et al., 1985).  
 
DON 
  DON is a non-natural amino acid that like Azaserine is similar in 
structure to glutamine (Figure 11) (Levenberg et al., 1957; Livingston et al., 
1970; Rais et al., 2016). More precisely, it is a diazo analog of glutamine that 
was first purified from a strain of Streptomyces bacteria in the early 1950s 
(Coffey et al., 1956; Kisner et al., 1980; Rais et al., 2016). Like Azaserine, 
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DON inhibits reactions requiring L-glutamine as a source of nitrogen for 
transamidation reactions (Kisner et al., 1980; Rais et al., 2016; Rosenbluth et 
al., 1976). Such reactions include those carried out by enzymes like 
glutaminase (Willis and Seegmiller, 1977), L-glutamine:D-fructose-6-
phosphate transaminase (responsible for glucosamine synthesis) (Wu et al., 
2001), formyl glycinamide ribonucleotide (FGAR) amidotransferase 
(Levenberg et al., 1957; Livingston et al., 1970; Moore and Lepage, 1957), 
GMP synthase (Rodriguez-Suarez et al., 2007), NAD Synthetase (Barclay and 
Phillipps, 1966) and CTPS (Kisner et al., 1980; Rais et al., 2016). All of these 
enzymes are inhibited by DON. DON is believed to act as a suicide inhibitor 
by entering the active glutaminase catalytic site of these enzymes and 
irreversibly and covalently binding there via alkylation (Alt et al., 2015; 
Ortlund et al., 2000; Pinkus, 1977). From DON’s earliest discovery, it was 
pegged as potentially having anti-neoplastic properties (Nagai et al., 1991; 
Xie et al., 2016) which have been confirmed by many later studies (Duvall, 
1960; Eagle, 1955; Masterson and Nelson, 1965; Moore and Hurlbert, 1961; 
Rais et al., 2016). 
 DON inhibits the glutamine utilizing enzyme, glutaminase  (Willis and 
Seegmiller, 1977). Glutaminase catalyzes the catabolism of glutamine into 
glutamate (Lee et al., 2016). Treatment of  the human lymphoblast line WI-
L2 with DON has been found to reduce glutamine catabolism by over 95% 
(Willis and Seegmiller, 1977).  Glutaminase expression has been found to be 
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upregulated in a number of different cancer types and is positively correlated 
with the malignancy of the tumors and the rate of cellular growth (Huang et 
al., 2014; Lee et al., 2016; Lora et al., 2004; Medina et al., 1992; Qie et al., 
2014). In addition, it has been found that the knockdown of glutaminase in 
breast cancer cells greatly reduced their proliferation (Qie et al., 2014). 
 DON is an inhibitor of the first, rate limiting enzyme responsible for 
the production of glucosamine 6-phosphate from glutamine: L-glutamine: D-
fructose-6-phosphate transaminase (Broschat et al., 2002; Wu et al., 2001). 
Glucosamine 6-phosphate is a precursor for nitrogen containing sugars such 
as O linked N-acetylglucosamine (O-GlcNAc) (Bond and Hanover, 2015; 
Roseman, 2001). O-GlcNAc modifications play a role in a number of metabolic 
disorders including cancer (Bond and Hanover, 2015).  
 NAD Synthetase, is another glutamine dependent enzyme (Tulpule, 
1963; Wojcik et al., 2006) that can be inhibited by DON (Barclay and 
Phillipps, 1966). NAD synthetase catalyzes the last step of NAD+ production 
(De Ingeniis et al., 2012). 
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DON inhibits de novo purine synthesis by impeding the production of 
FGAM from FGAR (Figure 2). This reaction occurs via the inhibition of the 
enzyme which carries out this reaction: FGAR amidotransferase (Levenberg 
et al., 1957; Livingston et al., 1970; Moore and Lepage, 1957) resulting in the 
buildup of FGAR within tissues and a reduced amount of IMP being available 
for the creation of AMP and GMP (Kisner et al., 1980). Another method of 
purine metabolism inhibition by DON occurs further downstream in the 
pathway via the inhibition of GMP Synthetase (Rodriguez-Suarez et al., 
Figure 11. Molecular structures of CTPS inhibitors DON and Azaserine. Both have structures 
that are similar to L-glutamine. 
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2007). 
DON also inhibits the de novo synthesis of pyrimidine nucleotides  
(Eidinoff, 1958; McKeehan, 1982; Moore and Hurlbert, 1961). One way this is 
done is by inhibition of the glutamine requiring reactions which converts 
UTP into CTP (Eidinoff et al., 1958; Kisner et al., 1980; Levenberg et al., 
1957; Livingston et al., 1970). Interestingly, a much higher concentration of 
DON, at least ten times as much, is required for pyrimidine synthesis 
inhibition as compared to what is required for purine synthesis inhibition 
(Moore and Hurlbert, 1961). It has also been discovered that DON inhibits 
pyrimidine synthesis further up in the pathway via the inhibition of 
carbamoyl phosphate synthetase (Figure 4.), although the form of carbamoyl 
phosphate that uses ammonia appears to be found only in certain tissue 
types such as the mammalian liver (Brown and Cohen, 1960; Livingston et 
al., 1970). 
  
CTPS as filamentous structures 
The discovery of CTPS filaments 
The ability of CTPS to assemble into filaments was independently 
discovered, more or less simultaneously, by three different groups in three 
different organisms (Liu, 2016). Nevertheless, the first publication concerning 
CTPS filaments identified them within the Drosophila and this author first 
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coined the name cytoophidia for the filaments which means, “cell snake” (Liu, 
2010, 2016). Liu et al. (Liu et al., 2010) first discovered these structures 
within the Drosophila female reproductive organs. Like most animals, the 
female Drosophila contains two ovaries (Jia et al., 2016). Each of these 
ovaries contains 16 structures referred to as ovarioles (Jia et al., 2016). Each 
ovariole consists of a string of 6 to 7 egg chambers developing in chronological 
order (Jia et al., 2016). Each of these egg chambers contains 15 large cells 
called nurse cells, and the egg chambers are enveloped by a thin epithelial 
layer of somatic follicle cells (Jia et al., 2016). It was within the egg chamber 
that large cytoophidia were found to be associated with the nurse cells while 
those short in length were discovered within the follicular cells (Liu, 2010). 
The cytoophidia were also found in the oocyte (Liu, 2010). The large 
cytoophidia were called macrocytoophidia while the short ones were referred 
to as microcytoophidia (Liu, 2010).  Subsequently, the author discovered 
these structures in a wide range of other tissues and cell types within the fly 
such as the cells of the brain, gut, testis, accessory glad, salivary gland, 
trachea, and lymph gland (Liu, 2010).  
Two months after the Drosophila publication, the discovery of 
filaments within the Caulobacter crescentus (C. crescentus) was published by 
(Ingerson-Maher et al., 2010).  These CTPS filaments were found within the 
inner curvature of the cell when electron cryotomography was performed 
(Ingerson-Mahar et al., 2010). CTPS was found to co-localize with another 
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curvature regulator protein within the filaments called crescentin. Both 
proteins worked together to regulate cellular shape (Ingerson-Mahar et al., 
2010). 
 That same year, (Noree et al., 2010) published that a screen of GFP 
labeled S. cerevisiae genes revealed that CTPS also assembled into filaments 
within these cells. The two CTPS isoforms—URA8 and URA7—were found to 
assemble together within these filaments (Noree et al., 2010). Fission yeast 
was also found to contain these CTPS filaments in both the cytoplasm and 
nucleus (Zhang et al., 2014).  
 The following year, (Carcamo et al., 2011) revealed that CTPS 
filaments could also assemble within mammalian cells such as normal 
human cells, human cancer cells, and spontaneously within mouse embryonic 
stem cells. These filaments can be found in both the nucleus as well as the 
cytoplasm of the cell (Carcamo et al., 2014; Gou et al., 2014; Zhang et al., 
2014). 
 
Regulation of CTPS filament assembly 
In all of the cell types studies thus far, the filaments have been found 
to be dynamic in that they are capable of assembly and disassembly under 
different conditions and/or are capable of translocating to different areas 
within the cell (Gou et al., 2014). The assembly of CTPS into filaments has 
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been studied in cells using live imaging of GFP labeled CTPS (Gou et al., 
2014). There were found to be multiple stages of filament assembly (Gou et 
al., 2014). First, there is a nucleation phase in which many foci form at the 
same time within the cytoplasm (Gou et al., 2014). In the second phase, these 
foci elongate and once they reach a certain length, they then go through a 
third phase of fusion (Gou et al., 2014). There are actually two different kinds 
of fusion: head-to-head fusion which increases the length of the filament, and 
there is side-by-side fusion, which increases the thickness of the filament 
(Gou et al., 2014). When filaments fuse side by side, they slide towards one 
another, which suggest movement along the cytoskeleton (Gou et al., 2014). A 
fourth phase then occurs for those middle sized filaments, a phase referred to 
as bundling. In this phase, the filaments become very long and thick (Gou et 
al., 2014).  At times, these long and thick filaments can then go on to 
circularize, where the ends come together (Gou et al., 2014). 
In the case E. coli, (Barry et al., 2016) found that purified CTPS from 
this cell would assemble into filaments upon incubation with its product 
alone—the nucleotide CTP. None of CTPS’s substrates such as UTP, ATP, 
nor glutamine resulted in filament assembly (Barry et al., 2014). Filament 
assembly was determined using right-angle light scattering on a fluorimeter 
as well as by ultracentrifugation (Barry et al., 2014). The addition of 
increasing amounts of CTP caused an increased amount of CTPS to localize 
to the pellet after ultracentrifugation (Barry et al., 2014). This suggests that 
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an increasing amount of CTPS was polymerizing upon titration of CTP. 
Furthermore, it was determined that direct binding of CTP to CTPS was 
necessary for this polymerization to take place because a non-CTP binding 
mutant of CTPS was unable to polymerize (Barry et al., 2014). Interestingly, 
incubation of the protein with DON resulted in the disassembly of CTPS, 
although if CTPS was incubated with both CTP and DON, filaments could 
still assemble (Barry et al., 2014). CTPS filaments resulting from DON and 
CTP incubation would disassemble upon addition of CTPS substrates and 
could not reform (Barry et al., 2014). This demonstrates that the 
polymerization equilibrium of CTPS is regulated by the products and the 
substrates of CTPS. If CTPS is incubated with high concentrations of CTP, 
the subsequent addition of DON will not result in filament assembly.  
It was discovered that the CTPS filaments found within the C. 
crescentus localize to different areas within the cells based on the cell cycle 
(Ingerson-Mahar et al., 2010). Two types of cells result from the 
asymmetrical division of these bacteria: the stalked, progenitor “mother cell” 
and a swarmer progeny “daughter cell” (Curtis and Brun, 2010; Osley and 
Newton, 1978; Skerker and Laub, 2004). Eventually, the swarmer cell 
elongates and differentiates into a stalked cell, but a stalked cell cannot 
regress into a swarmer cell (Curtis and Brun, 2010). A swarmer cell cannot 
go through cell division or replication but on the other hand, a fully matured 
stalked cell can (Curtis and Brun, 2010; Skerker and Laub, 2004). Thus, the 
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swarmer cell is in the G1 phase while the stalked cell is in the S phase 
(Curtis and Brun, 2010; Osley and Newton, 1978; Skerker and Laub, 2004). 
Then, in the late pre-divisional stage, the stalked cell will go into the G2 
phase (Curtis and Brun, 2010; Skerker and Laub, 2004). Time lapse 
microscopy reveals that during the early phases of the cell cycle in the 
stalked cell, the CTPS filaments are short in appearance (Ingerson-Mahar et 
al., 2010). But, as the cells advance though the cell cycle, these filaments 
become longer and then re-localize to the inner curvature of the cell where 
they stay for the rest of the cell cycle (Ingerson-Mahar et al., 2010). The 
authors found that if CTPS was even slightly overexpressed within these 
cells, this would result in filaments that were longer  and more widespread 
than usual, being found in about 63% of cells (Ingerson-Mahar et al., 2010). 
When CTPS was highly overexpressed in the cells, the prevalence of 
filaments was even more increased, being found in about 76% of cells 
(Ingerson-Mahar et al., 2010). Furthermore, the appearance of the filaments 
was even more striking—the filaments looked spread out and exuded from 
the inner curvature of the cell (Ingerson-Mahar et al., 2010). Therefore the 
expression level of CTPS strongly regulates the assembly of the filaments in 
the C. crescentus. When C. crescentus CTPS was expressed in E. coli, they 
found that it still assembled into filaments, suggesting that there are no 
species specific factors that regulate filament assembly  in the C. crescentus 
(Ingerson-Mahar et al., 2010). Interestingly, similar to what has been 
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observed in E. coli, the treatment of C. crescentus cells with DON results in 
the disassembly of the CTPS filaments, which may suggest that glutaminase 
activity of CTPS, is essential for C. crescentus CTPS assembly. 
It was found that the CTPS in S. cerevisiae assembled foci upon 
incubation with the end product CTP (Noree et al., 2010). Like the E.coli 
CTPS protein, they found that CTP had to bind to CTPS for filament 
assembly, as a strain of yeast cells expressing a non-binding mutant version 
of CTPS was incapable of filament assembly upon CTP incubation. 
Interestingly though, this incubation resulted in an increase in foci formation 
(Noree et al., 2010). ATP was also found to trigger foci assembly. Altogether, 
this suggests that nucleotides which promote tetramerization of the protein 
trigger foci assembly. It was also found that filaments assembled upon 
nutrient deprivation, namely, glucose deprivation (Noree et al., 2010). 
Therefore, glucose availability plays a role in the regulation of CTPS 
filaments within these cells. In addition, the cellular energy state, in the form 
of ATP levels, played a part in CTPS filament regulation: the depletion of 
ATP with sodium azide trigged filament assembly (Noree et al., 2010). The 
number of CTPS filaments within cells also increased upon treatment with a 
non-specific kinase inhibitor called staurosporine, suggesting that 
phosphorylation also plays a role in CTPS filament assembly within yeast 
cells (Noree et al., 2010).  
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Drosophila were found to have three isoforms of CTPS—isoforms A, B, 
and C  (Azzam and Liu, 2013). It was discovered that only isoform C localizes 
to the filaments, although isoform A played an important role in filament 
formation. In addition, it was discovered that a small portion of the amino 
terminus of isoform C was indispensable for filament assembly although by 
itself it was not enough to assemble into filaments (Azzam and Liu, 2013). 
The filaments contained within Drosophila tissue are spontaneously 
assembled, therefore they can be stained for and immediately observed under 
the microscope without any special conditions or drug treatment (Liu, 2010). 
The microcytoophidia in the follicular cells have different lengths, based on 
the developmental stage (Liu, 2010). In follicle cells within the germanium, 
before stage 4, filaments are under 1 µm in length but they increase in size in 
the later stages (Liu, 2010). By stage 8, the follicular filaments are around 4 
µm and then increase to 5 to 6 µm in stage 9 and 10 (Liu, 2010).  The 
macrocytoophidia associated with the nurse cells also increase in size as 
development progresses (Liu, 2010). Macrocytoophidia in stage 5 nurse cells 
are anywhere from 10 to 20 µm in length while at the last stage of 10, they 
range from 40 to 50 µm in length (Liu, 2010).  After the stage of 10, these 
macrocytoophidia begin to disassemble (Liu, 2010). The macrocytoophidium 
cannot be seen from stage 11-14 (Aughey et al., 2016; Liu, 2010).  
Interestingly, (Strochlic et al., 2014) found that none of these 
differences in filament assembly within the egg chamber was due to any 
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differences in CTPS protein levels. CTPS protein levels also regulate the 
assembly of filaments within Drosophila. It was found that if CTPS levels are 
knocked down, the follicular filaments will disassemble (Chen et al., 2011). 
On the other hand, the overexpression of CTPS promotes filament assembly 
(Azzam and Liu, 2013). When CTPS is overexpressed, the filaments within 
the follicular cells become longer and thicker, while the filaments inside of 
the germline cells become exceedingly long and tangled (Azzam and Liu, 
2013). Strochlic et al. (Strochlic et al., 2014) found that the kinase Ack 
localizes with CTPS in the nurse cell filaments but not in the follicular 
filaments. It was determined, using a loss of function Ack mutant, that Ack 
regulates CTPS filament assembly, although Ack was not found to directly 
phosphorylate CTPS (Strochlic et al., 2014). The protein that Ack 
phosphorylates in order to regulate CTPS activity is currently unknown 
(Strochlic et al., 2014). In wild type flies, the filaments associated with the 
nurse cells appear no sooner than stage 2 and then begin to disappear at 
stage 11 and above (Strochlic et al., 2014). But, in the mutant flies, filaments 
are already apparent in the germarium which is before stage 2. This is a 
much earlier stage than usual (Strochlic et al., 2014). They also found that 
the filaments from these mutant flies remain assembled in late 
developmental stages where they would normally be disassembled (Strochlic 
et al., 2014). This shows that Ack plays a crucial role when it comes to 
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regulating the stage at which filaments assemble during development 
(Strochlic et al., 2014).  
Recently, (Pai et al., 2016) identified ubiquitination as a means of 
filament regulation within Drosophila. They found that when filaments in 
both the nurse cells as well as the follicular cells are treated with MG132, a 
proteosomal inhibitor, a reduction in the number of filaments can be observed 
(Wang et al., 2015). The effect of this drug on the filaments was linked to a 
reduction ubiquitin because overexpression of ubiquitin abrogated this (Wang 
et al., 2015). This suggests that ubiquitin is a positive regulator of CTPS 
filament assembly within Drosophila. More specifically, it was discovered 
that the E3 ubiquitin ligase Cbl regulates filament formation by serving to 
stabilize the structure of the follicular cell CTPS filaments during endocycle 
stages (Wang et al., 2015). Using immunofluorescence staining one group 
found that myc, an oncogenic protein involved in cellular growth and 
proliferation, had increased protein expression during the stages of egg 
development where CTPS filaments were assembled (Aughey et al., 2016). 
These stages are between 2 and 10b. Therefore, there is a correlation between 
myc expression and filament assembly within the filaments (Aughey et al., 
2016). In addition, it was discovered that the knockdown of myc expression 
results in a reduction of filament assembly within the egg chamber (Aughey 
et al., 2016). Conversely, they found that if they increased the expression of 
myc, this results in a 50% increase in the length of the filaments (Aughey et 
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al., 2016). Overexpression also results in filament assembly in late phases of 
egg chamber development where they normally would not be (Aughey et al., 
2016). This suggests that myc is a positive regulator of filament assembly 
within Drosophila cells (Aughey et al., 2016). 
Unlike Drosophila, within mammalian cells, CTPS filaments are not 
typically assembled under normal culture conditions, but there are a few 
exceptions such as mouse 3T3 mouse fibroblast cells, Chinese hamster ovary 
cells (Stinton et al., 2013), rat NRK normal rat kidney epithelial cells, rat 
kangaroo epithelial cells, and mouse embryonic stem cells (Carcamo et al., 
2014). CTPS filaments can be triggered to assemble if subjected to certain 
conditions and treatments, for example, treatment with inhibitors such as 
the previously mentioned DON and azaserine (Carcamo et al., 2011; Keppeke 
et al., 2015). Both are capable of inducing CTPS filaments within cells (Chen 
et al., 2011). A phosphorylated form of Ack (Y284) has also been found to 
localize to the filaments contained within mammalian cells (Strochlic et al., 
2014).  This suggests that Ack may regulate filament assembly within 
mammalian cells, just as it does in Drosophila. Although CTPS has been 
found to assemble with Ack as well as IMPDH2 within the filaments, it is 
currently unclear if there are additional proteins with which CTPS can 
assemble.  
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The biological role of CTPS filament assembly 
Interestingly, (Barry et al., 2014) determined that an enzymatically 
inactive form of CTPS is contained within the filaments of the E. coli cell. The 
authors drew this conclusion when they saw a decrease in enzymatic activity 
concurrent to the CTP induced filament assembly as determined by 
absorbance level of CTP product (Barry et al., 2014). However, it appears that 
this inhibition must occur specifically by its product CTP in order for 
filaments to assemble because DON, which also inhibits CTPS activity, 
promotes filament disassembly. A possible mechanism for the inhibition of 
enzymatic activity upon filament assembly can be seen when one looks at the 
cryo-EM structure of the CTPS filament (Barry et al., 2014). The crystal 
structure shows that in the filamentous form, all the enzyme’s active sites are 
accessible to UTP, ATP, and glutamine, suggesting that active site blocking is 
not the mechanism by which the enzymatic activity is inhibited (Barry et al., 
2014). Rather, it is possible that there is obstruction of ammonia transfer 
between the glutaminase and synthetase active sites resulting from the 
filament structure disrupting the ability of the enzyme to undergo the 
conformational rearrangement necessary to undergo this transfer (Barry et 
al., 2014).  In order to determine the role that filament assembly plays in 
cellular physiology, this group created a non-filament assembling mutant of 
CTPS, CTPSE277R, which had a reduced ability to bind CTP (Barry et al., 
2014). They then replaced the wild type CTPS with this mutant within E.coli 
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cells (Barry et al., 2014).  What they found was that the cells had reduced 
growth as compared to cells with wild type CTPS: wild type doubling was 
approximately 51 min while mutant doubling time was approximately 130 
min (Barry et al., 2014).  In addition to this, the mutant protein also had an 
effect on the pools of other nucleotides and their precursors and products 
(Barry et al., 2014). For example, this mutant resulted in a decreased amount 
of the CTP precursor orotate, while CTP levels were increased as compared to 
wild type cells. Therefore, filaments are needed to regulate nucleotide 
metabolism and without them, growth defects result (Barry et al., 2014). 
Interestingly, although CTP levels within mutant cells were elevated, isotope 
tracing showed that the mutant incorporated radio labeled cytidine into the 
CTP pool at the same frequency as the wild type cell (Barry et al., 2014). This 
supports the idea that filament assembly is crucial for negative feedback 
inhibition within the cells which is needed in order to tightly regulate the 
CTP level. Without the ability to assembly filaments, the uncontrolled 
buildup of CTP occurs despite having CTP production rates comparable to the 
filament assembling CTPS. The authors found that filamentous CTPS is 
more strongly inhibited by CTP as compared to the diffuse form (Barry et al., 
2014). But in order for CTPS to assemble into filaments, the authors found 
that it must first overcome a large nucleation barrier (Barry et al., 2014). It is 
by coupling CTPS enzymatic activity to polymerization with a large 
nucleation barrier that the cell is capable of maintaining sharp control over 
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activity (Barry et al., 2014). The cell is thus able to induce sudden and quick 
changes in CTPS enzymatic activity at will. In addition, the sequestering of 
the proteins into these filaments ensures that the protein is ready to be 
quickly reactivated by depolymerization (Barry et al., 2014). 
When it comes to the C. crescentus, it appears as if the primary 
purpose of the CTPS within the filaments is to regulate the shape of the cell. 
Interestingly, (Ingerson-Mahar et al., 2010) found that  overexpression of 
CTPS resulted in cells that were unusually straight or hooked with less end 
curvature. And when they reduced the levels of CTPS within the cells, they 
found that in addition to slow cell growth, the cells displayed over curvature 
by a sharp kink near the mid part of the cell (Ingerson-Mahar et al., 2010). 
But the enzymatic activity of CTPS appeared to be separate from regulation 
of cellular shape (Ingerson-Mahar et al., 2010). Catalytically inactivating 
point mutations were created within the synthetase and the glutaminase 
domains (Ingerson-Mahar et al., 2010). The point mutation in the synthetase 
domain did not have an effect on filament assembly, but the point mutation 
in the glutaminase domain disrupted filament assembly (Ingerson-Mahar et 
al., 2010). The overexpression of the synthetase domain mutant, like 
overexpression of the wild type protein, resulted in unusually straight cell 
shape (Ingerson-Mahar et al., 2010). But the over expression of the 
glutaminase mutant, unlike what occurs with wild type protein, did not affect 
cell shape (Ingerson-Mahar et al., 2010). This demonstrates that CTPS 
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regulation of cell shape needs filamentous CTPS with a normally functioning 
glutaminase domain, but it does not have to be enzymatically active 
(Ingerson-Mahar et al., 2010).  In summation, evidence suggests that the 
biological role of filamentous CTPS is to regulate cell curvature within the C. 
crescentus.  
In regards to Drosophila, whether or not the CTPS within the 
filaments is active or not remains a point of debate within the field. (Aughey 
et al., 2014) did metabolic profiling on flies that were either wild type, 
overexpressing CTPS, or DON treated. They found that there are four 
different patterns of expression that come about from overexpressed, wild 
type, and DON treated flies: low-low-high, high-low-low, low-high-high, and 
high-high-low respectively (Aughey et al., 2014). The group was especially 
interested in two of the four patterns—one of which included metabolites 
involved in amino acid metabolism, and the other one which included 
dipeptides (Aughey et al., 2014). They found that in these two groups, while 
DON treatment greatly influences the levels of the metabolites in these two 
groups, there were no differences in that respect between the wild type and 
the overexpressing mutant (Aughey et al., 2014). Of particular interest was 
glutamine, which fell into the pattern of the group containing amino acid 
metabolites (Aughey et al., 2014). Although glutamine levels increased in the 
DON treated flies, the wild type and the mutant flies have similar amounts 
(Aughey et al., 2014). The similarity in level between the overexpression 
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mutant and the wild type supports the hypothesis that the CTPS assembled 
into filaments has no CTPS related enzymatic activity (Aughey et al., 2014). 
In addition to this, the authors developed a mathematical model to describe 
the CTPS incorporation into filaments (Aughey et al., 2014). The authors’ 
model predicted that the concentration of CTP did not increase with CTPS in 
a linear fashion and that CTP levels actually quickly plateaued upon 
overexpression of the enzyme (Aughey et al., 2014). This demonstrates that 
the amount of CTP within the cell is quickly buffered upon filament assembly 
when CTPS is overexpressed (Aughey et al., 2014). This is due to the fact that 
when CTPS is overexpressed, most of it localizes to the filaments. On the 
other hand, when CTP levels drop, CTPS can be rapidly removed from the 
filaments. (Aughey et al., 2014). In summation, the authors concluded that 
the cell assembles CTPS within Drosophila into filaments in order to dampen 
the enzyme’s activity levels (Aughey et al., 2014). In this way, the filament is 
a means to tightly regulate diffuse, active CTP for the maintenance of 
homeostasis within the cell (Aughey et al., 2014). 
 On the other hand, other groups such as (Strochlic et al., 2014), believe 
their findings support the idea that Drosophila filaments are enzymatically 
active. This group created mutant flies that had reduced CTPS expression. 
The flies had reduced egg production and plasma membrane defects in the 
germline cells (Strochlic et al., 2014). This group then created a mutant form 
of human CTPS which lacked the ability to be inhibited by its end products 
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(E161K), rendering it constitutively active (Strochlic et al., 2014). When the 
mutant was expressed in Drosophila, they not only found that it assembled 
into filaments within the ovaries, it also rescued membrane defects and the 
sterility of the mutant flies (Strochlic et al., 2014). In addition, this group 
argued that filaments assemble within the egg chamber during a time when 
they are most needed metabolically (Strochlic et al., 2014). During the middle 
of oogenesis, a huge amount of nucleotides are needed for DNA and RNA 
synthesis as a result of the occurrence of multiple rounds of endoreplication 
from stage 2-10 (Dej and Spradling, 1999). This endoreplication results in a 
1000 fold increase in DNA (Lee et al., 2009). In addition, during these very 
same stages, RNA production within the nurse cells is up, especially 
ribosomal RNA (Mermod et al., 1977). The fact that the CTPS filaments are 
there during a time that has a high demand for CTP, as well as the 
observation that a reduction of CTPS expression causes defects in oogenesis 
which can then be rescued with an enzymatically active form of CTPS that 
localizes to the filaments, supports the idea that these filaments are 
enzymatically active. In addition, it supports the hypothesis that they are 
assembled for the cause of promoting and supporting CTP biosynthesis and 
endoreplication. 
 The biological purpose that CTPS filaments serve within mammalian 
cells is not clear. CTPS tends to assemble with other proteins within the 
mammalian cells: with IMPDH, for example in HEp-2 cells (Carcamo et al., 
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2011) and with Ack in MCF7 cells (Strochlic et al., 2014). The role that co-
assembly plays within the metabolism of the cells is unknown. Determining if 
there are additional filament components besides CTPS, IMPDH, and Ack, 
and then determining their function within this structure would help to 
resolve this question. The question of whether there are additional filament 
components will be discussed in the following chapter. 
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Chapter 2: Identification of CTPS1 associating proteins 
within the filaments 
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Introduction  
The idea that the cytoophidium may not consist of only CTPS was first 
proposed by Liu (Liu, 2010) when he first observed the macrocytoophidium of 
the Drosophila. He saw that although the GFP-CTPS evenly labeled the 
whole length of many of the filaments, there were some filaments that had 
gaps in them (Liu, 2010). The lengths of these gaps were variable, but most of 
them were under 1 µm in length. The gaps were not in any consistent 
pattern; rather they were arbitrarily dispersed along the filaments (Liu, 
2010). This suggests that a protein other than CTPS was occupying these 
“gaps” which would explain why anti-CTPS antibody did not recognize it. 
The finding that CTPS co-localized with another protein within 
Drosophila macrocytoophidium came from Strochlic et al. (Strochlic et al., 
2014). Using immunofluorescence, they found that Ack, a non-receptor 
tyrosine kinase, localized with CTPS to macrocytoophidium within 
Drosophila egg chambers (Strochlic et al., 2014). In addition, using 
immunofluorescence, they discovered that Ack1-phospho-Y284, co-localized 
with CTPS within a human breast cancer cell line, MCF7 (Strochlic et al., 
2014). 
Evidence for the co-assembly of CTPS with yet another protein within 
mammalian cell filaments first came from Carcamo et al. (Carcamo et al., 
2011). Human autoantibodies were first used to identify filaments within 
HEp-2 cells obtained from INOVA diagnostics. Further analysis using co-
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staining with rabbit and anti-Drosophila CTPS antiserum demonstrated that 
CTPS localized to these filaments (Carcamo et al., 2011). Then, in order to 
determine if IMPDH also localizes to the filaments, they stained the cells 
with rabbit anti-IMPDH and demonstrated that IMPDH co-localized with 
CTPS within the filaments (Carcamo et al., 2011). In addition, IMPDH2 was 
immunoprecipitated from K562 cells using the autoantibody, It2006 
(Carcamo et al., 2011).  
Although IMPDH was identified as the target of the human 
autoantibody It2006 within the filaments, the immunoprecipitation of the 
K562 cell extract using filament positive HCV patient sera demonstrate that 
six of the nine sera—603, 606, 608, 609, 610, and 612, do not 
immunoprecipitate IMPDH or CTPS (Carcamo et al., 2014). This suggests 
that additional proteins can localize with CTPS and IMPDH within 
mammalian cell filaments, but the identification of these proteins or whether 
or not this is actually the case remains to be determined.  
One approach to determining filament components is the utilization of 
Bio-ID (Roux et al., 2013; Roux et al., 2012). Bio-ID is a way to screen for 
protein-protein interactions which take place in living cells (Roux et al., 2013; 
Roux et al., 2012).  This identification system has been implemented by a 
number of groups as a means to discover and explore proteins that interact 
with a protein of interest (Firat-Karalar and Stearns, 2015; Kim et al., 2014; 
Kim et al., 2016; Roux et al., 2012; Varnaite and MacNeill, 2016).  
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Bio-ID involves the use of biotin (vitamin H) which is a 
vitamin/coenzyme necessary for all life and is an important player in 
carboxylation reactions (Lehninger, 1993). Humans are incapable of 
synthesizing biotin, and must obtain it by dietary means, but plants, most 
bacteria and certain fungi can synthesize it themselves (Barat and Wu, 
2007). There is a specific class of metabolic enzymes called biotin carboxylase 
and decarboxylases that are biotinylated by post translational modification 
(Barat and Wu, 2007; Chapman-Smith and Cronan, 1999; Knowles, 1989; 
Samols et al., 1988). Biotin carboxylases play an important role in 
lipogenesis, amino acid metabolism and the transduction  of energy 
(Chapman-Smith and Cronan, 1999). Typically, these enzymes take CO2 from 
bicarbonate and catalyze the movement of this carboxylate to organic acids 
resulting in the production of different cellular metabolites (Chapman-Smith 
and Cronan, 1999; Samols et al., 1988). This process is carried out by the use 
of biotin as a cofactor acting as a mobile carboxyl carrier (Chapman-Smith 
and Cronan, 1999). Biotinylation modification is rare within cells, there being 
only between 1 and 5 proteins  species that get biotinylated within various 
organism (Cronan, 1990). This biotinylation is performed by a protein called 
biotin protein ligase (Barat and Wu, 2007). This enzyme catalyzes the 
covalent attachment of biotin to protein (Barat and Wu, 2007). In E. coli, this 
35 kD protein regulates the biotinylation of acetyl-CoA carboxylase subunit 
(Roux et al., 2012). The wild type version of the protein is highly selective and 
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extremely specific when it comes to biotinylation of its substrate (Roux et al., 
2012). Roux et al. (Roux et al., 2012) created a mutated version of this E.coli 
protein referred to as BirA*. The mutation R118G results in a version of the 
protein which has lost its high selectivity for biotinylation (Roux et al., 2012).  
In vitro, BirA* has been found to promiscuously add biotin groups to 
the primary amines (mostly lysines) of proteins in a manner that is 
dependent on proximity (Roux et al., 2012). In this system, BirA* is fused to a 
protein of interest then expressed within the cells (Roux et al., 2013; Roux et 
al., 2012). The fusion protein biotinylates proteins near it within the cell 
(Roux et al., 2013; Roux et al., 2012). Biotinylated protein can then be 
isolated using Streptavidin (Roux et al., 2012) or avidin (Barat and Wu, 
2007). Streptavidin comes from the bacteria Steptomyces avidinii and has a 
high affinity for biotin (Hendrickson et al., 1989). Avidin is a glycoprotein 
that is isolated from the egg whites of chicken eggs (Marttila et al., 2000). It 
too has an extremely high affinity for biotin (Marttila et al., 2000). Proteins 
can be then identified with a method such as mass spectrometry (Hesketh et 
al., 2017; Roux et al., 2012). In order to determine if there are additional 
CTPS interacting proteins within mammalian cell filaments, our lab 
implemented the Bio-ID system.  
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Materials and methods 
Cell culture and transfection 
HEK293 cells ( kindly given to us by Dr. Marc Kirschner) were cultured at 
37°C in DMEM (Cellgro) supplemented with 10% FBS (Hyclone), 2mM L-
glutamine (Gibco), 1% penicillin and 1% streptomycin. Cells were transfected 
using Lipofectamine 2000 in Opti-MEM Reduce Serum Medium 
(ThermoFisher Scientific, # 51985034) as per manufacturer’s instruction. 
 
Plasmid 
BirA*-CTPS: The following primers containing BAMHI  and XholI restriction 
site sequences 5’-CTTGCTCGAGATGAAGTACATTCTGGTTACTGG-3’ and 
3’-TTATGGATCCTCAGTCSTGATTTATTGATGGAAACTTCA-5’ were used 
for PCR amplification of CTPS1 originally within in a pEGFP-C1 vector. The 
PCR product of CTPS1 flanked by BAMHI  and XholI restriction site 
sequences was then subcloned into pcDNA3.1 mycBioID (Addgene plasmid 
#35700) C terminal to BirA* using BAMHI (New England Biolabs, #R3136s) 
and XhoI restriction site enzymes (New England Biolabs).  
V5 and SBP tagged HAL: HAL gene originally from the entry vector 
hORFeome v8.1 (GE Healthcare, OHS6084-202635094) was cultured in Luria 
Broth with 8% glycerol and then a mini prep was performed as per 
manufacturer’s instruction. This was then gateway cloned into two 
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destination vectors: pcDNA6.2/V5-DEST with C terminal V5 tag and 
pcDNA5/FRT/TO with N-terminal HA and SBP tag. 
 
 
  
Figure 12. BirA* vector. CTPS1 was subcloned into the vector C terminal to BirA* and myc by using XholI 
and BAMHI restriction site enzymes. 
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Transfection and cell culture 
HEK293 cells were grown in 60 mm dishes with or without coverslips.  
All the cells except for one dish without a coverslip were transfected with the 
above construct using lipofectamine 2000 (Invitrogen) according to the 
manufacturer’s instructions in Opti-MEM (ThermoFisher Scientific), a 
reduced serum media and left overnight. Transfected cells were then either 
left untreated or were incubated overnight with DON (Sigma-Aldrich) at a 
concentration of 200 µM. Cells were then incubated with biotin (Sigma-
Aldrich) at a concentration of 50 µM for 24 hours.  
 
Immunofluorescence 
Cells on coverslips were fixed with 4% formaldehyde for 20 min, 
permeabilized in 0.5% Triton X-100 for ten minutes and then blocked in Abdil 
(PBS with 0.1% Triton X-100, 2% BSA. 0.1% Sodium azide) for 10 min. 
Coverslips were then incubated with rabbit anti-IMPDH2 antibody (diluted 
1:200 in Abdil, Abcam, ab129165) and anti-mouse myc (diluted 1:100 in 
Abdil, Santa Cruz, sc-40) for an hour. Coverslips were then incubated with 
Alexa Fluor® 488 goat anti rabbit (diluted 1:200 in Abdil, ThermoFisher) and 
was visualized using Texas Red Goat anti mouse (diluted 1:200 in Abdil, 
ThermoFisher) in order to visualize IMPDH2 and myc tagged BirA*CTPS 
respectively. Histidine Ammonia Lyase (HAL) was identified using anti 
rabbit-HAL (1:100, Santa Cruz, sc-133646). Cellular DNA was detected using 
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DAPI. Images were taken using MetaVue software (Molecular Devices) 
controlling a CoolSnap ES camera (Photometrics) on a Nikon TE2000-U 
inverted microscope. The objective used was a 60x Plan Apo 1.40 NA Nikon. 
 
Immunoblotting 
Biotin incubated cells were lysed with a buffer consisting of 1% Triton X-100 
and 50mM Tris pH 7.4. A small portion of the lysate was run on a 12.5% SDS 
PAGE gel side by side to determine if cells expressing the construct had 
elevated protein biotinylation as compared to non-transfected cells. Protein 
was then transferred onto nitrocellulose blotting membranes (GE Healthcare, 
#RPN203D) using a semi-dry transfer unit (Amersham) for 1 hour with the 
power supply set to 100 mA. The membranes were blocked overnight in 5% 
BSA in tris-buffered saline with 0.4% Triton X-100. Biotinylated protein was 
detected by 2 hour room temperature incubation of membranes in peroxidase-
conjugated streptavidin (diluted 1:2000 in 5% BSA, Cell Signaling, #3999). 
Membranes were then washed 3 times in tris-buffered saline with 0.1% 
Triton X-100. Santa Cruz Western Blotting Luminol Reagent (#sc-2048) was 
used for detection and images were developed on film. 
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Capture of biotinylated proteins 
Cells were first washed 3 times with cold PBS. Cells were then lysed 
with lysis buffer (1% Triton X-100 and 50 mM Tris pH 7.4). Lysates were 
centrifuged for 5 min, 500 relative centrifugal force (rcf) at a temperature of 
4°C. Supernatants were transferred to a new tube and SDS was added to a 
final concentration of 2%. Neutravidin Agarose Resin (ThermoFisher 
Scientific, #29202) was prepared by washing 3 times in 10 ml of the lysis 
buffer, each time spun down 2000 rcf at 4°C for 5 minutes. Samples were 
then incubated with the resin at 4°C overnight. Beads were spun down at 
5000 rcf for five minutes and depleted supernatant was pipetted off.  Beads 
were then washed three times, 15 minutes each, with 2% SDS and spun 
down. 1x sample buffer was added to the beads and then samples were boiled 
for 5 minutes to release the biotinylated proteins. 
 
Silver Stain 
Two percent of the volume of the above samples was run on a 10% SDS 
PAGE gel. The gel was then fixed in de-stain (50% MeOH, 10% Acetic acid, 
0.05% formaldehyde, dH2O added up to 100 ml) for 15-30 minutes. The gel 
was washed with 50% EtOH and then incubated with shaking in 20 mg of 
Na2S2O3 anhydrous in 100 ml of deionized water, followed by washing with 
deionized water three times, 30 seconds each. The gel was then incubated in 
silver stain (200 mg AgNO3, 100 µl formaldehyde, dH2O added up to 100 ml), 
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then washed in water for 15 seconds and developed in 3 ml of Na2S2O3 
anhydrous solution, 6 g of Na2CO3, 100 µl of formaldehyde, with dH2O added 
up to 100 ml. 
 
Identification of proteins using mass spectrometry 
 The remaining eluted protein samples were separated on a 10% SDS 
PAGE gel and then gels were stained in Coomassie blue stain overnight in 
order to visualize any protein bands in the gel.  Each of the two lanes (DON 
and untreated) were cut into 5 parts consisting of the following areas: 150 kD 
and above, 75-150 kD, 50-75 kD, 37-50 kD, and 25-37 kD. These pieces were 
then put into microcentrifuge tubes, snap frozen, and shipped on dry ice to 
the Taplin Biological Mass Spectrometry Facility (Harvard Medical School) 
and analysis was performed by Ross Tomaino.  
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Results 
BirA*-CTPS1 localizes to filaments upon treatment with DON 
 In order for the 
BirA*-CTPS construct to 
be used as a tool for the 
identification of 
additional filament 
components, we first had 
to determine if it 
localized to the 
filaments. To this end, we transfected HEK-293 cells grown on glass 
coverslips with BirA*-CTPS1 and then on the following day, we treated them 
with 200 µM of DON overnight to induce the assembly of CTPS containing 
filaments. We then fixed and stained the cells. Immunofluorescence revealed 
that BirA*-CTPS1 localized with IMPDH to the filaments upon treatment 
with DON (Figure 13). 
 
 
 
 
Figure 13. BirA*-CTPS co-localizes with IMPDH2 in 
filaments. Immunofluorescence staining demonstrates 
that IMPDH (green) and BirA*CTPS (red) co-localize to 
filaments upon treatment with DON (see white arrows). 
DAPI (blue) was used for nuclear staining. 
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BirA*CTPS promiscuously biotinylates proteins within cells   
In order to determine if the created fusion protein was useful for the 
identification of proteins in close proximity to CTPS1 within the filaments, 
we had to determine if the 
BirA*-CTPS fusion protein 
would promiscuously biotinylate 
nearby cellular proteins. To do 
this, we expressed the BirA*-
CTPS construct in a dish of 
HEK-293 cells while leaving 
another dish of cells 
untransfected. The following 
day, we gave both transfected 
and non-transfected cells biotin 
and allowed the cells to incubate 
at 37ºC for a period of 24 hours 
which allowed ample time for 
biotinylation of cellular proteins. We then lysed the cells and performed a 
Western blot where we probed with streptavidin-HRP to determine and 
compare biotinylation levels of the BirA*-CTPS expressing cells and the wild 
type cells.  This analysis revealed that BirA*-CTPS transfected cells had a 
high amount of biotinylation while the control cells had significantly less 
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Figure 14. Biotinlyation of proteins in BirA*-
CTPS expressing cells and non-expressing 
cells. Cells containing BirA*-CTPS have 
markedly more biotinylated proteins than 
untransfected cells. This demonstrates that 
cells containing the BirA*-CTPS construct 
more indiscriminately biotinylate proteins than 
the untransfected cells. 
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biotinylation of proteins (Figure 14). These results indicate that the BirA*-
CTPS construct is less selective in its biotinylation of proximal cellular 
proteins than the endogenous, wild type biotin ligase of HEK293 cells. 
Because wild type HEK293 cells, like other mammalian cells, contain only a 
few biotinylated proteins, there would still be some selective protein 
biotinylation occurring although the levels are nowhere near to what is seen 
in BirA-CTPS containing cells.  
We were able to conclude that the fusion protein was a useful tool for 
identifying additional filament components because when BirA*-CTPS 
localizes to filaments within the cell, it is likely to biotinylate any other 
protein that may be within close proximity to it within the filaments.  
 
BirA*-CTPS identifies known filament components—IMPDH2 and CTPS1 
and one candidate protein Histidine Ammonia Lyase 
 It is currently unknown whether or not CTPS1 containing filaments in 
mammalian cells have additional proteins, other than IMPDH and Ack. In 
order to determine if there are additional proteins within the mammalian cell 
filaments, we transfected HEK293 cells with BirA*-CTPS and then the 
following day, we either treated them with DON overnight to induce 
filaments or left them untreated. We then incubated the lysates of these cells 
with Neutravidin resin in order to separate biotinylated proteins from non-
biotinylated proteins. Neutravidin is the deglycosylated version of native 
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avidin (Marttila et al., 2000). This 
removal of excess carbohydrate 
results in a more neutral 
isoelectric point and therefore less 
nonspecific protein binding 
(Marttila et al., 2000). We took a 
small amount of lysate from both 
the DON treated and the 
untreated control and separated 
this on a 10% SDS-PAGE gel. We 
then performed a silver stain 
analysis to determine if there were any differences in the protein 
biotinylation detectable by eye. Seeing this might indicate that certain 
proteins, which would normally not be in close proximity to CTPS, are 
localizing with the construct upon filament induction and getting 
biotinylated. We observed that both the DON treated and the untreated 
control had similar patterns of protein biotinylation. This does not 
conclusively mean that there are no other proteins assembling with CTPS 
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Figure 15. Silver stain of lysates from 
untreated and DON treated cells. A small 
amount of DON treated and untreated samples 
were run in a 10% SDS PAGE gel and a silver 
stain was performed to look for any DON 
specific protein biotinylation.  Arrows are 
pointing to a band that is more heavily 
biotinylated in the DON treated sample. 
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within the filaments, rather it may just be undetectable by eye in the gel 
(Figure 15).  In preparation for mass spec analysis, we then separated the 
remaining samples on a 10% SDS-PAGE gel and then identified protein 
bands by staining with Coomassie blue stain (Figure 16). We then cut the 
treated and untreated lanes into 5 sections each being sure to carefully 
section off any bands that were evident within one piece. Section 1 contained 
proteins >150 kD in weight +, section 2 contained protein bands 75-150 kD in 
weight, section #3 contained proteins 50-75 kD in weight, section #4  
contained proteins 37-50 kD in weight, while section #5 contained proteins 
that were 25-35 kD in weight. We froze the gel sections and shipped them on 
dry ice for protein identification via mass spectrometry. Mass spectrometry 
Figure 16. Coomassie dye stained gel of lysate from untreated 
and DON treated cells. This gel was then cut into sections which 
were then used for mass spec analysis as described in the text. 
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revealed a number of biotinylated proteins, including two of those known to 
be contained within the filaments—CTPS and IMPDH—although CTPS and 
IMPDH showed up in both the DON treated and untreated samples.  
Interestingly, another protein referred to as histidine ammonia lyase (HAL) 
not only was exclusively found  
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Table 1. Proteins unique to DON treated samples: Mass spectrometry revealed a number of 
proteins that were found only in the DON treated samples. The protein with the highest number of 
unique peptides was HAL (seen in red). 
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within the DON treated sample, but also had the highest number of unique 
peptides of all the proteins in the DON treated samples. HAL is an enzyme 
that releases ammonia during its reaction. Therefore, HAL may be localizing 
with CTPS within the filaments to provide ammonia for CTPS. CTPS 
requires ammonia in order to carry out its reaction. 
 
Verification of HAL as a 
filament component  
In order to determine 
if HAL localized to the 
filament upon cellular   
treatment with DON, we 
treated HEK293 cells with 
200 µM of DON overnight to 
induce filament assembly 
and then performed 
immunofluorescence where 
we stained for endogenous 
HAL. Immunofluorescence revealed that HAL localized to the filaments upon 
DON treatment (Figure 17).  
Figure 17. HAL localizes to filaments upon 
DON treatment. HEK293 cells were 
treated with Don overnight and then fixed 
and stained with anti-HAL antibody 
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Figure 18. Anti-HA antibody non-specifically cross reacts with filaments. (A)  HEK293 cells were 
transfected with HA-SBP-HAL, treated with DON overnight, and then stained for HA in order to 
determine if the transgenic HAL localized to the filaments .Although filaments could be seen in 
transfected cells upon staining with HA. (B) Untransfected cells also displayed filaments upon 
staining with anti- HA this demonstrates that the HA antibody non-specifically labeled any 
filaments contained within the cells. (C) The control with no primary antibody displayed no 
filaments. 
B C 
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In order to verify these results, we transfected cells with HA-SBP-HAL 
and then the following day we treated them overnight with DON in order to 
induce filament assembly. We then performed immunofluorescence staining 
for HA to determine if the recombinant, tagged, HAL protein localized to the 
filaments. 
Unfortunately, we discovered that the primary antibody, anti-HA, 
nonspecifically labeled filaments, therefore verification as to whether or not 
DON induced CTPS filaments contain HAL remains to be determined (Figure 
18). 
 
Discussion 
My study is the first to implement the Bio-ID system coupled with 
mass spectrometry to identify filament components. Using these two 
methods, I was able to identify the previously unidentified filament 
component candidate HAL. HAL was of great interest, not only because it 
had the highest number of unique peptides of all the proteins that were only 
biotinylated in the presence of DON, but also because of the role that it 
fulfills within the cell. HAL is the first enzyme involved in the degradation of 
histidine to glutamate (Schwede et al., 1999). HAL catalyzes the reaction that 
removes ammonia from L-histidine and results in the production of urocanic 
acid (Galpin, 1999).  
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The process of amino acid degradation occurs when they are released 
from protein digestion and turnover (Berg JM, 2002). This degradation 
mostly occurs within the liver (Berg JM, 2002). CTPS utilizes ammonia in the 
reaction that it catalyzes. But DON, being a glutamine analog, inhibits the 
ability of cells to use glutamine as an ammonia source. Therefore, it is 
interesting that HAL, which can create ammonia from a source other than 
glutamine, might be contained within the filaments. Perhaps it is providing 
ammonia for CTPS in the absence of glutamine. 
Although Bio-ID is a very useful system because it detects protein-
protein interactions within their natural cellular context and interactions 
that are weak and transient, there are some limitations to this system that 
could have affected our ability to detect filament components (Roux et al., 
2012). For example, cells are given an unnaturally high amount of biotin in 
order to enhance the biotinylation of the proximal proteins (Roux et al., 
2012). Biotin is covalently attached to primary amines, mainly lysines, and 
this results in a charge loss at these sites (Roux et al., 2012). This loss of 
charge could impede secondary modifications which may change the behavior 
of the fusion protein itself and the neighboring proteins (Roux et al., 2012). 
This could affect what proteins get biotinylated and also the ability of the 
fusion protein itself to biotinylate proximal proteins (Roux et al., 2012). In 
addition, the fact that this system depends on the number and availability of 
primary amines in nearby proteins, and has an estimated maximum activity 
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radius of only 20-30 nm, means that a high amount of biotinylation on a 
protein does not necessarily correlate with a high abundance of an 
association. Likewise, the lack of biotinylation does not mean there is no 
interaction or proximity of a protein (Roux et al., 2012). This means that 
there may be additional proteins within the filament that BirA*-CTPS did 
not biotinylate. Also, this system cannot be used as validation for a protein-
protein interaction. Rather, this system should be a screen to identify 
candidates, such as HAL, which should then be investigated and verified by 
other methods.  
One may ask, why would the cell put a group of different proteins all 
together within a single structure? For example, two known filament 
associating proteins, CTPS and IMPDH, are from two completely different 
pathways. What is known is that proteins rarely act alone within cells and 
more often than not come together as “molecular machines” in order to carry 
out various biological processes (De Las Rivas and Fontanillo, 2010; Herce et 
al., 2013; Westermarck et al., 2013). Essentially all functions within the cells 
require proteins to interact with other proteins (De Las Rivas and Fontanillo, 
2010; Herce et al., 2013; Westermarck et al., 2013). The correct assembly of 
the proteins is also of great importance and most often signaling cascade 
activation involves the assembly of multiprotein complexes (Westermarck et 
al., 2013). Therefore, it is possible that these proteins come together within 
the filaments in response to the triggering of some signaling cascade in which 
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they may take part. These proteins may come together in order to interact 
and regulate each other’s activity in a specific way that is needed for the 
current condition within the cell. In other words, perhaps those proteins that 
come together, under the condition that the cell brings them together, need to 
be regulated in a specific way in order for the cell to metabolically adapt to 
the changes that are occurring. If this is indeed the case, some follow-up 
questions could be, how exactly are these components being regulated once 
they are in contact with other proteins within the filament? And once 
assembled within the filaments, what task (or tasks) does this protein 
complex carry out? Additionally, how do the activities of these proteins differ 
when they are not assembled? 
Within a single organism or cell type, the specific proteins that 
assemble together into these filaments may vary depending on the particular 
condition or need at the time. Moreover, this could differ from organism to 
organism as different organisms have different requirements and needs. 
Therefore, determining the complete composition of the filaments may be a 
difficult if not impossible task to achieve. 
 
Future directions  
 Another way to verify HAL as a filament component is to knock down 
protein levels of endogenous HAL from the cells, and then perform 
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immunofluorescence using the endogenous anti-HAL antibody to determine if 
it still localizes to the filaments. If the knockdown of HAL results in reduced 
amounts of HAL within the filaments as compared to cells without 
knockdown that would verify HAL is a filament component. This would be 
further verified if the introduction of recombinant HAL within these 
knockdown cells results in the reappearance of the protein within the 
filaments.  
 If HAL is verified as a component, whether or not HAL is a core 
component of the filaments should be determined. Protein levels can be 
knocked down within cells and then filaments induced with DON. 
Immunofluorescence can then be performed to look at each of the currently 
known filament components to determine if filaments can still assemble. It 
may be that HAL is needed for IMPDH assembly into filaments, but not 
needed for CTPS assembly into filaments or vice versa. Alternatively, HAL 
may be necessary for any filament assembly to occur. If filaments can still 
assemble, that suggests that HAL is not a core component and is therefore 
not necessary for filament assembly. If filaments cannot assembly upon 
knockdown of HAL, that suggests that HAL is a core component and is 
necessary for filament assembly.   
The function of HAL within the filaments should also be determined 
subsequent to its verification as a filament component. It is known that HAL 
releases ammonia as a result of the reaction it catalyzes. Ammonia is used by 
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CTPS in its reaction. Therefore, one could ask if HAL activity is necessary for 
the maintenance of the filament structure. In order to address this question, 
a mutant of HAL can be synthesized which renders it enzymatically inactive.  
This can then be expressed within cells and the cells can be DON treated in 
order to induce filament assembly. Immunofluorescence can then be 
performed to determine if there are any changes to filament morphology. If 
there are changes to filament morphology, for example if there are little if 
any filaments assembled as compared to control cells with wild type HAL, 
this would suggest the HAL enzymatic activity is necessary for the 
maintenance of the filament structure. 
 A fusion protein consisting of BirA* and IMPDH can also be 
synthesized to determine if there are additional filament components. It is 
possible, that other filament components may be out of reach to BirA*-CTPS 
because they localize too far away from CTPS, but they may localize close 
enough to IMPDH for a BirA*-IMPDH fusion protein to biotinylate them. 
 Another way to identify filament components is to use IMP affinity 
purification. To do this, filaments can be induced within cells, and then cells 
can be gently lysed to release the filaments from the cell. To capture the 
filaments, IMP, a substrate of IMPDH, can be conjugated to sepharose beads. 
The beads can then be packed into a column and the cell lysis applied to the 
column. The beads can be washed with the lysis buffer and then filaments 
can be eluted with a molar excess of IMP. The eluate can then be run on an 
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SDS PAGE gel and the bands that show up in a DON dependent manner can 
be excised. Mass spectrometry can be performed on the proteins in this gel 
piece and identified proteins can then be verified as FINS components using 
immunofluorescence. 
Another method is subcellular fractionation which isolates the 
filaments from other cellular structures. This can be achieved by gradient 
centrifugation where components within the cell can be separated based on 
size and density.  
Yet another approach is to do a genome screen for filament forming 
fluorescence tagged proteins within mammalian cells (Narayanaswamy et al., 
2009; Noree et al., 2010; Shen et al., 2016). It can then be determined if any 
of these proteins co-assemble with CTPS within the filaments.  
In conclusion, there are many other methods that can be used in order 
to search for additional filament components, if they exist. 
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Chapter 3: The biological role of filament assembly 
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Introduction 
It is currently known that IMPDH reversibly assembles into linear 
polymers as a purified protein in vitro and into larger filamentous bundles in 
cells (Juda et al., 2014). This enzyme catalyzes the rate-limiting step in de 
novo guanine nucleotide biosynthesis. The question as to why IMPDH 
assembles into filaments and the role that these filaments serve within the 
cell is a question that is currently foremost in the field. Whether filament 
assembly within the mammalian cell is tied to a change in the enzymatic 
activity of IMPDH, or whether the filaments are even enzymatically active 
are big questions that have yet to be answered clearly. A major challenge in 
evaluating the effect of assembly on IMPDH catalytic activity is the fact that 
IMPDH is usually not polymerized in cultured cell lines grown in typical 
nutrient rich media. Filament assembly can be triggered, however, by 
treatment of cells with inhibitors of purine biosynthesis such as the IMPDH 
inhibitors MPA or ribavirin, inhibitors of enzymes acting both upstream and 
downstream of IMPDH such as methotrexate and DON, or by depleting the 
culture media of essential purine precursors such as glutamine or one-carbon 
units using methotrexate. This responsiveness of IMPDH to reduced flux 
through the guanine biosynthetic pathway suggests that assembly could be 
associated with a homeostatic mechanism to restore guanine nucleotide 
levels. Alternatively, the filaments may just serve as a place for the cells to 
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store inactive enzyme. The experimental conditions, however, have a big 
impact on IMPDH activity that is separate from filament assembly.  
Remarkably, (Labesse et al., 2013) studied purified IMPDH from the 
Pseudomonas aeruginosa and found that the addition of ATP, which triggers 
filament assembly in purified IMPDH protein, also resulted in an almost 3 
fold increase in enzymatic activity. They found no such increase in the 
enzymatic activity of filamentous human IMPDH1 (Labesse et al., 2013). 
Scott et al. (Scott et al., 2004) found that the addition of ATP resulted in a 
fourfold enhancement of the enzymatic activity in purified human IMPDH2. 
However, a number of other groups were unable to reproduce this ATP 
induced increase in activity for neither IMPDH2 nor IMPDH1 (Carr et al., 
1993; Labesse et al., 2013; Mortimer and Hedstrom, 2005; Thomas et al., 
2012). Nevertheless, the conclusion that filamentous IMPDH is at least 
enzymatically active can still be drawn from these findings. 
It was concluded by (Chang et al., 2015) that IMPDH filament 
assembly was associated with an upregulation of enzymatic activity. They 
determined that there was an association between filament assembly and 
active signaling pathways for cell growth within the cell (Chang et al., 2015). 
They assessed the buildup of GTP within the cells after 3’-deazauridine 
treatment. 3’-deazauridine treatment inhibits CTPS and increased IMPDH 
filament assembly (Chang et al., 2015). They also found an increase in 
cellular GTP levels (Chang et al., 2015), but the problem with just measuring 
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GTP levels is that increased levels can result not only from increased de novo 
IMPDH activity but also from increased RNA degradation, nucleotide 
salvage, or even reduced cellular GTP consumption. 
Therefore, thus far there is no direct evidence to show that there is an 
upregulation in IMPDH activity and thus increased flux through the de novo 
purine synthesis pathways upon filament assembly. Nonetheless, when 
considering the previous research altogether, it seems to be agreed upon 
within the field that IMPDH in filamentous form (if assembly is not triggered 
by an IMPDH inhibitor) is enzymatically active. Therefore, the question of 
how IMPDH filament assembly affects catalytic activity remains to be 
answered which is what we sought to do in our study described below. 
 
Materials and methods 
Cell culture and transfection 
HEK293 cells ( kindly given to us by Dr. Marc Kirschner) were cultured at 
37°C in DMEM (Cellgro) supplemented with 10% FBS (Hyclone), 2mM L-
glutamine (Gibco), 1% penicillin and 1% streptomycin. Cells were transfected 
using Lipofectamine 2000 in Opti-MEM Reduce Serum Medium 
(ThermoFisher Scientific, # 51985034) as per manufacturer’s instruction. 
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Immunoblotting 
SDS-PAGE gels were transferred by semi-dry transfer apparatus 
(Amersham) to nitrocellulose membranes. Membranes were blocked using 5% 
milk in tris-buffered saline. Anti-myc (Santa Cruz), and anti-IMPDH (Abcam) 
and anti-GAPDH antibodies (Santa Cruz) were used and detected with 
peroxidase coupled secondary antibodies and enhanced using chemi-
luminescence detection (Amersham). 
 
Immunofluorescence 
The R356A, Y12A, S275L and wild type constructs in the pcDNA3.1 vector 
were transfected into HEK293 cells grown on coverslips using Lipofectamine 
2000 (Invitrogen, # 11668027) as per manufacturer’s suggestion. Cells were 
then treated with 10 µM of MPA the following afternoon in order to induce 
filaments. The following day, cells were fixed with 4% formaldehyde for 20 
minutes at room temperature, permeabilized in 0.5% Triton X-100 for 10 
minutes and then blocked in Abdil (phosphate buffered saline with 0.1% 
Triton X-100, 2% BSA. 0.1% Sodium azide) for ten minutes. Cells were 
incubated with Anti-mouse myc (diluted 1:100 in Abdil, Santa Cruz, sc-40) for 
an hour and then for 30 minutes with secondary Texas red goat anti mouse 
antibody (diluted 1:200 in Abdil) to identify any transgenic IMPDH 
containing filaments. Nuclei were visualized using DAPI. Images were taken 
using MetaVue software (Molecular Devices) controlling a CoolSnap ES 
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camera (Photometrics) on a Nikon TE2000-U inverted microscope. The 
objective used was a 60x Plan Apo 1.40 NA Nikon. 
 
Vectors 
IMPDH: For expression in mammalian cells, IMPDH2 contained within a 
pcDNA3.1(+)/myc-His B vector was used. IMPDH2 being N terminal to the 
myc and 6 histidine tag. Expression is driven by the CMV promoter. For 
recombinant IMPDH2 expression in E. coli (for the purpose of protein 
purification), IMPDH contained within a pSMT3-Kan vector (derived from 
the pET-28a (+) vector) was used (Figure 19). This vector has a cleavable 
Smt3/SUMO tag cloned between the NhI and BAMHI sites. This SUMO tag 
can be cleaved off using a protease called Ubiquitin-Like protein (ULP1). 
IMPDH was cloned in C-terminal to this tag between the SacI and EagI 
restriction sites.  
ULP1: The coding  region for ULP1 (403-621) was amplified from the genomic 
DNA of the S. cerevisiae genomic DNA (W303-1A) by PCR which generated 
the coding region with a 5’ NheI restriction site sequence and a 3’ SacI 
restriction site sequence. This was then cloned in the corresponding 
restriction sites within the pET28b-Kan vector (Novagen).  
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Figure 19. pSMT3-Kan vector map 
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Mutagenesis 
Mutagenesis was conducted using QuickChange site-directed 
mutagenesis (Agilent) according to manufacturer’s instructions. Mutagenesis 
was conducted with the following forward primers and their corresponding 
reverse complements:  
R356A 5’-CAGAGTATGCACGGGCCTTTGGTGTTCCG-3’  
Y12A 5’-GATTAGTGGGGGCACGTCCGCAGTGCCAGACGACGGACTC-3’  
S275L 5’- GGATGTAGTGGTTTTGGACTTATCCCAGGGAAATTCCATCTTC-
3’ 
Settings used for the thermocycler were as follows: Step 1: 95ºC for 2 
minutes, Step 2: 95ºC for 30 seconds, Step 3: 55ºC for 1 minute, Step 4: 68ºC 
for 7.5 minutes, Step 5: 19 times to step 2, Step 6: 68ºC for 5 minutes, and 
Step 7: hold at 4ºC. PCR products were then placed on ice for two minutes to 
cool down. Digestion of the parent plasmid was achieved by the incubation of 
the PCR product with 1 µl of dpn1 enzyme (New England Biolabs, #R0176L) 
at 37ºC for 2 hours. The success of the PCR was then checked by running 5 µl 
of the PCR product on a 1% agarose gel with an equivalent amount of the 
template as a comparison. Transformation of DH5α cells with pcDNA3.1 
IMPDH2 vector was done as well as a transformation of BL21 (DE3) 
Competent E. coli cells with pSMT3-Kan IMPDH2 plasmids. Then, both cell 
types were cultured separately in Luria Broth and then the DH5α cells 
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containing the pcDNA3.1 vector mutants were placed in agarose plates 
containing ampicillin at a concentration of 100 µg/ml, while the BL21 (DE3) 
Competent E. coli cells containing the mutants in the pSMT3-Kan vector 
were placed on agarose plates containing kanamycin at a concentration of 30 
µg/ml. These plates were incubated overnight at 37ºC. The following 
afternoon, three colonies from each plate were plucked and each was grown 
up in 2 ml of Luria Broth overnight at 37ºC in a rotating incubator. The 
following morning glycerol stocks were made with 360 µl of the cells from 
each of the clones which were then flash frozen and stored at -80ºC. Mini 
preps were done with the remaining cells from each clone and this was sent 
off for sequencing to ensure that the correct mutations had been made and 
that there were no PCR errors. One glycerol stock of the correctly sequenced 
clone from each mutant and cell type was saved, while the others were 
discarded. 
 
ULP1 Protein Purification and expression 
Glycerol stocks: ULP1 plasmid was transformed into BL21 (DE3) Competent 
E. coli cells. Cells were cultured in 1 ml of Luria Broth for an hour, and then 
streaked on a kanamycin containing agar plate. The plate was incubated 
overnight at 37ºC. The following day, a colony was plucked from the plate and 
placed into 1 ml of Luria Broth with 30 µg/ml kanamycin. This was incubated 
120 
 
overnight, while shaking, at 37ºC.  The following day, 320 µl was placed into 
780 µl of sterile 50% glycerol, was flash frozen, then stored at -80ºC. 
Overexpression:  10 ml of Luria Broth was inoculated with cells from either a 
glycerol stock of from a plate. This was grown overnight at 37ºC. The 
following day, the 10 ml cultures were added to 1 L of pre-autoclaved Luria 
Broth containing 50 µg/ml of kanamycin.  This was grown at 37ºC until the 
OD600 reached 2. Cells were induced with 1 mM of IPTG at 20ºC overnight 
while shaking. The following morning, the cells were pelleted and frozen at -
80 ºC until purification or purification was begun immediately.   
Purification: Pellets were resuspended in 35 ml of lysis buffer (pH 7.6- 25 mM 
Tris, 500 mM NaCl, 10 mM imidazole, 10% glycerol, 1 mM BME). Cells were 
then lysed using a homogenizer. Lysates were cleared using Lynx 6000 at 
14,000 rpm, for 45 minutes at 5 ºC.  Cleared lysate was then put into a nickel 
(Ni)-column (either gravity or pre-packed). For the gravity column, the 
column was then washed 3 times in lysis buffer. The cleared lysate was 
incubated with 5 ml column for 1 hour. Column was washed 5 times. A pre-
packed nickel bead column was washed thoroughly with lysis buffer and then 
protein was eluted with 3-5 column volumes of elution buffer (pH 7.6- 25 mM 
Tris, 300 mM NaCl, 400 mM imidazole, 10% glycerol, 1 mM BME). The 
concentration was measured using a Bradford protein assay. The protein was 
then concentrated to 1-3 ml using an Amicon spin filter. The protein was 
loaded onto a Superdex 200 column. A gel of the fractions was then run and 
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the fractions containing the ULP1 were selected.  The pooled fractions were 
then concentrated to the desired volume or concentration. The protein was 
then flash frozen and stored at -80 ºC.  
 
IMPDH Protein Purification and expression 
Overexpression: Sterile pipette tips were gently scraped on the top of the 
R356A, Y12A, wild type, and S275L BL21 (DE3) glycerol stock cells and then 
the tips were each placed into a 25 ml of Luria Broth containing 50 µg/ml of 
Kanamycin and cultured overnight at 37ºC. The following day, each of these 
25 ml cultures was pipetted into flasks containing 1 L of pre-autoclaved Luria 
Broth with Kanamycin at a concentration of 50 ng/ml. These cells were grown 
up at 37ºC until they reached an OD600 of 0.8. Flasks were then cooled on ice 
for approximately 5 minutes, and then induced with 1 mM IPTG 
(GoldBio.com, #12481C50) for 4 hours at 30ºC. Cells were then pelleted for 5 
minutes at a speed of 8000 x g (rotor: Beckman Coulter, JA-10; centrifuge: 
Beckman Coulter Avanti J-E). Pellets were then stored at -80ºC. 
Purification:  Thawed pellets were re-suspended in 20 ml of lysis buffer per 
liter (pH8-50mM KPO4, 300mM KCl, 20mM imidazole, 0.8M urea). 
Resuspended pellets were poured into a beaker with a stirring rod, benzonase 
(Millipore, #2774110) was added to help break up the clumps, and the 
beakers were slowly stirred on ice for ten minutes. Cells were then 
homogenized using the Emulsiflex-C3 (Avestin) with 3 cycles of 10-15 
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thousand psi. Lysates were then cleared at a speed of 18,000 rpm for 20 min 
(rotor: Beckman Coulter JA 25.5; centrifuge: Beckman Coulter Avanti J-E). 
During the spinning, 1 ml per liter of nickel-NTA agarose beads (Qiagen, 
30210) were washed in 10 column volumes of dH2O once and then twice in 10 
column volumes of lysis buffer in a 50 ml centrifuge tube. Twenty µl samples 
of each of the cleared lysates were then taken out and set aside.  One ml of 
beads per liter was then added to the cleared lysates. This was then gently 
rotated at 4ºC for 2 hours. Beads were then harvested by centrifugation of 
lysates at 4000 rpm for 10 minutes (rotor: JS 5.3). Twenty µl of each depleted 
sample were set aside. The remaining depleted sample was discarded. Beads 
were then washed with ten column volumes of lysis buffer a total of three 
times. Elution buffer (pH 8- 50mM KPO4 , 300 mM KCl, 500 mM imidazole) 
was then added to the beads at a ratio of 1:1 bead volume to elution buffer 
volume. Beads were then rotated at 4°C for 15 minutes. The eluate was 
collected then this was repeated four more times to collect four more eluates 
subsequently for 5 minutes each. Protein was then separated on a 10% SDS 
PAGE gel then Coomassie stained to look at protein amounts in cleared 
lysate, depleted lysate, and eluates. Concentrations of each eluate were also 
determined using a Bradford protein assay. Eluates containing the most 
protein were then pooled.  The concentration of each pooled protein was then 
determined using a Bradford. A 20 µl sample of each protein type was then 
taken out and set aside. One mg of ULP1 was then added for every 100 mg of 
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IMPDH protein. The proteins were rotated slowly overnight at 4ºC to allow 
cleavage of the SUMO tag from the IMPDHs to occur.  The following day, the 
proteins alongside their pre-cleaved samples were separated on a 10% SDA-
PAGE gel to verify that the SUMO tag had been cleaved from the protein. 
The concentrations of the proteins were once again determined using a 
Bradford protein assay. Based on this concentration, the volume that the 
proteins were to be concentrated to (3K Amicon Ultra centrifugal filter unit, # 
Z740186) was determined. The protein was then filtered by syringe driven 
filtration (Millex-GP, Z359904) then loaded onto a Superdex 200 or a 
Superose 6 gel filtration column pre-equilibrated in gel filtration buffer: (50 
mM Tris, 100 mM KCl, 1 mM DTT, pH 7.4). A gel of the fractions was then 
run. Fractions that were most pure and had the most protein were pooled 
together. The concentrations of the pooled samples were then determined 
using a Bradford protein assay. The proteins were aliquoted, flash frozen in 
liquid nitrogen, and stored at -80ºC. 
 
IMPDH activity assay 
NADH standard curve: Fivefold dilutions of NADH were created and four 
different amounts of NADH from these dilutions were used for the standard 
curve: 0.016, 0.0032, 0.00064, and 0.000128 µmoles. The corresponding 
fluorescence level at each of these amounts of NADH was determined using a 
fluorimeter (Cary Eclipse). This was then plotted as fluorescence (AU) versus 
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NADH (µmol). A line was fitted to the scatter plot and an equation was 
derived from this.  
 
Determination of IMPDH specific activity: Reaction mixtures containing 
IMPDH2 were placed into a cuvette and the amount of NADH production 
over time was determined using a fluorimeter (Cary Eclipse) which 
determines the fluorescence over a period of 3 minutes (approximately 9 
measurements per minute). Each of these fluorescence readings at each time 
point was then plugged into the y value of standard equation to determine 
the x value, which is the corresponding µmoles of NADH at the given time 
point. The µmoles of NADH versus the time was plotted and a line was fit to 
the scatter plot. An equation was then derived from this line. The slope of 
this line, which is the µmoles of NADH produced per minute, was used to 
determine the specific activity which was written as “µmoles of 
NADH/min/mg”.  
IMPDH Activity assays: To determine the specific activities of the different 
IMPDH constructs, IMPDH activity buffer (50 mM tris, 100 mM KCl, 1 mM 
DTT, pH 7.4) with 5 mM NAD and 3 mM IMP was mixed together in a 
microcentifuge tube. The reaction was then initiated by the addition of 13.8 
µg of protein bringing the reaction mixture to a final volume of 100 µl. In the 
experiments where ATP or ATP and substrate were added, 13.8 µg of protein 
was pre-incubated with 1 mM ATP at room temperature for ten minutes and 
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the reaction was initiated with 5 mM NAD and 3 mM IMP or 13.8 µg of 
IMPDH was incubated with 1 mM ATP and 5 mM NAD or 1 mM ATP and 3 
mM IMP and then the reaction was initiated with various concentrations of 
the second substrate. In the case where protein was incubated with 1 mM 
ATP, 3 mM IMP and GTP, after the 10 minute incubation of 13.8 µg of 
IMPDH with 1 mM ATP and 3 mM IMP, IMPDH was subsequently 
incubated with various concentrations of GTP for 10 min before the initiation 
of the reaction. All activity assay reactions had a final volume of 100 µl.   
NADH production was measured in real time in a 100 µl cuvette (1 cm path 
length) in a Cary Eclipse fluorimeter (excitation: 340 nm, emission: 440 nm) 
equipped with a temperature controlled multi-cuvette holder maintained at 
37°C. The specific activity for each protein was then determined under each 
condition using the previously described procedure. The specific activities 
were normalized to the specific activity value without ATP incubation, or the 
specific activity value without substrate incubation. 
 
Negatively Stained electron microscopy and particle 
averaging/reconstruction 
Aliquots of purified protein, including wild WT IMPDH and the 
mutants Y12A, R356A, and S275L, were diluted to 2.5 µM in assembly buffer 
(50 mM Tris, 100 mM KCl, 1 mM DTT, pH 7.4) and incubated for 15 minutes 
at room temperature in the presence of various concentrations of ATP, GTP, 
126 
 
IMP, and NAD+, as outlined in Figures 20D and 23C. Following incubation, 
samples were applied to glow-discharged continuous carbon film EM grids 
and negatively stained using 1% uranyl acetate. Grids were imaged by 
transmission electron microscopy using an FEI Tecnai G2 Spirit operating at 
120 kV and a Gatan Ultrascan 4000 CCD via the Leginon software package 
(Suloway, et al., 2005). Image processing, including CTF estimation, particle 
picking, and two-dimensional reference-free classification, was performed 
using the Appion and RELION software packages (Lander et al., 2009; 
Scheres, 2012). The image data collected from all ATP/GTP/IMP/NAD+ 
combinations were combined and processed en masse (77,525 helical repeats 
in total). Following 2D classification, the resulting class averages were 
manually grouped according to the observed rise into one of three categories: 
“compressed” (rise ~94 Angstrom (Å)), “extended” (rise ~114 Å), or 
“undetermined” (filament ends, distorted and bent octamers, and poorly 
aligned particles). The proportion of helical repeats from each experimental 
dataset belonging to these three categories was then back-calculated. 
 
Electron cryo-microscopy and particle averaging/reconstruction 
Purified Y12A protein was diluted in assembly buffer to 4 µM, and 
incubated at room temperature in the presence of 0.1 mM ATP and 0.1 mM 
GTP for 15 minutes. Following incubation, the sample was applied to a glow-
discharged C-Flat holey carbon EM grid (Protochips), and blotted/plunged 
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into liquid ethane using a Vitrobot plunging apparatus (FEI). Imaging was 
performed using an FEI Tecnai G2 F20 operating at 300 kV and a Gatan K-2 
direct electron detector via the Leginon software package (Suloway, et al., 
2005). Image processing, including CTF estimation, particle picking, two-
dimensional reference-free classification, three-dimensional classification and 
3D refinement, was performed using the Appion and RELION software 
packages (Lander et al., 2009; Scheres, 2012). The map resolution, as 
determined by the relion_postprocess script using the Fourier shell 
correlation (FSC) = 0.143 criterion was 8.7 Å. The final electron density map 
was further sharpened using a b-factor of -987. 
 
 [13C2, 15N]-glycine incorporation into AMP and GMP 
 HEK-293 cells were maintained in DMEM (Cellgro) containing 10% 
FBS (HyClone) and 2 mM L-glutamine (Gibco). 24 hours prior to the glycine 
addition, two 10-cm dishes of 40% confluent HEK-293 cells were transfected 
with either the empty vector pcDNA 3.1/myc-His B or S275L IMPDH2 or 
Y12A IMPDH2 constructs using Lipofectamine-2000 (ThermoFisher 
Scientific) as per manufacturer’s instructions. The next day, cells were 
washed once in Dulbecco’s PBS (Gibco) and the media of the cells was 
replaced with DMEM containing 10% dialyzed FBS, 2 mM L-glutamine, and 
1.2 mM [13C2, 15N]-glycine (Cambridge Isotope Laboratories). After 6 hours, 
cells were washed once with Dulbecco’s PBS, released from plates with 0.25% 
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trypsin-EDTA, harvested, washed twice more with Dulbecco’s PBS, and 
counted. Cells from paired tissue culture dishes were pooled, resulting in 1-
10x106 cells per sample. 
Samples were then processed as described (Laourdakis et al., 2014). 
Briefly, 70 l of a solution containing 0.5 M perchloric acid and 200 M of the 
internal standard [13C9, 15N3]-CTP was added to each cell pellet. The cells 
were vortexed for 10 seconds and incubated on ice for 20 minutes. Lysates 
were then neutralized with 7 l of 5 M potassium hydroxide, vortexed for 10 
seconds, and incubated on ice for an additional 20 minutes. Cell debris was 
harvested by centrifugation at 11,000 x g for 10 minutes at 4°C. 
Supernatants were further clarified using Amicon Ultra 0.5 ml centrifugal 
filters (3 kD MWCO) as per manufacturer’s instructions. 
Collected extracts were analyzed by ultra-performance liquid 
chromatography-tandem mass spectrometry (UPLC-MS/MS) using a Waters 
Acquity UPLC HSS T3 column (1.8 mm, 2.1 mm x 50 mm). Quantitative 
analysis of nucleotides was performed using the multiple reaction monitoring 
(MRM) mode, and the peaks of nucleosides and nucleotides were analyzed 
using MassLynx V4.1. In addition, calibration standards were freshly 
prepared for every sample set analysis, and linear calibration curves were 
established. All reported data represent the mean and standard error of three 
biological replicates. P values were calculated using two-tailed unpaired 
Student’s t-tests in Graphpad Prism.  
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For each replicate, samples for immunofluorescence and Western 
blotting were prepared in parallel to samples for nucleotide extraction. Cells 
for immunofluorescence were stained as described previously for total 
IMPDH and myc tagged protein except that DRAQ5 (Biolegend) was used as 
the nuclear stain. Images were obtained using a Leica DM 5000 microscope 
coupled to a Leica TCS SP5 confocal laser scanner. For Western blot analysis, 
cells were lysed in RIPA buffer supplemented with Complete protease 
inhibitor cocktail (Roche). Proteins were separated by SDS-PAGE and 
transferred to nitrocellulose. Blots were stained with anti-IMPDH2 antibody 
EPR8365(B) (Abcam). 
 
Results 
Mutants of IMPDH alter the ability of IMPDH2 to polymerize 
In order to determine the effect of IMPDH2 polymerization on catalytic 
activity, we sought to identify residues within the putative octamer 
polymerization interface that when mutated to alanine would disrupt 
IMPDH2 polymerization. We used the IMPDH2 crystal structure (PDB code: 
1NF7) which contains stacked octamers that resemble IMPDH filaments 
(Labesse et al., 2013). Working with the assumption that these crystal 
contacts are the same as polymerization interfaces in IMPDH2 filaments, we 
engineered a series of mutants that we predicted would block polymerization 
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(Figure 20A). The myc-tagged mutants were then individually transfected 
into HEK293 cells. This was done to ensure that there were similar levels of 
each mutant being expressed within the cells, therefore, in subsequent 
assays, any observed differences between the behaviors of the mutants would 
not be attributed to a difference in protein expression. To our satisfaction, we 
found that the expression levels of the wild type and mutant constructs were 
comparable as were the endogenous IMPDH2 expressions within transfected 
cells (Figure 20B). In wild type, and mutant expressing cells, filament 
assembly was then induced by treatment with the IMPDH inhibitor MPA, 
overnight. This was then visualized using immunofluorescence staining with 
anti-myc antibodies. Of the amino acid residues selected for mutagenesis 
(threonine 10, aspartate 15, tyrosine 12 (Y12A), and arginine 356 (R356A))  
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Figure 20. Identification of filament disrupting and promoting point mutations of 
human IMPDH2. (A) The human IMPDH2 octamer (PDB file 1NF7). One octamer 
(color: greens-catlytic domains,pinks-regulatory Bateman domains) is shown with a 
subset of crystal packing neighbors (gray). Residues tyrosine 12 (red) and arginine 356 
(orange) located at crystal contact sites near the presumed filament assembly interface 
are indicated. (B) Immunoblot of HEK293 cell lysates with antibodies directed against 
myc-IMPDH2, total IMPDH, or loading control glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH). (C) Immunofluorescence images of HEK293 cells transiently 
transfected with the indicated IMPDH2-myc construct stained with anti-myc 
antibodies. Cells were either treated with 10 µM mycophenolic acid to induce IMPDH2 
assembly or not as indicated. Images are representative of 3 experiments. Scale bar, 20 
µm. (D) Negative stain electron microscopy of purified, recombinant IMPDH2 proteins 
incubated in the presence of 5 mM NAD, with and without 1 mM ATP. Images 
representative of 2 separate experiments. Scale bar 50 nm. 
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only Y12A and R356A strongly disrupted filament induction by MPA while 
wild type assembled as expected (Figure 20C).  
We then wanted to confirm that these mutations were acting directly 
on IMPDH2 self-assembly (as opposed to disrupting protein folding or 
interactions with assembly partners), so we used electron microscopy to 
directly visualize recombinant wild type and mutant IMPDH2. The wild type 
protein appears as a mixture of octamers and tetramers with occasional short 
filaments in the absence of ligands, and formed long polymers in the presence 
of ATP (Figure 20D). In the absence of ligands, Y12A and S356A appear as a 
mixture of octamers and tetramers without any short polymers, and no 
polymers were observed in the presence of ATP, indicating that the 
mutations directly interfere with polymerization (Figure 20D).  
Another mutation, S275L, was identified by another group during a 
study of human IMPDH1 sequence polymorphisms (Wu et al., 2010). This 
mutation results in constitutive IMPDH1 filament assembly when expressed 
in cells (Tse-Yu-Wu, 2011). We created this mutation in IMPDH2 for the 
purposes of our study and confirmed the propensity of S275L to assemble in 
transfected cells, even without MPA present (Figure 20C). Unlike the wild 
type protein, S275L robustly polymerizes in both the presence and absence of 
ATP, which demonstrated that the propensity of S275L to polymerize is an 
intrinsic result of the mutation (Figure 20D). S275L is localized adjacent to 
the NAD+ binding site and the basis for its constitutive filamentation is 
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unclear. Nevertheless, this construct served as a useful experimental 
counterpoint to the non-assembling mutants. 
 
Polymerization does not alter enzymatic activity of IMPDH in vitro 
 We then wanted to determine if polymerization altered the enzymatic 
activity of IMPDH2. To that end, we assessed the catalytic activity of 
purified, recombinant wild type and mutant IMPDH2 by monitoring NADH 
production in real time by fluorescence (Figure 21A & 21B). The increase of 
NADH fluorescence over time resulting from NAD, IMP and IMPDH2 
dependent reduction of NAD to NADH, can be detected with high specificity, 
using a fluorimeter. This can be used to quantify enzymatic activity (Figure 
21B). Initial reaction rates were measured under conditions where saturating 
amounts of the substrates NAD and IMP were used in the absence of ATP. 
We observed no evidence for increased activity of wild type IMPDH2 under 
polymerization conditions (Figure 21C). Similarly, non-polymerizing 
IMPDH2 mutants were unaffected by ATP (Figure 21C). These results 
confirmed our conclusion that these mutations likely do not disrupt protein 
folding. 
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Figure 21. IMPDH2 polymerization does not alter its catalytic activity in vitro. (A) 
Schematic of the IMPDH reaction illustrating production of NADH, which can be 
detected by fluorescence. (B) NADH fluorescence was monitored in reactions lacking 
NAD+, IMP, IMPDH (no enzyme), or in a reaction containing all reaction components 
(Complete). (C) IMPDH activity was measured for wild type and mutant forms under 
non-assembling conditions. All mutants showed no significant difference in activity 
compared to wild type (two-sided Student’s t test; P > 0.05). Bars denote mean and 
standard deviation. (D) IMPDH activity assays as in (C) were conducted in the absence or 
presence of ATP to induce assembly. ATP did not significantly alter activity in any case 
(two-sided Student’s t test). (E & F) Initial reaction rates are plotted as a function of 
substrate concentration for IMP or NAD+ comparing wild type IMPDH2 with non-
assembling mutants under polymerization conditions (1 mM ATP) or for wild type in the 
presence or absence of ATP (G&H). Michaelis constants determined from these titrations 
are given in Supplemental Table 1. 2-5 replicates per substrate concentration. 
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Purified wild type IMPDH2 has been found to polymerize upon 
incubation with its allosteric effector ATP (Labesse et al., 2013). But the non-
polymerizing mutants do not polymerize in the presence of ATP (Figure 20D). 
To determine if filament assembly had an effect on IMPDH2 enzymatic 
activity, we measured the activity of each variant in the presence or the 
absence of ATP (Figure 21D). We found no significant difference in enzymatic 
activity between polymerized IMPDH2 and non-polymerized IMPDH2 
(Figure 21D). Taken together, the comparable activity of IMPDH2 under 
polymerizing and non-polymerizing conditions indicates that assembly of 
purified IMPDH2 does not affect specific activity.  
Measuring the catalytic activity of IMPDH2 under saturating 
substrate concentrations as we previously did might mask subtle differences 
in IMPDH2 substrate affinity in the polymer compared with free enzyme. 
Therefore, we determined Mechaelis constants (Km) of mutant and wild type 
IMPDH2 by measuring the initial reaction velocity at a range of substrate 
concentrations under polymerizing and non-polymerizing conditions. The 
Table 2. IMP and NAD Km values for wild type, R356A, and Y12A 
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mutant and wild type IMPDH2 affinity for IMP (Figure 21E) and NAD 
(Figure 21F) were indistinguishable. This demonstrated that wild type 
IMPDH2 polymers and unassembled mutants have comparable substrate 
affinities. Consistent with this, we found that triggering wild type IMPDH2 
polymerization with ATP also did not affect IMP affinity (Figures 21G, also 
see Table 2). A 10-fold increase in the Km(app.) for NAD+ is likely due to an 
effect of ATP that is separate from polymerization since no difference in 
NAD+ substrate affinity was observed comparing wild type and non-
polymerizing mutants (Figure 21F).  We conclude that substrate affinity is 
not substantially altered by IMPDH2 polymerization. 
 
Polymerization of IMPDH2 into filaments does alter guanine nucleotide 
biosynthetic flux in vivo 
 Next, we considered whether IMPDH2 polymerization might 
alter its catalytic activity in the cellular context in a way not detectable for 
the purified protein in vitro, for example by regulating IMPDH2 interaction 
with other proteins.  To answer this question, we established a way to 
monitor IMPDH2 activity in live cells by monitoring the incorporation of 
isotopically labeled glycine provided in the culture media, into GMP, a 
downstream metabolic product of IMPDH, or AMP as a control.  Glycine is an 
important purine nucleotide precursor. Because IMPDH2 is rate limiting for 
guanine nucleotide synthesis, we hypothesized that if there were any changes 
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in its activity it would affect the rate of labeled glycine incorporation into the 
GMP pool. 
 For our experimentation, we compared the activity the filament 
promoting mutant, S275L, with the non-polymerizing mutant Y12A. 
Importantly, these forms exhibit identical catalytic parameters in vitro 
(Figures 21, C-H). HEK293 cells were transfected with each construct or 
empty vector and were immunostained with antibodies against IMPDH or 
anti-myc antibodies specific to the transfected proteins. Total IMPDH 
expression was increased by ~ 2-fold in IMPDH2-transfected cells compared 
to empty vector-transfected cells, evident from the increased 
immunofluorescence signal (Figure 22A) and by immunoblot (Figure 22B). 
S275L and Y12A expressed at similar levels. As expected, S275L-transfected 
cells showed robust IMPDH2 filaments whereas Y12A-expressing cells 
showed diffuse, cytoplasmic staining (Figure 22A).  
To determine if cells expressing S275L mutant had increased 
nucleotide synthesis as compared to cells expressing Y12A, cultures of 
transfected cells were incubated for 6 hours in culture medium containing 
[13C2, 15N]-glycine at a 3 fold molar excess over unlabeled glycine. This resulted 
in a three unit mass increase in glycine-derived metabolites which allowed 
for the quantitation of pulse-labeled AMP/GMP. The nucleotides were 
extracted and quantified via liquid chromatography-mass spectrometry. 
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Unlike the percentage of isotopically labeled AMP, the isotopically labeled 
GMP fraction was modestly  
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Figure 22. . IMPDH filament formation does not alter GMP synthesis. (A) 
Representative images of HEK293 cells transfected with either empty vector or 
vectors expressing either S275L or Y12A IMPDH2. Transfection of S275L 
IMPDH2 results in constitutive filament formation while transfection of Y12A 
IMPDH2 abrogates filament formation of both transfected and endogenous 
IMPDH. (B) Representative immunoblot of total IMPDH expression in 
transfected HEK293 cells. The higher molecular weight band is the transfected 
protein whereas the lower band is endogenous IMPDH. (C) Incorporation of 
[13C2, 15N]-glycine into AMP and GMP. Center bars represent mean and error 
bars represent standard error for three biological replicates conducted on 
different days. Indicated p values were calculated with a two-tailed, unpaired 
Student’s t test. No statistical differences (P < 0.05) were found between 
samples for incorporation of [13C2, 15N]-glycine into AMP pools.  
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increased in both IMPDH2-transfected cells as compared to empty vector 
control which was consistent with an increase in total IMPDH activity 
(Figure 22C). Interestingly, the percent of GMP incorporating labeled glycine, 
and therefore synthesized by way of IMPDH, was indistinguishable in S275L 
and Y12A expressing cells (Figure 22C). This finding demonstrates that 
polymerized and non-polymerized IMPD2 have comparable catalytic activity 
in vivo. 
 
GTP effects on IMPDH octamer conformation and catalytic activity 
 A recent study found that eukaryotic IMPDHs are subject to feedback 
inhibition by low millimolar GDP or GTP (Buey et al., 2015). The crystal 
structure of Ashbya gossypii IMPDH bound to GDP (PDB: 4Z87) revealed a 
collapsed conformation of the IMPDH octamer mediated by the binding of 
three GDP molecules to sites within the Bateman domain (Buey et al., 2015). 
Two sites overlap with the canonical Bateman domain ATP-binding sites, 
implying that competition between adenine and guanine nucleotides for these 
allosteric regulatory sites and/or binding of a guanine nucleotide to the third 
site can trigger a dramatic conformational change in the IMPDH octamer 
from an expanded, catalytically active form to a collapsed, inactive form. 
Residues that mediate GTP binding are conserved in eukaryotic but not 
prokaryotic IMPDHs, though the ability of human IMPDH to adopt the 
collapsed state has not been reported. To examine this directly we carried out 
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a comprehensive investigation of IMPDH2 conformational states using 
negative stain and cryo-electron microscopy. We sought to determine which 
conformations the human octamer can adopt in the free and filament 
contexts and what role ligands play in determining these conformations. 
We explored a range of combinations and concentrations of ATP, GTP, 
and substrates and assessed the structural consequences using negative stain 
images and two-dimensional, reference-free classification of IMDPH2 
filaments. We identified four major classes of filament segments: expanded, 
collapsed, bent, and ‘poorly aligning’ (Figure 23, A-D). The spacing between 
octamer centers in the expanded conformation is ~110 Å compared to ~95 Å 
in the collapsed conformation. The bent conformation is well-resolved with 
one side matching the spacing of the collapsed conformation and the other 
side matching the expanded conformation, suggesting that in some cases 
octamers may occupy conformational states intermediate in the transition 
between expanded and collapsed, with IMPDH2 monomers present in mixed 
states within a single octamer. We defined as 'poorly aligning' segments that 
were assigned to classes without detailed features. This finding demonstrates 
the surprising plasticity of the filaments to accommodate both expanded and 
collapsed octamer conformations. We quantified the frequency of these 
classes in the presence or absence of ATP, GTP and substrates (Figure 23B). 
This analysis shows that binding of either substrate shifts the conformational 
equilibrium toward the expanded octamer, and that GTP promotes the  
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Figure 23. Ligands influence IMPDH filament architecture by altering the conformation of 
IMPDH protomers  (A & B) (A) Representative class averages of IMPDH filaments in four 
different conformational states, with the height of one IMPDH octamer indicated. (B) 
Quantification of the fraction of IMPDH helical segments in each conformational state as a 
function of ligand concentrations. (C) Negative stain EM reconstruction of IMPDH filament 
structures in the expanded substrate-bound (0.1 mM ATP, 2 mM NAD+) and collapsed GTP-
bound (0.1 mM ATP, 0.1 mM GTP) conformations. The refined helical rotation are rise for the 
expanded filament are 30° and 111 Å, and for the collapsed filament 35.5° and 94 Å, 
consistent with the rise measured directly from two-dimensional class averages in (A).  (D) 
The heights of crystal structures of P. aeruginosa IMPDH-ATP and A. gossypii IMPDH-GDP 
closely match the refined helical rise of the human IMPDH filaments in the expanded and 
collapsed states, respectively. 
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collapsed conformation, suggesting that the balance of GTP and substrates 
tunes the conformational state of the IMPDH filament.  
We performed three-dimensional reconstructions of IMPDH2 filaments 
under conditions where the equilibrium was shifted most strongly toward the 
expanded conformation (0.1 mM ATP, 3 mM IMP, 5 mM NAD+) or the 
collapsed conformation (0.1 mM ATP, 0.1 mM GTP) (Figure 23C), yielding 
structures at ~20 Å resolution. The structures reveal helical polymers formed 
from stacked octamers that differ significantly from each other in their 
refined helical rise (111 Å for expanded and 95 Å for the collapsed state), 
consistent with the 2-dimensional class averages. In the collapsed 
conformation there is a 30.5° rotation between octamers and the collapsed 
filament exhibits an additional 5° of rotation between octamers. It appears 
that the filament assembly contacts between octamers are relatively fixed, 
and the differences in helical symmetry arise primarily from differences in 
the connection between the regulatory Bateman domain and the catalytic 
domain.  
Strikingly, neither filament conformation matches the ~130 Å spacing 
of the human IMPDH2 octamer in its crystal lattice (Figure 20A). Rather, the 
expanded conformation most closely resembles the ATP-bound active octamer 
conformation first reported for Pseudomonas IMPDH (Labesse et al., 2013), 
while the collapsed conformation is most similar to the Ashbya GDP-bound 
inhibited form (Figure 23D) (Buey et al., 2015). The identification of 
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conditions that shift the conformation of IMPDH between collapsed and 
expanded conformations suggests the potential for cooperativity in the 
transition of polymerized octamers between states. This model would imply 
that polymers may function to coordinate octamer conformational changes en 
masse. 
 
 
GTP bound human IMPDH2 takes on a collapsed octamer conformation 
and ATP induced polymerization does not protect against allosteric GTP 
inhibition 
We now wished to confirm that GTP-bound human IMPDH2 adopts a 
collapsed conformation similar to Ashbya IMPDH with high-resolution cryo-
electron microscopy. We determined the 8.7 Å structure of GTP-bound Y12A 
IMPDH2 (Figure 24A). At this resolution alpha-helices are well-defined, 
allowing us to model the overall conformation of the protein by rigid-body 
fitting of the human IMPDH catalytic and Bateman domains into the EM 
density (Figures 24B & 24C). Comparison of this atomic model to the Ashyba 
GDP-bound IMPDH2 crystal structure (PDB ID 4Z87) unambiguously 
demonstrates that under these conditions Y12A assumes the collapsed 
conformation (Figure 24D) and not the extended form (Figure 24E). 
Since both polymerized and octomeric IMPDH2 can adopt the 
expanded and collapsed conformations, we hypothesized that polymerization 
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might stabilize the expanded conformation, reducing negative feedback 
inhibition and allowing higher steady state GTP accumulation in certain 
biological contexts. To test this, we measured the effect of GTP on the activity 
of wild type and mutant IMPDH2 under polymerization conditions. Contrary 
to our hypothesis, we observed comparable low millimolar GTP-mediated 
inhibition of all three forms (Figure 24F). Although we cannot rule out subtle 
differences in the kinetics or cooperativity of inhibition in the two contexts. 
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Figure 24. Human IMPDH adopts the collapsed, inhibited conformation when bound to 
GTP.(A) Cryo-EM reconstruction of human Y12A IMPDH2 non-polymerizing mutant in 
the presence of 0.1 mM ATP and 0.1 mM GTP, at 8.7 Å resolution. Both catalytic (greens) 
and Bateman (pinks) domains are well resolved. (B) The atomic model of IMPDH2-ATP-
GTP, generated by fitting the catalytic domain and Bateman domains into the cryo-EM 
structure as two separate rigid bodies.  (C) Close-up view of a single IMPDH monomer fit 
in the cryo-EM structure. (D) A monomer of the A. gossypii IMPDH-GDP crystal structure 
(gray) (PDB ID 4Z87) aligned to the human IMPDH2-ATP-GTP model (color) on the 
catalytic domain (green). A rotation of ~3° relates the human Bateman domain (pink) to 
the A. gossypii structure. (E) The same alignment as (D), but to the P. aueriginosa 
IMPDH-ATP monomer, in which the Bateman domains are related by a 14° rotation. (F) 
Dose-dependent inhibition of wild type and mutant IMPDH2 activity by GTP. IMPDH2 
was incubated with 1 mM ATP and 3 mM NAD+ for 10 minutes at room temperature to 
promote polymerization and then the indicated concentration of GTP was added for an 
additional 10 minutes prior to reaction initialization by addition of 5 mM IMP. Mean 
values are plotted and were fit to a three-parameter dose-response curve. Each data point 
represents 3-6 replicate reactions. 95% confidence intervals are plotted as dotted lines of 
the corresponding color. (G) Model: human IMPDH exists in a conformational equilibrium 
between an expanded active conformation and a collapsed inactive conformation that can 
be shifted by binding to substrates or GTP. Unlike other metabolic filaments, the 
conformational equilibrium of IMPDH is unaffected by polymerization because the 
filament form can accommodate both active and inactive conformations. 
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Discussion 
 IMPDH is a rate limiting enzyme that is crucial for the process of de 
novo purine nucleotide synthesis. IMPDH catalyzes the reaction which 
converts IMP into XMP which is the first committed step in guanine 
nucleotide production. Because of this, it is considered to be the gatekeeper 
for the production of guanine nucleotides therefore making it essential to 
almost all organisms studied thus far.   
IMPDH also has important clinical relevance. Highly proliferative 
cells, such as cancer cells, have a great demand for guanine nucleotides and 
this demand cannot be met using the salvage pathway (Natsumeda et al., 
1984). In fact studies have shown that IMPDH2 in particular is highly 
upregulated in cancers such as leukemias (Konno et al., 1991; Nagai et al., 
1991)  This makes IMPDH an enzyme of consequence in cancer. 
 Within the past ten years the finding that this enzyme is capable of 
assembling into filamentous structures has been of great interest. Within 
mammalian cells, it was found that IMPDH can be triggered to polymerize 
within mammalian cells by use of IMPDH in inhibitors (Ji et al., 2006). In 
addition, these IMPDH filaments were found within the peripheral blood 
mononuclear cells of Hepatitis C patients undergoing ribavirin treatment 
(Carcamo et al., 2011). In vitro, IMPDH filament assembly was also found to 
be triggered by ATP (Labesse et al., 2013). 
148 
 
 Studies have found that the incubation of purified P. aeruginosa 
IMPDH with ATP is associated with increased enzymatic activity (Labesse et 
al., 2013) which suggests that polymerization of this bacterium species 
upregulates IMPDH activity. On the other hand, ATP had no effect on the 
activity of Ashbya gossypii IMPDH (Buey et al., 2015), which suggests that 
the effect of ATP on IMPDH activity might vary from species to species. 
Nevertheless, how polymerization impacts human IMPDH2 enzymatic 
activity was not clear. Furthermore, previous studies examining IMPDH2 
enzymatic activity have failed to directly tie IMPDH2 polymerization with 
enzymatic activity. Our study sought to remedy this. 
Unlike previous studies, our study aimed to directly tie the 
polymerization of human IMPDH2 to its enzymatic activity level. In order to 
do this, we utilized electron microscopy to capture a visual representation of 
human IMPDH2—polymerized as well as non-polymerized—under the exact 
experimental conditions which we measured enzymatic activity. The inability 
of the non-polymerizing mutants to assemble in vitro showed that these 
mutations specifically affected inter-octamer contacts and were not 
influenced by cellular factors just as we hypothesized. We then compared the 
activity of polymerized and non-polymerized human IMPDH2 and found that 
they were comparable. These results are in contradiction to the findings of a 
previous group which reported a greater than fourfold increase in human 
IMPDH2 activity upon incubation with ATP (Scott et al., 2004) although they 
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did not connect this with IMPDH2 polymerization. On the other hand, our 
findings are consistent with the more recent findings from other labs which 
have been unable to corroborate the finding that ATP increased human 
IMPDH2 activity (Buey et al., 2015; Thomas et al., 2012).  In addition, as of 
now, no groups have found any increase in activity upon human IMPDH1 
polymerization (Buey et al., 2015; Labesse et al., 2013; Mortimer and 
Hedstrom, 2005).  One group has proposed a possible explanation for the 
irreproducible results from the single lab. One possibility is that the 
increased activity could be the result of contaminating nucleotidases 
(Mortimer and Hedstrom, 2005).  Such contamination can results from 
incomplete purification. The stimulation of IMPDH activity by various 
nucleotides has been traced to nucleotidase contamination (Holmes et al., 
1974). 
 Substrate affinity is an important aspect of enzymatic activity. 
Previous to our study, there have been no studies concerning the impact that 
human IMPDH2 polymerization has on the affinity of the substrates NAD 
and IMP. In this study we compared the NAD and the IMP affinity for 
polymerized and non-polymerized human IMPDH2 and to our surprise we 
found that there was no increase in the substrate affinity for polymerized 
human IMPDH2. We hypothesized that there would be increased affinity of 
substrates upon IMPDH2 polymerization because we believed that filament 
assembly increased nucleotide synthesis. Therefore, when we saw no increase 
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in polymerized IMPDH2 activity, we believed that increased substrate 
affinity was the method that polymerized human IMPDH2 would use instead 
to increase nucleotide synthesis.  We found that ATP actually decreased the 
affinity that NAD had for human IMPDH2, an affect that was reported by 
(Labesse et al., 2013) for P. aeruginosa IMPDH. Labesse et al. (Labesse et al., 
2013) compared the affinity of NAD and IMP for P. aeruginosa IMPDH with 
and without ATP and found that ATP increased the affinity that IMP had for 
IMPDH almost 50 fold, while it had the opposite effect on NAD.   We believe 
this reduced affinity of NAD+ for IMPDH2 in the presence of ATP is likely 
due to competitive binding of ATP to the NAD+ site rather than an effect of 
polymerization since no difference in NAD+ substrate affinity was observed 
comparing wild type and non-polymerizing mutants.  
In addition to human IMPDH2 being allosterically regulated by ATP, 
it is also allosterically regulated by GTP (Buey et al., 2015). GTP binds to 
three sites on the Bateman domain of IMPDH and induces the 
aforementioned collapsed or closed octamer confirmation where the finger 
domains of the monomers from both tetramers are brought into contact with 
each other. This conformational change results in inhibition of IMPDH 
enzymatic activity (Buey et al., 2015).  The authors discussed in great detail 
this “closed” octamer conformation of IMPDH, which contrasts with the open 
octamer conformation promoted by ATP. We discovered that filaments could 
also be composed of collapsed octamers in addition to the previously 
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discovered open octamer filaments. This discovery displays the flexibility of 
the inter-octamer contacts within the filaments, which allows them to 
accommodate both types of conformations, which differ by ~20 Å in helical 
rise. The ability of IMPDH2 filaments to accommodate multiple functional 
states of the enzyme in different conformations is unexpected.  Recent 
structures of the metabolic filament CTP synthase have shown that, while 
different ligands influence the conformation of the enzyme, a single 
conformation is stabilized in the filament, creating a direct link between 
assembly and enzyme activity (Barry et al. 2014). Thus, the ability of IMPDH 
filaments to accommodate different functionally important conformational 
states while remaining assembled in the filament is unusual. The fact that 
we found filament segments enriched in one conformation or the other, 
however, suggests that there may be cooperativity in the conversion of 
polymerized octamers between the two conformations. In addition, we 
discovered a small population of filaments which contained bent octamers. 
This suggests that in certain cases octamers might occupy conformational 
states that are intermediate in the transition between extended and 
collapsed, with IMPDH2 monomers existing in mixed states within a single 
octamer.  We hypothesized that ATP competed for binding with GTP at the 
two canonical nucleotide binding sites in the Bateman domain. Furthermore, 
we hypothesized the polymerization triggered by ATP would stabilize the 
open confirmation of the octamers, thus making it difficult for GTP to bind 
152 
 
and inhibit the enzyme. Our results did not support our hypothesis. By way 
of electron microscopy, we discovered a previously unknown phenomenon 
which was that closed octamers polymerized in wild type IMPDH2.  The 
closed octamers from the filament disrupting mutants were incapable of 
polymerizing, but both polymerizing and non-polymerizing IMPDH2 
activities were inhibited by GTP.  This demonstrated that closed octamers, 
whether in filamentous form or in separate units, result in IMPDH2 having 
reduced activity levels. This would explain why there was no difference 
between polymerized and non-polymerized IMPDH2 with respect to GTP 
inhibition. 
 So why does IMPDH2 polymerize? The answer to this question may lie 
in the moonlighting functions that IMPDH possesses which have nothing to 
do with its enzymatic activity. IMPDH is capable of moving back and forth 
from the cytoplasm to the nucleus and this movement is regulated by the cell 
cycle as well as cellular conditions (Kozhevnikova et al., 2012). While in the 
cytoplasm, IMPDH has been observed to be associated with polyribosomes 
(Mortimer et al., 2008), which suggests that it may have some sort of 
involvement in translation regulation. Within the Drosophila, IMPDH 
localizes to the nucleus in response to increased oxidative stress and during 
the G1 phase of cell cycle (Kozhevnikova et al., 2012). Depletion of 
deoxynucleotide pools also results in the nuclear buildup of IMPDH 
(Kozhevnikova et al., 2012). Within the nucleus, IMPDH is known to act as a 
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transcriptional repressor for a variety of different genes by binding directly to 
regulatory sequences within the genome (Kozhevnikova et al., 2012). Genes 
that are regulated by IMPDH within the Drosophila include all four of the 
histone genes and E2F which is the major regulator of the G1/S transition, 
and other genes involved mainly in transcriptional regulation, signaling, and 
development (Kozhevnikova et al., 2012). The effects of IMPDH inhibition 
can be seen both on a transcriptional and protein level (Kozhevnikova et al., 
2012). In light of this, it is easy to imagine that filament assembly and 
disassembly may be a method that the cell uses to regulate IMPDH2 
participation in these activities. Assembling IMPDH into filaments may serve 
as an “on” switch by limiting the ability of IMPDH to act as a transcriptional 
repressor. This could result in the prolonged expression of a number of genes 
all at once. Alternatively, the disassembly of IMPDH may be an “off” switch, 
resulting in the efficient repression of a number of genes at once. Thus, 
filament assembly and disassembly could be a way for the cell to induce 
relatively quick changes in metabolism by influencing the expression of a 
group of genes at one time in response to sudden changes. Filament assembly 
and disassembly has been found to take place within as little as 1-15 minute’s 
time (Calise et al., 2014; Juda et al., 2014). 
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Future directions 
 The question as to whether or not polymerization regulates IMPDH 
involvement in gene expression can be tested using S275L mutants as well as 
the non-polymerizing mutants such as Y12A. These mutants can be 
expressed in cells and then the mRNA as well as the protein levels of the 
IMPDH2 regulated genes can be determined using qPCR and a Western blot, 
respectively. We would expect that if filament assembly does indeed regulate 
IMPDH2’s involvement in gene regulation, then we would see a difference 
between the gene expression levels when these two cell types are compared. 
Because IMPDH2 is constitutively compartmentalized into filaments within 
the S275L expressing cells, we would expect that IMPDH would be unable to 
transfer to the nucleus to suppress gene expression. This would result in a 
higher number of transcripts and more protein expression for IMPDH 
regulated genes such as the histone genes and E2F. On the other hand, 
because IMPDH2 cannot assemble into filaments in Y12A expressing cells 
and thus is always free to relocate to the nucleus and suppress the activity of 
its target genes, I expect that the gene expression of the histone genes, E2F, 
etc. would have lower transcript levels as well as lower protein expression as 
compared to S275L expressing cells. 
We can also determine if IMPDH2 ability to bind to DNA is affected by 
filament assembly by performing chromatin immunoprecipitation in S275L 
cells and in Y12A cells. If polymerization of IMPDH2 prevents its ability to 
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bind to DNA, there would be reduced DNA binding in the S275L cells as 
compared to the Y12A cells. 
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Chapter 4: Models describing possible roles for filament 
assembly 
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Increased awareness of the significance of metabolic enzyme 
polymerization 
The discovery of assemblies within cells is increasing quickly and it 
has been noted that metabolic enzymes are more likely than other proteins to 
form these assemblies (O'Connell et al., 2012; Wilson and Gitai, 2013; Yeates 
et al., 2010). This suggests that the assembly of metabolic structures serves 
an important role in cellular metabolism (Petrovska et al., 2014). The 
assembly of metabolic enzymes can be found in a variety of organisms such as 
bacteria, yeast, flies, and mammals (Ingerson-Mahar et al., 2010; Liu, 2010; 
Noree et al., 2010). In the yeast cell, glutamine synthetase as well as yeast 
CTPS1—Ura7—have each been found to assemble into their own separate 
structures (Noree et al., 2010). These assemblies occur in response to a 
depletion of carbon sources (i.e. glucose) and/or the energy source ATP (Noree 
et al., 2010).  
The assembly of metabolic enzymes has also been discovered within 
mammalian cells. Some examples include acetyl-CoA carboxylase upon 
exposure to citrate (Beaty and Lane, 1983) and of course the nucleotide 
producing enzymes IMPDH and CTPS which were the focus of the work in 
this thesis.  
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Exploring the role of CTPS filament assembly 
Most studies in the literature concerning CTPS assembly within 
mammalian cells involve the use of inhibitors, such as DON, which directly 
inhibit CTPS activity. However, it has also been demonstrated that the 
inhibition of IMPDH results in the assembly of CTPS filaments in a small 
percentage of cells (Chang et al., 2015). CTPS has been found within the 
filaments of HEp-2 cells obtained from a specific manufacturer called INOVA 
Diagnostics Inc. as well, but how these filaments came to be assembled 
within these cells is unknown (Carcamo et al., 2011). More recently, using 
purified protein, a group at the University of Washington found that 
polymerized human CTPS actually has increased catalytic activity as 
compared to its non-polymerized form (unpublished). This is the complete 
opposite of what was found for E.coli CTPS (Barry et al., 2014). In addition to 
this, the University of Washington group also found that human CTPS 
actually polymerized in the presence of its substrates UTP, ATP, and GTP, 
while it disassembled in the presence of GTP (unpublished). Again, just the 
opposite was found for E.coli CTPS—CTP induced CTPS polymerization in 
this bacteria while substrates induced the disassembly of CTPS (Barry et al., 
2014). The University of Washington group determined that these differences 
between the behaviors of the human and E. coli CTPS were due to drastic 
dissimilarities in the structure of the filaments that these two organism form 
(unpublished).  This difference in structure was traced to an insert located 
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within the GAT domain of human CTPS1 which mediates human filament 
assembly (unpublished). This GAT-GAT assembly interaction utilizes an 
interface that is different from what is used by E.coli enzyme (unpublished).  
 
Exploring the physiological role of IMPDH filament assembly 
 The bulk of studies carried out on the polymerization of nucleotide 
biosynthetic enzymes in mammalian cells have focused on IMPDH filaments. 
Under typical, nutrient rich culture conditions, with few exceptions (i.e. 
mouse embryonic stem cells), IMPDH is not constitutively polymerized 
within mammalian cells. But, IMPDH will polymerize in response to depleted 
cellular GTP pools. The depletion of GTP can result from perturbation at a 
number of different points along the purine nucleotide biosynthesis pathway 
—glutamine depletion (glutamine is required upstream of IMPDH in the de 
novo pathway), THF depletion (also required upstream of IMPDH), inhibition 
of GMP synthetase (an enzyme downstream of IMPDH) and of course, 
inhibition of IMPDH itself. Nevertheless, the purpose that IMPDH 
polymerization fulfills within the mammalian cell has been unclear. We 
attempted to address this unknown using purified recombinant IMPDH2. As 
a result of our analysis, we finally determined that the ATP triggered 
assembly of human IMPDH2 did nothing to alter the protein’s catalytic 
properties. This included enzymatic activity (Figure 21D), substrate affinity 
(Figure 21E-H), and the ability to resist allosteric inhibition (Figure 24F). 
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The in vitro finding that polymerization did not alter enzymatic activity was 
confirmed in vivo using isotopically labeled glycine. Therefore, despite us 
having answered some very important questions concerning the catalytic 
activity of IMPDH filaments, we are still left with an incomplete 
understanding regarding the purpose of IMPDH polymerization. 
Alternatively, filament assembly may serve to regulate IMPDH in a way that 
has nothing to do with its enzymatic activity. Furthermore, filament 
assembly may serve to affect the expression of other genes. Kozhevnikova et 
al. (Kozhevnikova et al., 2012) have demonstrated that within Drosophila 
cells, IMPDH can bind to single stranded DNA and regulates the expression 
of a number of different genes by acting as a transcriptional repressor. These 
IMPDH regulated genes include the five histones, E2F (a transcription factor 
important for cell cycle advancement), as well as other genes involved in 
development, signaling, and transcriptional regulation such as JIL1 and Mlc2 
(Kozhevnikova et al., 2012). It has also been demonstrated that human 
IMPDH is capable of binding to DNA and RNA in vitro and in vivo and that 
human IMPDH is much more selective when it comes to the sequences that it 
binds to as compared to microbial IMPDH (McLean et al., 2004). This 
supports the idea that human IMPDH may bind to specific regulatory 
sequences of genes within the cell. Furthermore, analogous to what was 
found in the Drosophila (Kozhevnikova et al., 2012), McLean et al. (McLean 
et al., 2004) found that human IMPDH is located in both the cytoplasm and 
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the nucleus of cells. Therefore, it is possible that just like the Drosophila 
IMPDH, human IMPDH regulates genes expression and a study to determine 
the genes that human IMPDH regulates would be important. To that end, 
first a ChIP assay would have to be performed to determine where within the 
genome human IMPDH binds. This would clarify to which regulatory 
sequences of which genes IMPDH binds. As the next step, it would have to be 
determined in what way IMPDH regulates these genes, by acting as a 
transcriptional activator, or by acting as a transcriptional repressor as found 
in the Drosophila, or both. Therefore, polymerization may be a way for the 
cell to prevent IMPDH2 from inhibiting or activating the expression of 
certain genes that the cell may need to be turned on—or off—under the given 
conditions. The non-polymerizing IMPDH2 mutants—R356A and Y12A—are 
not only incapable themselves of assembling into filaments (Figure 25, anti-
myc staining), they also inhibit the ability of endogenous, wild type IMPDH 
from assembling into filaments (Figure 25, anti IMPDH staining). This 
means that R356A and Y12A are dominant negative making them ideal for 
addressing the purpose of human IMPDH polymerization in cells. 
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Exploring the physiological role of IMPDH filament assembly: the 
lymphocyte 
Interestingly, our lab has demonstrated that upon activation of 
lymphocytes isolated from the spleen of mice, IMPDH assembles into 
Figure 25. Non-polymerizing mutants Y12A and R356A prevent IMPDH polymerization in a 
dominant negative manner Cells with high expression of the mutant protein (indicated with 
the white arrow) show that not only are the mutants incapable of self-polymerization (anti-
myc staining), they also prevent wild type, endogenous from assembling polymerizing (anti-
IMPDH staining). 
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filaments (unpublished). An immediate assumption would be that in this 
cellular context, polymerization does increase IMPDH activity in order to 
accommodate the huge increase in guanine nucleotide demand that comes 
with clonal expansion. Another possibility is that polymerization does not 
increase enzymatic activity but rather serves a function separate from the 
enzymatic activity of IMPDH. The redistribution of IMPDH could trigger a 
change in the expression of other genes on a transcriptional (McLean et al., 
2004; Kozhevnikova et al., 2012 ) or a translational level (Mortimer et al., 
2008) which may facilitate the clonal expansion of the lymphocytes. As a 
transcriptional regulator, the redistribution of IMPDH into filaments may 
allow the expression and/or inhibition of certain genes necessary for the 
lymphocyte to successfully undergo clonal expansion and mount an immune 
response. In order to determine this, first a ChIP assay can be done to 
determine to which one of the regulation sequences of which genes the mouse 
IMPDH binds. It can then be determined if IMPDH acts as a repressor or an 
activator for the expression of these genes. Once this has been determined, 
non-polymerizing mutants (Y12A) can be expressed within a set of T-cells, 
while expressing an equivalent amount of wild type IMPDH into another 
group of T-cells. The T-cell receptors on both groups of cells can then be 
stimulated and gene expression in cells expressing the non-polymerizing 
mutant Y12A and wild type IMPDH can be compared using RNAseq, paying 
special attention to differences found in IMPDH regulated genes. A model for 
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filament assembly in T-cells could be that naïve, resting T-cells, have diffuse 
IMPDH which works to inhibit and/or activate genes who’s expression, or 
inexpression, are important for maintaining a resting state (Figure 26A). For 
example, IMPDH may suppress genes that promote proliferation and cell 
growth such as E2F, while it promotes the expression of genes that 
negatively regulate cell growth such as  p21. Upon activation of the T-cell by 
the presentation of the antigen, the naïve T-cells are signaled to assemble 
IMPDH into filaments, thus sequestering the protein and making it 
unavailable to influence gene expression (Figure 26B). These genes then 
either become activated or become inactivated which promotes the rapid 
proliferation of T-cells.  
Figure 26. Role of IMPDH filament assembly in T-cell activation.(A) In its diffuse 
form, IMPDH may be free to activate or repress genes within the T-cell which 
maintains its naïve state. (B) Stimulation of the T-cell receptor, may signal the 
assembly of IMPDH into filaments, thus preventing it from regulating the expression 
of genes it regulates in its non-polymerized form. As a result, T-cells are free to 
proliferate and therefore undergo clonal expansion. 
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Exploring the physiological role of IMPDH filament assembly: tumor cells 
Interestingly our lab discovered IMPDH filaments in many, but not all, 
of the tumor cells occupying the cortex area of tumors within mice. These 
tumors were extracted from SCID mice that had been injected with MDA-
MB-231 triple negative breast cancer cells (unpublished). Highly proliferative 
cells have been found to be heavily dependent on the de novo pathway to 
provide the guanine nucleotide needed (Majd et al., 2014), so unsurprisingly, 
it has been found that various cancers upregulate IMPDH gene expression 
(Tong et al., 2009). Thus, in this particular cellular context, it would be useful 
to first compare the enzymatic activity of IMPDH in tumor cells containing 
filaments with adjacent tumor cells containing no filaments. This can be done 
by first expressing the Y12A mutant in one set of MDA-MB-231 cells and 
expressing the S275L mutant in another set of MDA-MB-231 cells. The 
incorporation of isotopically labeled glycine into a product immediately 
downstream of IMPDH, such as XMP or GMP can then be quantified and 
compared between these two cell types. It is possible that just as we 
discovered for HEK cells, no difference in IMPDH activity will be found when 
these two MDA-MB-231 cells types are compared. On the other hand, just as 
might be possible in the lymphocytes, the redistribution or relocation of 
IMPDH into filaments may serve to regulate the ability of IMPDH to 
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influence the expression of certain genes. A change in the metabolism or 
advancement/development of the tumor may prompt the  
 
 
assembly of IMPDH into filaments and thus alter the expression of certain 
genes which are required to accommodate these changes (Figure 27). Such 
changes could be a sudden acceleration of growth rate or a tumor cell 
switching to an invasive phenotype (Figure 27).  
Figure 27. Role of IMPDH filament assembly in cancer development. 
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Therefore, one can imagine, if IMPDH polymerization is triggered, it 
might be unable to suppress genes involved in cell cycle advancement, be 
unable to suppress the expression of developmental genes such as Notch and 
Wnt (Andersson et al., 2011; Cadigan and Nusse, 1997) which often become 
activated in tumor cells (Cadigan and Nusse, 1997; D'Angelo et al., 2015; Hu 
et al., 2012; Wang et al., 2014), or be unable to suppress the expression of 
other genes that promote other tumorgenic properties such as invasion 
(Figure 27). At the same time, it may be unable to promote genes that 
negatively regulate cell cycle progression and other tumorgenic properties 
(Figure 27).  
Another important experiment would be to create stable MDA-MB-231 
triple negative breast cancer cell lines expressing S275L or Y12A. Gene 
expression levels between filament assembling tumor cells (expressing 
S275L) and tumor cells without IMPDH polymerization (expressing Y12A) 
can then be compared using RNAseq. Furthermore, it can be determined if 
there are any differences in the tumorigenic properties of filament containing 
tumor cells (cells expressing S275L mutant), and non-filament containing 
tumor cells (cells expressing Y12A mutant). Properties that can be compared 
include metastatic capability, invasion abilities, proliferation, migration 
capabilities, and non-adherent cell growth. These can be analyzed in vitro, 
within cells in culture, but can also be examined in vivo by injecting these 
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S275L and Y12A expressing cells within SCID mice and then examining and 
comparing tumor development (i.e. tumor size/weight and metastases) within 
the S275L MDA-MB-231  cell injected mice, and the Y12A MDA-MB-231 cell 
injected mice. Additionally, we can determine if any discovered differences in 
properties can be traced to particular genes that IMPDH regulates. This can 
be achieved by knocking down the expression level, or overexpression of these 
IMPDH regulated genes, one at a time in wild type MDA-MB-231 cells, and 
then testing tumorigenic properties to determine which of these properties 
are affected. 
 
Exploring the physiological role of IMPDH filament assembly: open versus 
closed octamer filaments 
Our work has demonstrated that not only does ATP induce 
conformational changes in human IMPDH, the nucleotide GTP does as well. 
We found that the binding of GTP to human IMPDH2 induced a closed or 
compressed octamer conformation. Furthermore, these closed octamers of the 
wild type protein assembled themselves into filaments. In addition to this, a 
bent or mixed octamer filament was also discovered (Figure 23). The 
biological significance of these closed octamer filaments is unknown 
considering that both closed individual and polymerized octamers experience 
the same inhibition of activity (Figure 24F). It is possible that the assembly of 
the closed octamers into filaments serves no purpose. The octamers of 
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purified wild type IMPDH, whether open or closed, may just have a natural 
proclivity to assemble themselves into filaments in vitro due to the symmetry 
of the enzyme’s octameric (and tetrameric) structure. The fact that wild type 
IMPDH can still spontaneously polymerize into octamers and even short 
filaments in the absence of ATP does support this idea. But, upon exposure to 
ATP, basically all of the IMPDH protein is octameric and contained within 
long filaments. Therefore, it may be that because the addition of ATP 
promotes more of the protein to assemble into octamers by stabilizing the 
octameric structure, more robust filament assembly naturally follows. On the 
other hand, without ATP, less of the protein is found in octamers, and 
therefore filaments are smaller and more infrequent. It would be interesting 
to determine which filament types—open, closed, or mixed—bundles into the 
huge filaments that are seen using immunofluorescence within cells (Figure 
23). It may be possible that the composition of the bundles varies depending 
on how the filament is induced. For example, it is possible that the 
composition of the IMPDH filaments assembled within activated T-cells is 
different from that of the filaments induced in PBMC by ribavirin therapy.  
 
Exploring the physiological role of filament co-assembly 
The assembly of IMPDH with CTPS in cells may serve an entirely 
different purpose than when assembled alone. It is possible that when 
assembled with CTPS, there are other proteins, perhaps CTPS itself, which 
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alter the enzymatic activity of IMPDH by increasing its activity. We have 
identified a candidate filament component—histidine ammonia lysase 
(HAL)—which is known to be involved in histidine catabolism. This enzyme 
takes histidine and converts it into urocanic acid. Most importantly, during 
this reaction, ammonia is released. Interestingly, CTPS utilizes ammonia 
during its reaction and the protonated form of ammonia, ammonium, actually 
increases IMPDH activity 100-fold. It is possible that under nutrient rich 
conditions within the cell, IMPDH, CTPS and HAL are diffuse and have little 
to no contact with each other within the cells (Figure 28, step 1).  A drop in 
the levels of precursor necessary for nucleotide synthesis, or an increased 
demand for these precursors, such as increased glutamine demand in cancer 
cells, may trigger the assembly of CTPS and IMPDH into filaments. HAL 
may then be attracted to this filamentous form of the proteins or be recruited 
to assemble with CTPS and IMPDH in order to become a source of ammonia 
for CTPS and activate IMPDH activity (Figure 28, steps 2 & 3). In this way, 
HAL would stimulate both CTPS and IMPDH to increase the nucleotide 
production under this starved state (Figure 28, step 4). Also, ammonia is a 
by-product of catabolism in general, and can become toxic to cells (Slivac et 
al., 2010). The fact that this by-product can be used as a source for CTPS to 
produce pyrimidines and can enhance the enzymatic activity of IMPDH may 
be a way for the cell to counteract this toxicity and promote survival by 
increasing the nucleotide pools needed for cellular growth. 
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1 2 3 
4 
Figure 28. A hypothesis for the role of IMPDH, CTPS and HAL co-assembly in 
nucleotide synthesis.(1) In nutrient enriched conditions, CTPS, IMPDH and HAL are 
diffuse and have no contact with each other. (2) Upon depletion of nucleotide 
precursors, all three proteins co-assemble within filaments. (3) HAL may then provide 
the ammonia needed to activate IMPDH and for CTPS to carry out its reaction. (4) This 
then results in enhanced nucleotide production 
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Conclusion 
There is still much to learn in regards to the polymerization of IMPDH 
and CTPS into filaments. These structures merit study because they likely 
have clinical implications. That they have clinical importance is supported by 
the fact that they assemble within the PBMC of patients undergoing drug 
therapy, they assemble within activated lymphocytes, and they can be found 
within tumor cells. By discovering the significance of this assembly within 
cells, we might be able to better treat neoplastic diseases as well as diseases 
of the immune system. At the very least, this knowledge would expand our 
general understanding concerning how polymerization of metabolic enzymes 
regulates their function and activity within the cell. 
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Abstract 
 
Inosine monophosphate dehydrogenase (IMPDH) is a rate-limiting enzyme 
involved in purine nucleotide biosynthesis. It is responsible for catalyzing the 
oxidation of inosine monophosphate (IMP) into xanthosine monophosphate 
(XMP).  Concurrently, the cofactor NAD+ is reduced to NADH.  Poly (ADP-
ribose) polymerase 1 (PARP-1) also utilizes NAD+ as a substrate to synthesize 
poly(ADP-ribose).  It has been demonstrated that inhibition of PARP-1 
activity can be an effective cancer therapeutic. . However, most PARP-1 
inhibitors, including Olaparib, were developed as NAD+ analogs. Therefore, 
these inhibitors likely interfere with other NAD+-dependent pathways such 
as the one involved in de novo purine metabolism.  In this chapter, we 
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describe a method to quantitatively measure IMPDH activity by taking 
advantage of the autofluorescence of the product NADH.  We use this method 
to analyze the effects of Olaparib and non-NAD+-like PARP-1 inhibitor (5F02) 
on IMPDH activity.  We found that Olaparib, unlike 5F02, significantly 
inhibits IMPDH activity in a dose-dependent manner.  Our results suggest 
that IMPDH inhibition is an off-target effect of Olaparib treatment.  The 
consequences of this effect should be addressed by future clinical studies. 
 
1 Introduction 
 
Poly(ADP-ribose) polymerase 1 (PARP-1) uses NAD+ as the substrate to 
assemble long and branching polymer named as poly(ADP-ribose) (pADPr) 
(1).  PARP-1 regulates a range of biological processes, including DNA repair 
and transcriptional control (2, 3).  Deregulation of PARP-1 activity has been 
observed in multiple cancer types (4).  PARP-1 inhibitors have been proven 
effective in eliminating BRAC1/2-associated ovarian and prostate cancer cells 
(5, 6).  However, current PARP-1 inhibitors have been developed as NAD+ 
competitors (7).  Because NAD+ is utilized by the cell in a variety of metabolic 
processes (8), it is very likely that NAD+-dependent PARP-1 inhibitors 
interfere with other NAD+-dependent pathways, which leads to undesirable 
side-effects (9).  New PARP-1 inhibitors have been recently developed based 
on H4-dependent route of PARP-1 activation (10, 11). These inhibitors are 
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expected to show superior specificity and efficacy relative to the conventional 
ones (11).  We have used an IMPDH activity assay to compare the specificity 
of these new PARP-1 inhibitors to that of the commonly used clinical drug, 
NAD+-dependent Olaparib.  
 
 
IMPDH catalyzes the oxidation of IMP into XMP [Figure 1].  The cofactor 
NAD+ is simultaneously reduced into NADH [Figure 1].  There are a number 
of conventional approaches to quantifying NADH. Colorimetric or 
bioluminescent assays are often used to determine total intracellular levels of 
NAD+ and NADH, as well as their ratio (15).  Because this method relies on 
assessing the total NAD+ levels in the cell lysate and a number of other 
enzymes reduce NAD+ in their reactions, it is not specific to IMPDH activity.  
In this chapter, we describe a method which determines the specific activity 
of IMPDH directly. This involves the use of a fluorimeter to measure the 
buildup of fluorescence as NADH is being produced by purified IMPDH 
protein. We used this IMPDH activity assay to test whether PARP-1 
inhibitors, the NAD+ analog Olaparib, and non-NAD+-like 5F02, reduce the 
production of NADH in the IMPDH reaction. This would be suggestive of 
NAD+ competition (11).  We found that Olaparib decreases the IMPDH 
activity significantly in a dosage-dependent manner in vitro, supporting our 
hypothesis that NAD+-dependent PARP-1 inhibitors interfere with NAD+-
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dependent purine metabolism [Figure 2] (11).  In contrast, treatment with 
5F02 did not result in any significant reduction of NADH production in the 
IMPDH assay [Figure 2] (11).  Altogether, these results support the idea that 
NAD+-independent inhibitors are more specific to PARP-1 than the currently 
used Olaparib (11). 
 
 
2  Materials 
 
2.1 Lysis buffer  
30 mL of 50 mM Tris pH 8, 300 mM NaCl, 10 mM imidazole, 10mM β-
ME, 800 mM urea 10% glycerol. 
 
2.2 Wash buffer 
2 mL of 50 mM Tris pH 8, 300 mM NaCl, 15 mM imidazole, 10 mM β-ME, 
800 mM urea, 10% glycerol. 
 
2.3 Elution buffer 
2 ml of 50 mM Tris pH 8, 300 mM NaCl, 250 mM imidazole, 10 mM β-
ME,  800 mM urea, 10% glycerol. 
 
2.4 Dialysis buffer   
2 L of 50 mM Tris pH8, 1mM DTT, 100 mM NaCl, 10% glycerol, 800 mM 
Urea. 
 
2.5 Purified His tagged WT IMPDH 
 
2.6 IMPDH reaction mixture master mix      
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1. Prepare a 2x solution of IMPDH activity buffer consisting of 100 mM 
Tris pH 7.4, 200 mM KCl, and 20 mM MgCl2.  
2. Prepare a 10 mM stock solution of NAD in H2O. 
3. Prepare a 0.3 M stock solution of IMP in 250 mM Tris pH 7.4 
4. Now create a “master mix” consisting of 1x IMPDH activity buffer, 
3mM IMP and 1 mM NAD. For five replicates of four samples (20 in 
total), mix 1 ml of 2x IMPDH activity buffer (50 µl  x 20), 20 µl of 0.3 
IMP stock solution(1µl x 20) and finally 200 µl of a 50 mM NAD stock 
solution (10 µl x 20). 
 
2.7  Cary Eclipse fluorescence spectrophotometer (Agilent Technologies) 
 
3 Methods 
 
3.1 Purification of His tagged WT IMPDH 
1. Allow 100 µL of BL21 (DE3) cells to thaw on ice. Mix 1 µl of purified DNA 
of IMPDH in pET-28a(+) vector with cells and allow to sit on ice to 30 
minutes. 
2. Heat shock at 42°C for 40 seconds. Place back on ice for 2 minutes. 
3. Add 1 ml of Luria Broth to tube of cells/DNA and grow at 37°C in shaking 
incubator for 1 hour. 
4. Take 10 0µl of cells and spread of agar plate with Kanamycin 
concentration of 50 µg/ml. Put in 37°C incubator overnight. 
5. Pluck single colony from agar plate using pipette tip and place in 20 ml of 
Luria Broth with Kanamycin concentration of 50 µg/ml. 
6. Grow cells overnight at 37°C. 
7. Add 25 ml culture to 1L of autoclaved Luria Broth. Add kanamycin to 
final concentration of 50 µg/ml and place in shaking incubator at 37°C 
8. Allow cells to grow to OD600. 
9. Induce with 1 mM IPTG for 3.5 hours at 30°C. 
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10. Pellet cells at 4000 rpm, for 20 minutes, at 4°C. Pour of supernatant, and 
freeze pellets at -80°C overnight. 
11. Re-suspend pellet in 30 ml of Lysis buffer 
12. Sonicate on ice with output control= 4, 50% duty cycle for 1 set of 10 
pulses and one constant for 8 seconds. 
13. Pellet cell debris by centrifugation for 15 minutes at 18000 rpm at 4°C 
14. Wash 1 ml of beads in dH2O and then lysis buffer. Add to lysate. 
15. Rotate lysates for 3 hours at 4°C. 
16. Harvest beads at 1000 x g for 10 minutes at 4°C. 
17. Wash beads 3 times with 15 ml of lysis buffer and 2 times with 1 ml of 
wash buffer. 
Elute protein from beads by rotating beads in elution buffer at 4°C for 15 
minutes.  
18. Repeat this three times, collecting the protein after each elution. You 
should have a total of 3 eluates at the end. 
19. Analyze protein elutions on a 10% SDS PAGE gel to decide which eluates 
to pool together. 
20. Dialyze protein in snake skin tubing overnight and then twice for one 
hour in approximately 600 ml of dialysis buffer each time. 
 
3.2 IMPDH activity assay 
1. Prepare the following samples each in a separate 1.5 ml microcentrifuge 
tube: 
Without treatment: 61 µl of master mix + 34.4 µl of dH2O 
With 0.5 mM Olaparib: 61 µl of master mix +0.5 µl of Olaparib (from 
100mM stock) + 33.9 µl dH2O. 
With 0.5 mM 5F02: 61 µl of master mix + 0.5 µL of 5F02 (from 100mM 
stock) + 33.9 µl dH2O. 
Vehicle only: 61µl of master mix +0.5 µL of DMSO + 33.9 µl dH2O . 
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2. Set the fluorimeter to measure NADH concentrations at 37°C with an 
emission wavelength of 440 nm and an excitation wavelength of 340 nm. 
Set measurement time for ten minutes. 
3. Add 4.6 µl (1µg) of His-tagged IMPDH protein (0.22 µg/µl) to each of the 
above samples to start the reaction. Flick the tube slightly to mix and then 
add to a 100 µl quartz cuvette. Place the cuvette in the fluorimeter to begin 
measurements.  
4. Create a standard curve for NADH florescence by plotting fluorescence vs 
various µM concentrations of NADH. Use the equation from this line to 
determine the specific activity of IMPDH (µM NADH/min/mg) for each of 
the above reactions. Significant differences are then determined using the 
Student’s t-test. 
5. Repeat the steps 1-4 with increasing concentrations of Olaparib and 5F02 
such as1mM, 2 mM, 4 mM, 6 mM and 8 mM.  An example of the result is 
shown in Figure 2 (11). 
 
4. Notes 
 
1. It is best to obtain the enzymatic readings of protein immediately after 
purification.  
2. The protein should be stored in aliquots of the volume you typically use in 
one day. 
3. Aliquots should be flash frozen in a methanol and dry ice bath then stored 
at -80 degrees. 
4. When defrosting protein, it is best to do it quickly using the warmth of 
one’s hands. Once close to being completely melted, flick tube, and then 
place on ice. 
5. Keep protein on ice during entire use. 
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Figure 29. The schematic illustration of IMPDH catalyzing reaction.IMPDH uses NAD as the 
substrate to convert IMP to XMP with the production of NADH 
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Figure 30. Graph showing the relative IMPDH activity in the IMPDH reaction 
with PARP-1 inhibitors (Olaparob and 5F02) compared to the control (DMSO 
only). Under 1mM NAD concentration condition in the reaction, Olaparib inhibits 
IMPDH activity significantly with the 2-3 fold decrease in a dosage-dependent 
manner. In contrast, Non-NAD-like inhibitor 5F02 only showed very little 
inhibition effect on IMPDH activity even in the highest dosage (8mM). *P<0.05; 
**P<0.01. 
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Figure 31. Coomassie-stained gel of purified IMPDH2 wild type and mutant 
proteins. 
